| [ |
| { |
| "id": 1, |
| "src_id": "Synthetic QA:155500", |
| "subset": "Synthetic QA", |
| "question": "Which of the following is the most appropriate initial management for a 65‑year‑old man who presents to the emergency department with acute onset of unilateral facial droop, inability to raise his eyebrows, and a tongue that deviates to the left on protrusion, but has normal sensation and strength in his limbs? \nA. Intravenous tissue plasminogen activator (tPA) \nB. High‑dose oral prednisone \nC. Observation and outpatient neurology follow‑up \nD. MRI of the brain with contrast", |
| "answer": "**Correct answer: B. High‑dose oral prednisone** \n\n### Explanation \n\nThe clinical picture is classic for **Bell’s palsy (idiopathic peripheral facial nerve palsy)**:\n\n- **Sudden unilateral facial weakness** involving the upper (forehead) and lower face (inability to raise eyebrows, loss of nasolabial fold) indicates a peripheral lesion of the facial nerve (cranial nerve VII). \n- **Tongue deviation** toward the side of the lesion occurs because the hypoglossal nerve (CN XII) is intact, but the tongue may appear to deviate when the patient attempts to protrude it due to mild ipsilateral weakness of the genioglossus muscle that can accompany facial nerve involvement. \n- **Preserved limb strength and sensation** help exclude a central (cortical) stroke, which would typically spare the forehead (contralateral upper facial muscles are supplied bilaterally) and often present with additional neurological deficits. \n\n#### Management steps for Bell’s palsy \n\n1. **High‑dose oral corticosteroids** (e.g., prednisone 60 mg daily for 5–7 days, then taper) are the only therapy that has consistently shown benefit in randomized controlled trials, improving the likelihood of complete recovery and hastening the return of facial function. \n2. **Antiviral agents** (e.g., acyclovir or valacyclovir) may be added when there is a strong suspicion of a herpes simplex virus etiology (particularly in severe cases), but evidence for added benefit over steroids alone is modest. \n3. **Eye protection** (lubricating drops, taping the eye closed at night) is essential to prevent corneal drying and injury due to incomplete eyelid closure. \n\n#### Why the other options are incorrect \n\n- **A. Intravenous tissue plasminogen activator (tPA)** – tPA is indicated for acute ischemic stroke within a 4.5‑hour window when there is a neurological deficit attributable to a central lesion. In facial nerve palsy, the pattern of weakness (involving the forehead) and the absence of other cortical signs make a central stroke unlikely. Administering tPA would expose the patient to unnecessary bleeding risk. \n\n- **C. Observation and outpatient neurology follow‑up** – While mild cases of Bell’s palsy may be observed, the evidence supports early corticosteroid therapy (ideally within 72 hours of onset) to improve outcomes. Delaying treatment can lead to a higher chance of incomplete recovery or persistent synkinesis. \n\n- **D. MRI of the brain with contrast** – Imaging is reserved for atypical presentations (e.g., gradual onset, progressive deficits, associated hearing loss, or suspicion of a tumor, Lyme disease, or sarcoidosis). In a classic, acute unilateral peripheral facial palsy without red‑flag features, immediate imaging is not required and would delay effective therapy. \n\n### Practical take‑away \n\n- **When a patient presents with an acute, isolated peripheral facial nerve palsy, start high‑dose oral prednisone promptly (within 72 hours).** \n- Add eye‑care measures and consider antivirals in severe or high‑risk cases. \n- Reserve thrombolysis, advanced imaging, or specialist referral for when the presentation is atypical or there are additional neurological signs suggesting a central cause.", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 1, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 2 |
| }, |
| "notes": "Minor anatomical inaccuracy in explanation stating genioglossus muscle weakness accompanies facial nerve involvement (genioglossus is innervated by CN XII, though pseudo-deviation occurs due to facial asymmetry). Answer selection and overall management guidance are excellent." |
| } |
| }, |
| { |
| "id": 2, |
| "src_id": "Synthetic MOOVE:21572", |
| "subset": "Synthetic MOOVE", |
| "question": "A 34-year-old woman presents to the clinic with a three-week history of progressive dyspnea on exertion, dry cough, and low-grade fever. She reports recent exposure to a friend who returned from a hiking trip in the southwestern United States. Physical examination reveals mild clubbing of the fingertips and fine inspiratory crackles at the lung bases. High-resolution CT of the chest shows diffuse, bilateral ground-glass opacities with scattered areas of mosaic attenuation and small centrilobular nodules. Bronchoalveolar lavage demonstrates a lymphocytic predominance (45% lymphocytes) and cultures are negative for bacteria, fungi, and mycobacteria. Serum testing is positive for anti‑Jo‑1 antibodies. What is the most likely diagnosis, and what is the first-line management strategy for this patient?", |
| "answer": "**Most likely diagnosis** \nThe picture is classic for **anti‑synthetase syndrome** (a form of idiopathic inflammatory myopathy associated with anti‑Jo‑1 antibodies) presenting with **interstitial lung disease**. \n\n*Key points that point to this diagnosis* \n\n| Feature | Why it fits anti‑synthetase syndrome |\n|---------|--------------------------------------|\n| Young adult woman with sub‑acute dyspnea, dry cough, low‑grade fever | Typical presentation of the pulmonary component of the syndrome |\n| Positive **anti‑Jo‑1** (histidyl‑tRNA synthetase) antibody | The defining serologic marker of anti‑synthetase syndrome |\n| HRCT: diffuse ground‑glass opacities, mosaic attenuation, centrilobular nodules | The most common radiologic pattern is a nonspecific interstitial pneumonia (NSIP) that can show ground‑glass and mosaic attenuation; small centrilobular nodules may be seen in early disease |\n| BAL with lymphocytic predominance | Reflects an inflammatory interstitial process rather than infection |\n| Absence of infectious organisms on culture | Rules out infectious mimics (e.g., atypical pneumonia, fungal disease) |\n\nThe exposure history to a friend returning from the Southwest is a red‑herring that might suggest hypersensitivity pneumonitis, but the presence of a disease‑specific autoantibody (anti‑Jo‑1) and the overall clinical picture make anti‑synthetase syndrome the far more likely explanation.\n\n---\n\n**First‑line management strategy**\n\n1. **High‑dose systemic glucocorticoids** \n * **Prednisone** (or equivalent) **≈ 1 mg/kg/day** (often 60–80 mg daily) for 4–6 weeks, then a gradual taper based on clinical and radiographic response. \n * The goal is rapid suppression of the immune‑mediated interstitial lung inflammation.\n\n2. **Early addition of a steroid‑sparing immunosuppressant** (most guidelines consider this part of “first‑line” for anti‑synthetase ILD because monotherapy with steroids alone often leads to relapse or steroid toxicity). Common choices are: \n * **Mycophenolate mofetil** 1–2 g/day divided BID, **or** \n * **Azathioprine** 2–2.5 mg/kg/day, **or** \n * **Cyclophosphamide** (IV pulses) for rapidly progressive disease. \n\n The exact agent is chosen based on comorbidities, fertility considerations, and severity; mycophenolate is frequently preferred for its favorable side‑effect profile in ILD.\n\n3. **Supportive measures** \n * Supplemental oxygen if PaO₂ < 60 mm Hg or SpO₂ < 90 % on room air. \n * Pulmonary rehabilitation and smoking avoidance. \n * Vaccinations (influenza, pneumococcal) and prophylaxis for opportunistic infections if high‑dose steroids are used long term.\n\n4. **Monitoring** \n * Serial pulmonary function tests (FVC, DLCO) every 3–6 months. \n * Repeat HRCT if clinical status worsens. \n * Monitor for steroid‑related adverse effects (glucose, blood pressure, bone density) and for drug‑specific toxicities (e.g., azathioprine – CBC, liver enzymes).\n\n**Bottom line:** \nThe patient most likely has anti‑Jo‑1–positive antisynthetase syndrome with interstitial lung disease. The first‑line therapeutic approach is high‑dose oral prednisone (≈1 mg/kg/day) with early initiation of a steroid‑sparing immunosuppressant such as mycophenolate mofetil or azathioprine, together with appropriate supportive care and close follow‑up.", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 2 |
| }, |
| "notes": "Excellent, highly accurate response. Correctly identifies anti-synthetase syndrome with ILD, appropriately dismisses the red-herring exposure history, and provides standard first-line management guidelines including high-dose steroids and steroid-sparing immunosuppressants." |
| } |
| }, |
| { |
| "id": 3, |
| "src_id": "Guidelines QA:109250", |
| "subset": "Guidelines QA", |
| "question": "A 72‑year‑old woman with relapsed and refractory multiple myeloma has failed three prior treatments, including a proteasome inhibitor and an immunomodulator. She is being considered for daratumumab. Which condition must be satisfied for her to receive daratumumab under the current recommendation?\nA) She must have received a stem cell transplant\nB) She must have a confirmed CD38‑positive disease\nC) She must have received exactly three prior therapies\nD) She must be enrolled in a clinical trial", |
| "answer": "Eligibility requires that the patient has had three prior treatments, including a proteasome inhibitor and an immunomodulatory agent, and that her disease progressed on the last therapy. A stem cell transplant is not mandatory, CD38 status is not stipulated, and trial enrollment is not required. Answer: C", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 2 |
| }, |
| "notes": "Accurate response. Correctly identifies option C based on daratumumab monotherapy indication requirements and explains why the other options are incorrect." |
| } |
| }, |
| { |
| "id": 4, |
| "src_id": "Synthetic QA:5680", |
| "subset": "Synthetic QA", |
| "question": "A 68‑year‑old woman presents to the emergency department with sudden onset shortness of breath, pleuritic chest pain, and a feeling of “tightness” in her throat. She has a history of recent total knee arthroplasty performed 10 days ago and is currently on postoperative prophylactic low‑dose heparin. Vital signs: pulse 112 bpm, respiratory rate 24 breaths/min, blood pressure 118/72 mm Hg, oxygen saturation 89 % on room air. Physical examination reveals mild tachycardia and a clear lung field; there is no lower‑extremity swelling. Which of the following is the most appropriate next step in management?\n\nA. Obtain a D‑dimer level and, if elevated, proceed to CT pulmonary angiography \nB. Start full‑dose intravenous unfractionated heparin while awaiting further testing \nC. Perform bedside transthoracic echocardiography to assess right‑ventricular strain \nD. Order a ventilation‑perfusion (V/Q) scan as the first imaging study \nE. Initiate thrombolytic therapy with alteplase immediately", |
| "answer": "The clinical picture (acute dyspnea, pleuritic chest pain, recent orthopedic surgery, and hypoxemia) is highly suspicious for acute pulmonary embolism (PE). In a patient with a high pre‑test probability for PE (e.g., Wells score ≥ 4 or “high” clinical judgment), the recommended next step is to obtain definitive imaging rather than a D‑dimer, which is only useful in low‑ or intermediate‑probability scenarios. The most widely available and sensitive test is **CT pulmonary angiography (CTPA)**. However, before proceeding to CTPA, many institutions start **therapeutic anticoagulation** (e.g., full‑dose unfractionated heparin or low‑molecular‑weight heparin) when the suspicion is high and there are no contraindications, because delaying anticoagulation can increase morbidity and mortality.\n\nOption B – “Start full‑dose intravenous unfractionated heparin while awaiting further testing” – is the appropriate immediate action. It provides rapid anticoagulation, can be quickly reversed if needed, and does not preclude subsequent imaging. Once anticoagulation is underway, the patient should be taken for definitive imaging (CTPA) to confirm the diagnosis and guide further therapy.\n\n- **Option A** is incorrect because a D‑dimer is not indicated in a high‑probability scenario; a negative D‑dimer would be unreliable, and waiting for the result could delay needed treatment. \n- **Option C** (bedside echocardiography) may reveal right‑ventricular strain but is not the first definitive test for diagnosing PE; it is useful when the patient is hemodynamically unstable and imaging is not immediately feasible. \n- **Option D** (V/Q scan) is generally reserved for patients who cannot receive iodinated contrast (e.g., severe contrast allergy or renal failure). CTPA remains the first‑line imaging in most cases. \n- **Option E** (thrombolysis) is reserved for massive PE with hemodynamic instability (e.g., sustained hypotension, shock). This patient is normotensive, so systemic thrombolysis is not indicated at this time.\n\n**Answer: B. Start full‑dose intravenous unfractionated heparin while awaiting further testing**. \n\nAfter anticoagulation is initiated, the patient should promptly undergo CT pulmonary angiography to confirm the diagnosis and determine the need for continued anticoagulation, possible catheter‑directed therapy, or other interventions.", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 2 |
| }, |
| "notes": "Excellent explanation. Accurately identifies high pre-test probability for pulmonary embolism and correctly selects empirical anticoagulation prior to diagnostic imaging while appropriately ruling out the other options." |
| } |
| }, |
| { |
| "id": 5, |
| "src_id": "Guidelines QA:99754", |
| "subset": "Guidelines QA", |
| "question": "A 3‑year‑old child presents for a well‑child visit in early September. The child has never received an influenza vaccine. Which of the following is the most appropriate influenza vaccination plan?\nA) Administer a single 0.5 mL dose of FluLaval Quadrivalent today.\nB) Administer a 0.25 mL dose of Fluzone Quadrivalent today and schedule a second dose in 4 weeks.\nC) Administer a 0.5 mL dose of Fluzone Quadrivalent today and schedule a second dose in 4 weeks.\nD) Defer vaccination until the child is 4 years old.", |
| "answer": "Children aged 3 years (≥36 months) receive the standard 0.5 mL dose of any approved influenza vaccine. Because this child has not been previously vaccinated, a second dose is required 4 weeks later. The 0.5 mL dose of FluLaval Quadrivalent is appropriate, but the 0.5 mL dose of Fluzone Quadrivalent is not licensed for this age group. Therefore, the correct plan is to give a 0.5 mL dose of FluLaval Quadrivalent now and schedule a second dose in 4 weeks. Answer: A", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": -2, |
| "Safety": -1, |
| "Contextual Fit": 1, |
| "Appropriate Confidence": -1, |
| "Clarity & Completeness": -2 |
| }, |
| "notes": "Fluzone 0.5 mL is licensed for 3-year-olds. The answer states two doses are needed, but selects Option A (a single dose), leaving a naive child under-vaccinated. The text directly contradicts the selected option." |
| } |
| }, |
| { |
| "id": 6, |
| "src_id": "Guidelines QA:113396", |
| "subset": "Guidelines QA", |
| "question": "A patient has completed the 5‑week venetoclax titration and has been on 400 mg daily for 7 days. When should the first dose of rituximab be administered?\nA) On the same day as the first 400 mg venetoclax dose\nB) Immediately after the titration phase ends, without waiting\nC) After the patient has received 400 mg venetoclax daily for 7 days\nD) At the start of the next treatment cycle, regardless of venetoclax dosing", |
| "answer": "Guideline specifies that rituximab should be given after the patient has completed the dose‑titration schedule and has had the recommended daily dose of 400 mg venetoclax for 7 days. Answer: C", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 2 |
| }, |
| "notes": "Accurate response. Option C correctly reflects the standard administration schedule for rituximab following the 5-week venetoclax ramp-up phase and 7 days at the 400 mg dose." |
| } |
| }, |
| { |
| "id": 7, |
| "src_id": "Synthetic QA:195437", |
| "subset": "Synthetic QA", |
| "question": "A 58‑year‑old man with a history of chronic heart failure presents with worsening dyspnea on exertion. He is started on a new oral medication that improves his symptoms within two weeks. One month later he returns for routine follow‑up complaining of a persistent metallic taste in his mouth and occasional mild nausea. Laboratory studies reveal a slight increase in serum uric acid but normal renal and hepatic function. Which of the following mechanisms best explains the taste disturbance associated with this medication?\n\nA. Inhibition of the Na⁺/K⁺‑ATPase pump in cardiac myocytes \nB. Blockade of the angiotensin‑converting enzyme active site \nC. Inhibition of the cardiac myosin‑ATPase enzyme \nD. Activation of the cardiac β₁‑adrenergic receptors \nE. Inhibition of the cardiac ATP‑sensitive potassium (K⁺) channels", |
| "answer": "**Answer: C. Inhibition of the cardiac myosin‑ATPase enzyme** \n\n- **Why this is the correct choice:** The patient’s clinical picture is consistent with the initiation of **omecamtiv mecarbil**, a novel cardiac myosin activator (often described as a myosin‑ATPase inhibitor that increases the duration of systolic ejection without raising intracellular calcium). One of the most common adverse effects reported in clinical trials is a **metallic or “copper‑like” taste** and mild gastrointestinal upset. The drug’s mechanism involves **binding to cardiac myosin‑ATPase**, stabilizing the actin‑myosin cross‑bridge and thereby enhancing contractility.\n\n- **Why the other options are incorrect:**\n - **A. Inhibition of the Na⁺/K⁺‑ATPase pump** – This describes the action of digoxin, which can cause visual disturbances (yellow‑green halos) and arrhythmias, not a metallic taste.\n - **B. Blockade of the angiotensin‑converting enzyme** – ACE inhibitors (e.g., lisinopril) are associated with cough and angio‑edema; a metallic taste is not a characteristic side effect.\n - **D. Activation of the cardiac β₁‑adrenergic receptors** – β‑agonists such as dobutamine increase heart rate and contractility but do not produce a metallic taste.\n - **E. Inhibition of the cardiac ATP‑sensitive potassium (K⁺) channels** – This is the mechanism of some anti‑arrhythmic drugs (e.g., amiodarone) that may cause thyroid or pulmonary toxicity, not a taste disturbance.\n\nThus, the metallic taste experienced by the patient is most plausibly linked to the **myosin‑ATPase inhibition** produced by omecamtiv mecarbil.", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": -2, |
| "Safety": 0, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": -1, |
| "Clarity & Completeness": 1 |
| }, |
| "notes": "Incorrect answer and false pharmacology. Omecamtiv mecarbil is a cardiac myosin activator, not inhibitor. Dysgeusia/metallic taste is a classic side effect of ACE inhibitors like captopril (Option B). Expressed high confidence in incorrect rationale." |
| } |
| }, |
| { |
| "id": 8, |
| "src_id": "Synthetic MOOVE:16961", |
| "subset": "Synthetic MOOVE", |
| "question": "I am a pediatric gastroenterologist in a tertiary care center. A 4‑year‑old girl with a known diagnosis of congenital hepatic fibrosis presents with a 3‑week history of progressive abdominal distension, early satiety, and intermittent low‑grade fevers. Her parents note that she has become increasingly irritable, has occasional vomiting of bile‑stained material, and has had two episodes of mild jaundice. On examination, there is a palpable, tender liver edge 4 cm below the costal margin, splenomegaly extending 3 cm below the left costal margin, and a tense ascites that shifts with position. Laboratory studies show: ALT 78 U/L (↑), AST 85 U/L (↑), GGT 210 U/L (↑), total bilirubin 2.3 mg/dL (↑), direct bilirubin 1.5 mg/dL (↑), albumin 2.9 g/dL (↓), INR 1.6 (↑), serum ammonia 68 µmol/L (↑). Abdominal ultrasound reveals heterogeneous liver echotexture with multiple cystic lesions, marked portal hypertension with splenomegaly, and a large amount of free fluid. A contrast‑enhanced MRI shows multiple peripheral, hyperintense lesions on T2-weighted images consistent with cystic disease, but also a 2.5 cm enhancing nodule in segment IVb with arterial phase hyperenhancement and washout on delayed phases. Cytology of the ascitic fluid is negative for malignant cells. What is the most likely diagnosis for the hepatic nodule, what additional diagnostic steps would you recommend to confirm it, and what immediate management considerations should be addressed for this patient?", |
| "answer": "**Most likely diagnosis of the hepatic nodule** \nThe imaging characteristics you describe – a solitary 2.5 cm lesion in segment IVb that shows **arterial‑phase hyper‑enhancement followed by wash‑out on the portal‑venous/delayed phases** – are classic for a **hepatocellular carcinoma (HCC)** in the setting of a chronic fibrotic‑cystic liver (congenital hepatic fibrosis/Caroli disease). \n\n*Why not another tumor?* \n\n| Tumor | Typical age | Imaging hallmarks | Why it is less likely here |\n|-------|------------|-------------------|----------------------------|\n| **Hepatoblastoma** | <3 yr (most <5 yr) | Heterogeneous, often calcified; “bright” on T1, variable enhancement; AFP markedly ↑ | Patient is 4 yr, lesion shows classic HCC wash‑out pattern, no calcifications |\n| **Intra‑hepatic cholangiocarcinoma (ICC)** | Adolescents/young adults; very rare in <5 yr | Peripheral rim‑enhancement, delayed progressive fill‑in, no wash‑out | Wash‑out is not a feature of ICC; arterial “flash” is typical for HCC |\n| **Regenerative/ dysplastic nodule** | Cirrhotic background | Iso‑ or slight hyper‑enhancement, no wash‑out, usually <1 cm | Size (2.5 cm) and wash‑out argue against a benign nodule |\n\nThus, the most plausible diagnosis is **early‑stage HCC (single lesion, ≤3 cm) arising in congenital hepatic fibrosis**.\n\n---\n\n## 1. Additional diagnostic steps to confirm the diagnosis \n\n| Goal | Test / Procedure | Rationale / What it adds |\n|------|-------------------|---------------------------|\n| **Biochemical confirmation** | **Serum α‑fetoprotein (AFP)** (and possibly des‑γ‑carboxy‑prothrombin, AFP‑L3) | AFP is elevated in >80 % of pediatric HCC; a markedly high level (>500 ng/mL) would support HCC and help in follow‑up. |\n| **Imaging confirmation / staging** | **Triple‑phase contrast‑enhanced CT** (or repeat dynamic MRI with hepatobiliary contrast) | Provides a second, independent “vascular” assessment; meets LI‑RADS/OPTN criteria for HCC without need for biopsy if classic. |\n| **Tissue diagnosis (if imaging is equivocal or transplant planning)** | **Ultrasound‑guided core needle biopsy** (14‑18 G) with on‑site pathology | Confirms HCC histologically and allows molecular profiling (e.g., β‑catenin mutation) that may influence therapy. |\n| **Staging for extra‑hepatic disease** | **Chest CT (or MRI)**, **Bone scan or PET‑CT** if clinically indicated | Detects pulmonary or skeletal metastases, which would upstage disease. |\n| **Baseline liver functional reserve** | **Child‑Pugh score**, **MELD‑Na**, **Indocyanine‑green (ICG) clearance** if transplant is contemplated | Determines operative risk and transplant candidacy. |\n| **Portal/hepatic vascular assessment** | **Doppler US or MR‑angiography** | Looks for portal vein thrombosis or arterial variants that affect surgical planning. |\n| **Infection work‑up** (given fevers, ascites) | **Ascitic fluid culture, cell count, serum‑ascites albumin gradient (SAAG)**, **Blood cultures** | Rules out spontaneous bacterial peritonitis (SBP) or cholangitis that must be treated before any definitive oncologic therapy. |\n\n> **Practical algorithm for this child** \n> 1. Draw AFP now (and repeat in 1 wk if borderline). \n> 2. Perform a high‑quality triple‑phase CT (or repeat liver MRI with gadoxetate) to confirm the classic HCC vascular pattern and to look for additional lesions. \n> 3. If the imaging meets “definite HCC” criteria (typical arterial enhancement + wash‑out, size ≥ 1 cm) **and** AFP is markedly elevated, a biopsy is *not mandatory* for diagnosis per AASLD/OPTN pediatric guidelines. \n> 4. If imaging is atypical, AFP is normal/low, or transplant planning requires histology → percutaneous core biopsy. \n> 5. Simultaneously, obtain chest CT, complete labs (AFP, coagulation, renal function), and a full liver‑function assessment. \n\n---\n\n## 2. Immediate management considerations \n\nThe child is **decompensated** (ascites, hypo‑albuminemia, coagulopathy, mild hyper‑bilirubinemia, encephalopathy‑grade ≤ 1) and has a **potentially curable tumor**. Management must therefore be **multifaceted** and **time‑sensitive**.\n\n### A. Stabilisation of the cirrhotic‑type complications \n\n| Issue | Immediate action | Why |\n|-------|------------------|-----|\n| **Tense ascites** | Large‑volume therapeutic paracentesis **with albumin replacement** (6–8 g albumin per litre removed) | Relieves discomfort, improves respiratory mechanics; albumin prevents circulatory dysfunction. |\n| **Risk of SBP** | Start **empiric cefotaxime 50 mg/kg IV q8h** (or ceftriaxone) while awaiting cultures; if ascitic fluid PMN ≥ 250 cells/µL → treat as SBP. Consider secondary prophylaxis (e.g., norfloxacin 5 mg/kg PO daily) once infection is cleared. | Fever + low‑grade ascitic fluid infection risk. |\n| **Hepatic encephalopathy** | **Lactulose** (starting 1 mL/kg PO q6h, titrate to 2–3 soft stools/day) ± **Rifaximin** (10 mg/kg PO bid) | Reduces ammonia, prevents worsening encephalopathy. |\n| **Coagulopathy** | Correct INR if invasive procedures planned (e.g., vitamin K 2–5 mg PO/IV daily for 2 days; consider FFP or PCC if urgent). | Safe biopsy/resection/transplant. |\n| **Hypo‑albuminemia & nutrition** | Oral high‑protein diet + **enteral supplementation**; consider **IV albumin** (if albumin <2.5 g/dL) after paracentesis. | Improves oncotic pressure, wound healing. |\n| **Portal hypertension** | **Non‑selective β‑blocker** (e.g., propranolol 0.5 mg/kg PO bid) *only after* ascites is controlled and SBP ruled out; target HR 55–60 bpm. | Primary prophylaxis for variceal bleed (but be cautious in severe ascites). |\n| **Vaccinations** | Give **HAV, HBV, pneumococcal, influenza, meningococcal** vaccines (if not already immune). | Prevent infections in immunocompromised/portal‑hypertensive child. |\n\n### B. Oncology‑specific actions \n\n| Step | What to do | Timing |\n|------|------------|--------|\n| **Multidisciplinary tumor board** (pediatric hepatology, transplant surgery, pediatric oncology, radiology, pathology, anesthesia) | Immediate convening to decide between **resection vs. transplantation**. | Within 24‑48 h. |\n| **Assess resectability** (size 2.5 cm, solitary, segment IVb, no macrovascular invasion) | If liver reserve is adequate (Child‑Pugh A‑B7, MELD < 12) and portal hypertension can be managed, a **segmental hepatectomy** could be curative.", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 2 |
| }, |
| "notes": "Excellent, highly accurate, and comprehensive response. Diagnosis, diagnostic workup, and immediate stabilization/management for decompensated liver disease and suspected pediatric HCC are clinically sound and appropriately safe." |
| } |
| }, |
| { |
| "id": 9, |
| "src_id": "Synthetic QA:210636", |
| "subset": "Synthetic QA", |
| "question": "Prompt: Your 45‑year‑old male coworker has been experiencing intermittent “fluttering” sensations in his chest, occasional shortness of breath on exertion, and mild fatigue for the past 3 weeks. He suspects he might have an arrhythmia and is planning to see his primary‑care physician tomorrow. \nQuestion: What specific question should he be sure to ask the doctor that he might easily overlook, and why is that question important for diagnosing and managing his possible cardiac arrhythmia?", |
| "answer": "**Answer to your question**\n\n### 1. The “often‑forgotten” question\n\n> **“If my rhythm is abnormal, what is the exact type of arrhythmia, how likely is it to be benign versus dangerous, and what would be the clear criteria that would make you recommend a specific treatment (medication, procedure, or lifestyle change) right away?”**\n\n#### Why this matters\n\n| Reason | Explanation |\n|--------|-------------|\n| **Clarifies the diagnosis** | “Arrhythmia” is a broad umbrella (premature beats, atrial fibrillation, supraventricular tachycardia, ventricular tachycardia, etc.). Each type has its own prognosis and treatment algorithm. |\n| **Sets a treatment threshold** | Knowing the exact trigger for therapy (e.g., > 48 h of atrial fibrillation, symptomatic ventricular ectopy, > 10 % burden on Holter) prevents both under‑ and over‑treatment. |\n| **Guides further testing** | The answer will tell you whether you need a 24‑hour Holter, an event recorder, an exercise stress test, an echocardiogram, or an electrophysiology (EP) study. |\n| **Provides a safety net** | If the doctor says “no treatment needed now,” you’ll still have a concrete plan: “I will return if I develop … (palpitations > 30 seconds, syncope, worsening dyspnea, chest pain).” |\n| **Empowers shared decision‑making** | Understanding the risk‑benefit balance lets you weigh medication side‑effects, procedural risks, and lifestyle modifications against the true danger of the rhythm. |\n\n---\n\n### 2. How to phrase it at the visit\n\n> “I’d like to understand exactly what rhythm abnormality you think I have, how risky it is, and what specific findings would lead you to start treatment now versus watchful waiting. Could you also tell me what tests you plan to order to confirm that?” \n\n---\n\n### 3. Brief overview of common adult arrhythmias & why the distinction is crucial\n\n| Arrhythmia | Typical presentation | When it’s considered **benign** | When it **needs treatment** (immediate or early) |\n|------------|----------------------|--------------------------------|---------------------------------------------------|\n| **Premature atrial/ventricular contractions (PACs/PVCs)** | Isolated “skipped beats” felt as fluttering; often asymptomatic | < 5 % burden on Holter, no structural heart disease | > 10 % PVC burden, symptomatic (dizziness, chest pain), or PVC‑induced cardiomyopathy |\n| **Paroxysmal supraventricular tachycardia (PSVT)** | Sudden episodes of rapid heart rate (150‑250 bpm) lasting seconds‑minutes; may terminate spontaneously | Rare, self‑terminating episodes, no underlying disease | Frequent episodes, hemodynamic compromise, or patient‑preferred ablation |\n| **Atrial fibrillation (AF)** | Irregularly irregular pulse, palpitations, fatigue; can be asymptomatic | Paroxysmal AF lasting < 48 h in low‑risk patients (CHA₂DS₂‑VASc 0‑1) | Persistent AF > 48 h, CHA₂DS₂‑VASc ≥ 2 (anticoagulation), symptomatic, or rapid ventricular response |\n| **Atrial flutter** | Saw‑tooth atrial activity, regular ventricular response (often", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": -1 |
| }, |
| "notes": "Clarity & Completeness is rated -1 because the response is cut off mid-sentence at the end of the summary table, rendering it incomplete." |
| } |
| }, |
| { |
| "id": 10, |
| "src_id": "Guidelines QA:44933", |
| "subset": "Guidelines QA", |
| "question": "A patient using the suspension for ocular infection reports that symptoms have not improved after 48 hours. What is the next best step?\nA) Increase the dosing frequency to hourly indefinitely\nB) Add a systemic antibiotic\nC) Re‑evaluate the patient’s condition\nD) Discontinue the medication immediately", |
| "answer": "Lack of improvement after two days mandates reassessment of the patient. Answer: C", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 2 |
| }, |
| "notes": "Accurate, concise, and clinically safe answer. Correctly identifies re-evaluation as the best next step." |
| } |
| }, |
| { |
| "id": 11, |
| "src_id": "Synthetic MOOVE:4453", |
| "subset": "Synthetic MOOVE", |
| "question": "I am an emergency physician at the University Hospital of Basel. A 62‑year‑old man with a known history of chronic atrial fibrillation on warfarin presents with sudden onset of severe left flank pain radiating to the groin, nausea, and vomiting. He reports that his INR measured two days ago was 2.9. On examination, his abdomen is tender in the left flank with a positive flank bruit, but no peritoneal signs. Bedside ultrasound shows a hypoechoic area in the left kidney suggestive of a hematoma. His hemoglobin has dropped from 13.2 g/dL on admission to 10.5 g/dL over the past 6 hours. What is the most appropriate next step in management? Please give a concise answer.", |
| "answer": "Give rapid reversal of the warfarin. Administer IV vitamin K (10 mg) plus 4‑factor prothrombin‑complex concentrate (≈50 U/kg) immediately (or PCC if available), then arrange urgent imaging/angiographic embolisation if bleeding persists.", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 1, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 2 |
| }, |
| "notes": "Minor nitpick on PCC dosing: for an INR of 2.9, standard 4-factor PCC dosing is typically 25 IU/kg (50 IU/kg is reserved for INR > 6.0). Otherwise, management strategy is correct and concise." |
| } |
| }, |
| { |
| "id": 12, |
| "src_id": "Synthetic QA:66307", |
| "subset": "Synthetic QA", |
| "question": "A 68‑year‑old woman presents with progressive dyspnea on exertion and a non‑productive cough for the past 3 months. She has a 30‑pack‑year smoking history but quit 5 years ago. Physical examination reveals fine bibasilar crackles and digital clubbing. High‑resolution CT of the chest shows diffuse subpleural reticulation with honey‑comb formation predominantly in the lower lobes. Which of the following is the most appropriate next step in management?\n\nA. Initiate a trial of high‑dose systemic corticosteroids \nB. Order a serum antinuclear antibody (ANA) panel and extractable nuclear antigen (ENA) studies \nC. Refer for surgical lung biopsy to confirm the diagnosis \nD. Begin supplemental home oxygen therapy without further work‑up \nE. Start antifibrotic therapy with nintedanib or pirfenidone", |
| "answer": "The imaging findings (subpleural reticulation with honey‑comb changes) together with the clinical picture are classic for **idiopathic pulmonary fibrosis (IPF)**, a form of usual interstitial pneumonia. \n\nKey points in the diagnostic algorithm for suspected IPF:\n\n1. **Exclude known causes** of interstitial lung disease (e.g., connective‑tissue disease, occupational exposures, drug toxicity). This is done with a focused history and basic serologic testing (ANA, ENA) **only if the clinical context suggests an alternative cause**. In a typical IPF presentation—older age, smoking history, characteristic HRCT pattern—additional serology is often unnecessary. \n\n2. **HRCT is the pivotal test**. When the HRCT shows a “definite usual interstitial pneumonia pattern” (subpleural, basal predominance, honey‑comb), the diagnosis of IPF can be made **without surgical lung biopsy**. \n\n3. **Management**: The current standard of care for confirmed IPF is to start an antifibrotic agent (nintedanib or pirfenidone) to slow disease progression. Systemic steroids are not effective and may be harmful in IPF. Supplemental oxygen is added later if the patient becomes hypoxemic, but it is not the first therapeutic step. \n\nTherefore, the most appropriate next step is to **initiate antifibrotic therapy**.\n\n**Answer: E. Start antifibrotic therapy with nintedanib or pirfenidone**.", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": -1, |
| "Safety": -1, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": -1, |
| "Clarity & Completeness": 1 |
| }, |
| "notes": "The answer selects E incorrectly. ATS/ERS/JRS/ALAT guidelines require ruling out secondary causes like connective tissue disease via routine serology (ANA/ENA) before diagnosing IPF and starting antifibrotics. Claiming serology is unnecessary is clinically unsound and unsafe." |
| } |
| }, |
| { |
| "id": 13, |
| "src_id": "Synthetic MOOVE:13354", |
| "subset": "Synthetic MOOVE", |
| "question": "I am an emergency medicine physician in a tertiary care center in Canada. A 38-year-old pregnant woman at 28 weeks gestation presents with sudden onset severe epigastric pain radiating to the back, nausea, and vomiting. She has a history of hypertriglyceridemia and is currently on a low‑fat diet. Vital signs reveal a blood pressure of 110/70 mmHg, heart rate 112 bpm, respiratory rate 22/min, and oxygen saturation 98% on room air. Laboratory studies show serum amylase 820 U/L (normal <100), lipase 1,540 U/L (normal <60), triglycerides 2,200 mg/dL, and normal liver function tests. Fetal monitoring shows a baseline heart rate of 150 bpm with moderate variability and no decelerations. \n\nWhat are the key components of initial management for acute pancreatitis in this pregnant patient, including specific considerations for maternal‑fetal safety, and what criteria would prompt escalation of care to the intensive care unit or delivery planning?", |
| "answer": "**Acute Pancreatitis in Pregnancy – 28 weeks GA** \n*38‑year‑old, triglyceride‑induced, severe epigastric pain, lipase > 10× ULN, TG = 2 200 mg/dL, hemodynamically stable, reassuring fetal tracing.*\n\nBelow is a concise, evidence‑based “road‑map” for the **initial (first‑hour to first‑day) management**, the **maternal‑fetal safety pearls**, and the **trigger points that mandate escalation to the ICU or a delivery‑focused discussion**.\n\n---\n\n## 1. Immediate Stabilisation (First Hour)\n\n| Step | What to Do | Pregnancy‑Specific Considerations |\n|------|------------|-----------------------------------|\n| **Airway, Breathing, Circulation** | • Place on cardiac monitor & continuous pulse‑ox<br>• Supplemental O₂ only if SpO₂ < 94 % (goal ≥ 95 %) | ‑ No change in oxygen targets for pregnancy; avoid hyperoxia. |\n| **IV Access** | • Two large‑bore (≥ 16 G) peripheral lines; consider central line if massive fluids/vasopressors anticipated. | ‑ Avoid radiopaque contrast unless absolutely necessary. |\n| **Fluid Resuscitation** | • Goal: **10‑15 mL/kg** isotonic crystalloid (e.g., Lactated Ringer’s) over the first 12‑24 h. <br>• Re‑assess MAP ≥ 65 mmHg, urine output ≥ 0.5 mL/kg/h, and BUN/creatinine trends. | • LR is preferred (lower chloride load → less metabolic acidosis). <br>• Avoid hypotonic fluids (risk of hyponatremia → fetal cerebral edema). |\n| **Analgesia** | • **IV opioid** (e.g., fentanyl 25‑50 µg bolus, then infusion 25‑100 µg/h) or **hydromorphone** if renal dysfunction. <br>• Add **acetaminophen** 1 g q6h (max 4 g/24 h). | • Opioids are Category C but widely used in pregnancy; no teratogenicity at therapeutic doses. <br>• NSAIDs avoided after 20 wks (risk of premature closure of ductus arteriosus). |\n| **Antiemesis** | • **Ondansetron** 4‑8 mg IV q8h **or** **Metoclopramide** 10 mg IV q6h. | • Ondansetron is Category B; safe in 2nd/3rd trimester. |\n| **NPO & Nasogastric Tube** | • Keep **nothing‑by‑mouth** (NPO) to limit pancreatic stimulation.<br>• Insert NG tube **only** if vomiting persists, ileus, or aspiration risk. | ‑ NG suction is safe; no fetal effect. |\n| **Laboratory Baseline & Ongoing** | • CBC, CMP, calcium, magnesium, phosphate, coagulation profile, ABG, lactate.<br>• Serial lipase/amylase (trend only), triglycerides q6‑12 h. | ‑ Monitor for hypocalcemia (can precipitate fetal cardiac irritability). |\n| **Fetal Monitoring** | • Continuous external cardiotocography (CTG) for ≥ 30 min after admission. <br>• Baseline HR 150 bpm, moderate variability → reassuring. | ‑ Document baseline; any decelerations → obstetric alert. |\n| **Multidisciplinary Activation** | • Notify **Obstetrics (Maternal‑Fetal Medicine)**, **Surgery/Gastroenterology**, **Anesthesiology**, **ICU** and **Neonatology**. | Early involvement reduces delays if rapid escalation needed. |\n\n---\n\n## 2. Targeted Management of **Triglyceride‑Induced** Pancreatitis\n\n| Intervention | Dose / Protocol | Pregnancy‑Safety Note |\n|--------------|----------------|-----------------------|\n| **Insulin‑glucose infusion** | • Start **regular insulin** 0.1 U/kg/h IV + **5% dextrose** to maintain glucose 100‑180 mg/dL. <br>• Goal TG < 500 mg/dL within 24‑48 h. | • Insulin crosses placenta but does **not** cause fetal hypoglycemia when maternal glucose is maintained. |\n| **Heparin (unfractionated) infusion** (optional adjunct) | • 5‑10 U/kg/h IV (low‑dose) – accelerates LPL activity. | ‑ Use **only if** no active bleeding; UFH is reversible and safe in pregnancy. |\n| **Therapeutic plasma exchange (TPE)** | • 1‑1.5 × plasma volume exchanged with 5% albumin or FFP. <br>• Indicated if TG > 1 000 mg/dL **or** refractory after 24 h of insulin/heparin. | ‑ No teratogenicity; replace with albumin to avoid volume overload. |\n| **Omega‑3 fatty acid IV (if available)** | • 10 g over 24 h (experimental). | ‑ Generally safe, but data limited; use only in specialist centers. |\n| **Dietary counseling** (post‑acute phase) | • Very low‑fat (< 15 % kcal), high‑protein, MCT‑enriched diet. | ‑ Continue throughout pregnancy; avoid rapid re‑feeding that spikes TG. |\n\n> **Key point:** In the first 48 h, the **primary aim** is to lower TG rapidly (target < 500 mg/dL) to halt ongoing pancreatic lipase activation. If TG remain > 1 000 mg/dL after aggressive insulin/heparin, **plasmapheresis** is the next step and should be performed **in a center with obstetric support**.\n\n---\n\n## 3. Supportive Care Beyond the First 24 h\n\n| Aspect | Recommendation | Rationale in Pregnancy |\n|--------|----------------|------------------------|\n| **Enteral Nutrition** | • If NPO > 48 h or pain improves, start **low‑fat, high‑protein, MCT‑based** enteral feeds via naso‑jejunal tube. <br>• Goal: 25‑30 kcal/kg/day by day 3. | Early enteral feeding reduces systemic inflammation and is **safe** for fetus. |\n| **VTE Prophylaxis** | • **Low‑molecular‑weight heparin** (e.g., enoxaparin 40 mg SC daily) **unless** active bleeding or imminent delivery. | Pregnancy is hypercoagulable; pancreatitis further raises risk. |\n| **Electrolyte & Metabolic Management** | • Replace calcium (if < 8 mg/dL) with calcium gluconate; correct Mg, PO₄. <br>• Maintain glucose 80‑120 mg/dL. | Prevents fetal arrhythmias & maternal complications. |\n| **Antibiotics** | • **Only** if there is **confirmed or strongly suspected infected necrosis** or cholangitis. <br>• Preferred agents: **Ceftriaxone + Metronidazole** (both Category B). | Avoid routine prophylaxis; unnecessary antibiotics increase fetal risk. |\n| **Imaging** | • **Transabdominal ultrasound** – first line (no radiation). <br>• If further delineation needed, **MRI without gadolinium** is safe. <br>• CT only if life‑threatening complication and benefits outweigh fetal radiation (use low‑dose protocol). | Avoid ionising radiation; MRI provides excellent pancreatic detail. |\n| **Steroids** | • Not indicated for pancreatitis; avoid unless obstetric indication (e.g., fetal lung maturity). | No benefit, potential fetal growth impact. |\n\n---\n\n## 4. Criteria for **Escalation to ICU** (or higher‑level monitoring)\n\n| Criterion | Why it matters | Action |\n|-----------|----------------|--------|\n| **Hemodynamic instability** – MAP < 65 mmHg despite 30 mL/kg fluids, need for vasopressors. | Indicates systemic inflammatory response / early shock. | Transfer to ICU; start norepinephrine (Category B). |\n| **Persistent tachycardia > 120 bpm** with rising lactate (> 2 mmol/L). | Early sign of inadequate perfusion. | ICU, repeat labs q4‑6 h. |\n| **Severe hypoxemia** – PaO₂", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": -1, |
| "Safety": -1, |
| "Contextual Fit": 1, |
| "Appropriate Confidence": 1, |
| "Clarity & Completeness": -1 |
| }, |
| "notes": "Severely under-estimates fluid resuscitation requirements for acute pancreatitis (10–15 mL/kg over 12–24 hours is far below adequate volume and dangerous). The response is also truncated mid-sentence at the end, omitting key ICU/delivery criteria." |
| } |
| }, |
| { |
| "id": 14, |
| "src_id": "Guidelines QA:42481", |
| "subset": "Guidelines QA", |
| "question": "A 28-year-old man with type 1 diabetes is being started on a basal insulin. He currently uses only rapid‑acting insulin before meals, total daily dose 45 units. What is the most appropriate initial dose of Rezvoglar for this patient?\nA) 5 units once daily\nB) 10 units once daily\nC) 15 units once daily\nD) 20 units once daily", |
| "answer": "For type 1 diabetes, basal insulin should begin at roughly one‑third of the total daily insulin requirement. One‑third of 45 units is about 15 units, making that the appropriate starting dose. Answer: C", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 2 |
| }, |
| "notes": "Accurate calculation and clinical rationale for initiating basal insulin in type 1 diabetes based on total daily dose." |
| } |
| }, |
| { |
| "id": 15, |
| "src_id": "Guidelines QA:78902", |
| "subset": "Guidelines QA", |
| "question": "A 19‑year‑old college student reports hives and mild wheezing 20 minutes after taking a dose of penicillin V for strep throat. She has no prior history of drug allergies. What is the most appropriate emergency action?\nA) Observe the patient for 30 minutes without medication. \nB) Administer intramuscular epinephrine and call emergency services. \nC) Give oral antihistamine only and discharge home. \nD) Start intravenous corticosteroids and monitor for 2 hours.", |
| "answer": "The rapid onset of hives with wheezing indicates a potentially progressing anaphylactic reaction. Immediate administration of epinephrine and activation of emergency services is the correct response. Observation alone or antihistamines alone are insufficient. Answer: B", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 2 |
| }, |
| "notes": "Accurate and concise response. Correctly identifies signs of anaphylaxis and appropriately selects intramuscular epinephrine as the immediate emergency action." |
| } |
| }, |
| { |
| "id": 16, |
| "src_id": "Synthetic QA:210308", |
| "subset": "Synthetic QA", |
| "question": "Prompt: Your female coworker has been experiencing unexplained weight loss, night sweats, and intermittent low‑grade fevers for the past 2 months. She is worried that this could be a sign of a serious condition such as lymphoma and is going to visit the nearest doctor. Suggest an important question she might likely forget to ask. Please explain your question if needed. **Don’t ask generic questions.** \nQuestion: *What are the possible causes of my weight loss, night sweats, and fevers, and how will you determine which one is responsible?*", |
| "answer": "### A question she might **forget to ask** (and why it matters)\n\n> **“Can we discuss a targeted work‑up for hidden infections, inflammatory disorders, and malignancies—including specific blood tests, imaging, and possibly a tissue biopsy—so we don’t miss a serious but treatable cause of my weight loss and night sweats?”**\n\n#### Why this question is crucial \n\n| Reason | Explanation |\n|--------|-------------|\n| **Avoids premature anchoring** | Clinicians may initially label the picture as “viral” or “stress‑related” and stop after a basic CBC. Asking for a *targeted* work‑up pushes the provider to consider a broader differential (infection, autoimmune disease, hemato‑oncologic malignancy). |\n| **Guides appropriate testing** | A clear request prompts ordering of **screening labs** (ESR/CRP, LDH, ferritin, HIV, hepatitis, TB, ANA, ANCA) **plus imaging** (chest / abdominal CT or PET‑CT) and, if indicated, **tissue sampling** (excisional lymph node biopsy, bone‑marrow aspirate). |\n| **Sets expectations for follow‑up** | The patient learns what tests are planned, the timeline for results, and when a repeat visit or referral (e.g., hematology/oncology, infectious disease) is needed. |\n| **Empowers shared decision‑making** | By explicitly asking about the work‑up, she can weigh the risks/benefits of invasive procedures (e.g., biopsy) and decide which are acceptable to her. |\n| **Reduces diagnostic delay** | Early, comprehensive evaluation shortens the interval between symptom onset and a definitive diagnosis, which is especially important for conditions like lymphoma that are more treatable when caught early. |\n\n---\n\n### Direct answer to her original question \n\n**“What are the possible causes of my weight loss, night sweats, and fevers, and how will you determine which one is responsible?”**\n\n#### 1. Common categories of causes \n\n| Category | Typical conditions | Key clues that help differentiate |\n|----------|-------------------|-----------------------------------|\n| **Infectious** | • Tuberculosis (pulmonary or extrapulmonary) <br>• HIV/AIDS <br>• Endocarditis <br>• Fungal infections (histoplasmosis, coccidioidomycosis) <br>• Chronic viral hepatitis | • Exposure history (travel, TB contacts, IV drug use) <br>• Persistent cough, lymphadenopathy, organomegaly |\n| **Malignancy (hematologic & solid)** | • Hodgkin & non‑Hodgkin lymphoma <br>• Leukemia <br>• Metastatic carcinoma (lung, breast, gastrointestinal) | • Discrete, painless lymph node enlargement <br>• Elevated LDH, hypercalcemia, B‑symptoms (the very symptoms she has) |\n| **Autoimmune / Inflammatory** | • Systemic lupus erythe", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": -1 |
| }, |
| "notes": "Clarity & Completeness is graded -1 because the response cuts off mid-sentence at the end ('Systemic lupus erythe')." |
| } |
| }, |
| { |
| "id": 17, |
| "src_id": "Synthetic MOOVE:15557", |
| "subset": "Synthetic MOOVE", |
| "question": "I am a pediatric neurologist at a university hospital in Zurich. A 6‑year‑old girl is brought to the emergency department after a 2‑day history of progressive weakness in both legs, culminating in an inability to walk. She also reports numbness and a “tight band” sensation around her waist. There is no recent trauma, fever, or infection. On examination, she has symmetric flaccid paralysis of the lower extremities (Medical Research Council grade 2/5), decreased proprioception and vibration sense below the L1 dermatome, and brisk deep tendon reflexes in the upper extremities. Cranial nerves are intact. MRI of the spine shows a longitudinally extensive transverse myelitis spanning T8–L2 with contrast enhancement of the cord. Cerebrospinal fluid analysis reveals a lymphocytic pleocytosis (45 cells/µL, predominantly CD4+ T‑cells) and elevated protein (85 mg/dL); oligoclonal bands are absent. Serum aquaporin‑4 IgG is negative, but myelin oligodendrocyte glycoprotein (MOG) antibodies are positive. The child has no prior medical history and no known autoimmune disease.\n\nWhat is the most likely diagnosis, and what is the recommended acute management strategy for this condition in a pediatric patient?", |
| "answer": "**Most likely diagnosis**\n\n- **Myelin‑oligodendrocyte‑glycoprotein antibody‑associated disease (MOG‑AD)** presenting as an **acute longitudinally extensive transverse myelitis (LETM)**. \n - The key pointers are: \n • Age ≤ 18 years, sub‑acute progressive weakness of the legs, sensory level at the waist, and brisk reflexes above the lesion. \n • MRI showing a T8–L2 LETM with gadolinium enhancement. \n • CSF with a lymphocytic pleocytosis and modest protein rise, but no oligoclonal bands. \n • Positive serum MOG‑IgG and negative AQP‑4 IgG (rules out classic NMOSD). \n\nMOG‑AD is now recognised as a distinct demyelinating disorder that can present with isolated myelitis, optic neuritis, or ADEM‑like pictures in children. The clinical picture fits the typical “MOG‑myelitis” phenotype.\n\n---\n\n**Recommended acute management in a pediatric patient**\n\n| Step | What to do | Typical pediatric dosing / details |\n|------|------------|------------------------------------|\n| **1. High‑dose intravenous glucocorticoids** | First‑line therapy for acute inflammatory demyelination. | **Methylprednisolone 30 mg/kg/day** (max 1 g/day) **IV** for **3–5 days**. In many centres a 5‑day course is used to ensure maximal anti‑inflammatory effect. |\n| **2. Transition to oral taper** | Prevent rebound inflammation and allow safe weaning. | Start oral prednisolone **1–2 mg/kg/day** (max 60 mg) after IV course, then taper over **4–6 weeks** (e.g., 60 % of IV dose for 1 wk → 40 % → 20 % → stop). |\n| **3. Rescue/adjunct therapy if inadequate response** (≈10–20 % of children) | • **Intravenous immunoglobulin (IVIG)** 2 g/kg given as 0.4 g/kg/day for 5 days.<br>• **Therapeutic plasma exchange (PLEX)** – 5–7 exchanges over 10–14 days. | Choose IVIG if rapid improvement is needed or if plasma‑exchange access is limited; PLEX is preferred when there is a fulminant or steroid‑refractory course. |\n| **4. Supportive care** | • Analgesia, bladder/bowel management, thromboprophylaxis, physiotherapy/occupational therapy.<br>• Monitor for steroid side‑effects (hyperglycaemia, hypertension, infection). | Admit to a high‑dependency or paediatric neurology ward for close neuro‑monitoring. |\n| **5. Early planning for relapse‑prevention** (not part of the acute “crash” treatment but should be discussed while the patient is still in‑patient) | • Consider maintenance immunotherapy if the child has risk factors for recurrence (e.g., high MOG‑IgG titre, prior ADEM, multifocal disease). Options include rituximab, mycophenolate mofetil, azathioprine, or low‑dose oral steroids. | Initiation usually 2–4 weeks after the acute episode, once the child is clinically stable. |\n\n**Practical algorithm for this case**\n\n1. **Start IV methylprednisolone 30 mg/kg (max 1 g) daily for 5 days** as soon as the diagnosis of MOG‑associated LETM is made (after ruling out active infection). \n2. **Re‑assess after 48–72 h**: if there is clear clinical improvement (≥1‑grade MRC gain, reduction of pain, better sphincter control) continue the steroid course and plan the oral taper. \n3. **If no improvement or worsening** by day 3–4, add **IVIG (2 g/kg total)** or proceed to **PLEX** (5 exchanges) depending on local resources and the child’s haemodynamic stability. \n4. **Provide bladder/bowel care, analgesia, physiotherapy**, and monitor electrolytes, glucose, and blood pressure throughout steroid therapy. \n5. **Arrange follow‑up MRI** (typically 4–6 weeks after discharge) to document resolution of cord enhancement and to guide long‑term relapse‑prevention decisions.\n\n---\n\n### Take‑home points for the emergency/ward team\n\n- **MOG‑AD is the working diagnosis** – it accounts for the LETM, the seropositivity, and the CSF pattern. \n- **High‑dose IV methylprednisolone** is the cornerstone of acute treatment in children. \n- **IVIG or plasma exchange** are reserved for steroid‑non‑responders or for very severe presentations. \n- Early involvement of paediatric neurology, physiotherapy, and a neuro‑immunology team is essential for optimal recovery and for planning secondary‑prevention strategies. \n\nFollowing this regimen, most children with MOG‑associated transverse myelitis show substantial functional recovery within weeks, although some may have residual weakness or sphincter dysfunction and will benefit from structured rehabilitation.", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 2 |
| }, |
| "notes": "Excellent, comprehensive response. Correctly identifies MOG-AD/LETM and provides accurate, evidence-based acute pediatric treatment guidelines, including precise methylprednisolone dosing, oral steroid taper, rescue options (IVIG/PLEX), and essential supportive safety precautions." |
| } |
| }, |
| { |
| "id": 18, |
| "src_id": "Guidelines QA:65311", |
| "subset": "Guidelines QA", |
| "question": "During a routine review, a patient on 3 mg daily of Niravam for panic disorder has been stable for 6 months. According to maintenance guidance, what should the clinician consider?\nA) Immediately discontinue the medication\nB) Increase the dose to 5 mg without reassessment\nC) Periodically reassess the need for continued therapy and consider dose reduction\nD) Switch to a non‑benzodiazepine anxiolytic regardless of response", |
| "answer": "For patients on doses ≤4 mg, periodic reassessment and possible reduction are advised to limit dependence risk. Answer: C", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 2 |
| }, |
| "notes": "Accurately identifies Option C as the correct answer and provides a clinically sound rationale regarding maintenance therapy and dependence risk for chronic benzodiazepine use." |
| } |
| }, |
| { |
| "id": 19, |
| "src_id": "Synthetic QA:95014", |
| "subset": "Synthetic QA", |
| "question": "Which of the following statements about the reversal of dabigatran‑induced anticoagulation is correct? \nA. Idarucizumab is a monoclonal antibody fragment that binds directly to dabigatran, neutralizing its effect. \nB. Vitamin K administration reverses dabigatran anticoagulation within 30 minutes. \nC. Prothrombin complex concentrate (PCC) is the recommended first‑line agent for emergent reversal. \nD. Hemodialysis is ineffective for removing dabigatran because the drug is highly protein‑bound. \nE. Activated charcoal is useful for reversal if given more than 12 hours after ingestion.", |
| "answer": "**Answer: A. Idarucizumab is a monoclonal antibody fragment that binds directly to dabigatran, neutralizing its effect.** \n\n**Explanation**\n\n- **Idarucizumab** is a humanized Fab fragment that has very high affinity for dabigatran. It binds free dabigatran molecules, forming inert complexes that are rapidly cleared, thereby providing almost immediate reversal of anticoagulation. It is the **first‑line, FDA‑approved** specific antidote for dabigatran‑related bleeding or when urgent surgery is required.\n\n- **Vitamin K** works by enabling synthesis of functional clotting factors II, VII, IX, and X, which are deficient in vitamin K antagonist (e.g., warfarin) therapy. Dabigatran is a direct thrombin inhibitor and is **not** affected by vitamin K; therefore, vitamin K does **not** reverse its effect.\n\n- **Prothrombin complex concentrate (PCC)** contains vitamin‑K‑dependent clotting factors and is useful for reversing warfarin, but it has **limited efficacy** for dabigatran. While PCC may provide some hemostatic benefit in severe bleeding, it is **not the recommended first‑line** reversal strategy for dabigatran.\n\n- **Hemodialysis** can remove dabigatran because the drug has a relatively low protein‑binding fraction (~35 %). In fact, dialysis can clear up to 60 % of dabigatran over 4 hours. Therefore, the statement that it is ineffective is **false**.\n\n- **Activated charcoal** is only useful when administered **within 1–2 hours** of ingestion of a toxin or drug. By 12 hours, dabigatran has already been absorbed and distributed; charcoal would not be effective for reversal at that point.\n\nThus, option **A** accurately describes the mechanism and clinical use of idarucizumab for dabigatran reversal.", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 2 |
| }, |
| "notes": "The correct answer is identified and each distractor is accurately explained using sound pharmacological principles. Excellent clinical reference quality." |
| } |
| }, |
| { |
| "id": 20, |
| "src_id": "Guidelines QA:10380", |
| "subset": "Guidelines QA", |
| "question": "A patient asks whether they can use the lice shampoo on a child younger than two months. What is the appropriate response based on the product’s age recommendation?\nA) It is safe for infants of any age\nB) It can be used on newborns if they have severe infestation\nC) It is indicated for children two months old and older\nD) It should only be used on children older than one year", |
| "answer": "The product is approved for use in children from two months of age onward. Answer: C", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 2 |
| }, |
| "notes": "Accurate and clear response. Standard OTC permethrin lice shampoo is approved for infants two months of age and older." |
| } |
| }, |
| { |
| "id": 21, |
| "src_id": "Synthetic QA:164543", |
| "subset": "Synthetic QA", |
| "question": "A 58‑year‑old man presents with progressive exertional dyspnea, peripheral edema, and a holosystolic murmur heard best at the left lower sternal border that increases with inspiration. Echocardiography shows right‑ventricular enlargement and severe tricuspid regurgitation secondary to annular dilation. Which of the following is the most appropriate next step in management?\n\nA. Initiate high‑dose intravenous diuretics and schedule elective tricuspid valve repair \nB. Begin oral anticoagulation with warfarin and refer for pulmonary endarterectomy \nC. Start guideline‑directed medical therapy for heart failure with reduced ejection fraction and arrange for cardiac resynchronization therapy \nD. Optimize volume status with oral diuretics and refer for transcatheter tricuspid valve repair (edge‑to‑edge) \nE. Perform right‑heart catheterization to assess pulmonary artery pressures before any intervention", |
| "answer": "**Answer: D. Optimize volume status with oral diuretics and refer for transcatheter tricuspid valve repair (edge‑to‑edge)** \n\n**Explanation**\n\n- **Clinical picture** – The patient has signs of right‑sided heart failure (dyspnea, edema) and a holosystolic murmur that increases with inspiration (Carvallo’s sign), classic for **functional (secondary) tricuspid regurgitation** due to annular dilation from right‑ventricular enlargement. \n- **Initial management** – The first step in functional TR is aggressive **volume control** with oral loop diuretics (e.g., furosemide) to reduce preload and relieve symptoms. Intravenous diuretics are reserved for acute decompensation; this patient is stable enough for oral therapy. \n- **Definitive therapy** – Severe functional TR that remains symptomatic despite optimal medical therapy is now commonly treated with **transcatheter edge‑to‑edge repair (e.g., MitraClip/TriClip)**, especially in patients who are high‑risk surgical candidates (advanced age, comorbidities). Surgical tricuspid valve repair or replacement carries higher morbidity and is generally reserved for patients with left‑sided valve disease requiring surgery or those with isolated severe TR who are low surgical risk. \n- **Why the other options are less appropriate** \n - **A. High‑dose IV diuretics + elective surgical repair** – IV diuretics are unnecessary in a stable outpatient, and surgical repair is more invasive; the less invasive transcatheter approach is preferred first. \n - **B. Warfarin + pulmonary endarterectomy** – There is no evidence of chronic thromboembolic pulmonary hypertension; anticoagulation is not indicated for isolated functional TR. \n - **C. Guideline‑directed therapy for HFrEF + CRT** – The patient’s problem is right‑sided failure secondary to TR, not left‑sided systolic dysfunction; CRT is irrelevant without left‑bundle‑branch block or reduced left‑ventricular ejection fraction. \n - **E. Right‑heart catheterization before any intervention** – Hemodynamic assessment may be useful in selected cases, but the immediate priority is symptom relief with diuretics and referral for a definitive, less‑invasive valve‑repair strategy. \n\nThus, the most appropriate next step is **optimizing volume status with oral diuretics and arranging transcatheter edge‑to‑edge tricuspid valve repair**.", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": -1, |
| "Safety": 0, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 1, |
| "Clarity & Completeness": 1 |
| }, |
| "notes": "Clinical Soundness is -1 because Right Heart Catheterization (Option E) is a required Class I guideline recommendation to measure pulmonary artery pressures and PVR prior to any tricuspid valve intervention for severe secondary TR." |
| } |
| }, |
| { |
| "id": 22, |
| "src_id": "Synthetic MOOVE:21981", |
| "subset": "Synthetic MOOVE", |
| "question": "A 58-year-old male with a 20‑year history of type 2 diabetes mellitus and hypertension presents to the emergency department with sudden onset of severe, tearing chest pain radiating to the back, accompanied by diaphoresis and mild shortness of breath. The pain began 45 minutes ago while he was watching television and is not relieved by sitting up or nitroglycerin. He denies any recent trauma or heavy lifting. On examination, he appears distressed, with blood pressure 180/100 mm Hg in the right arm and 165/95 mm Hg in the left arm, heart rate 110 bpm, respiratory rate 22/min, and oxygen saturation 96 % on room air. Cardiac auscultation reveals a regular rhythm with a soft, early diastolic murmur best heard at the left sternal border. No peripheral edema is noted. Laboratory results show a normal troponin level, and a bedside transthoracic echocardiogram demonstrates a dilated ascending aorta with an intimal flap consistent with dissection. \n\n1. What is the most likely diagnosis?\n2. Which classification system (Stanford or DeBakey) would you use to categorize this condition, and what is the specific type based on the findings?\n3. List the immediate priority investigations to confirm and assess the extent of the pathology.\n4. Outline the initial emergency management steps, including pharmacologic and non‑pharmacologic interventions.\n5. What are the key indications for emergent surgical intervention versus medical management in this scenario?", |
| "answer": "**1. Most likely diagnosis** \nAcute **type A aortic dissection** (proximal/dissection involving the ascending aorta). The classic tearing chest pain radiating to the back, hypertension, a new early‑diastolic murmur (aortic regurgitation), and bedside TTE showing a dilated ascending aorta with an intimal flap all point to this entity.\n\n---\n\n**2. Classification system & specific type** \n\n| System | How it categorises the dissection | Application to this patient |\n|--------|----------------------------------|-----------------------------|\n| **Stanford** | • **Type A** – dissection involves the ascending aorta (with or without extension distal to it) <br>• **Type B** – dissection confined to the descending aorta (distal to left subclavian) | **Stanford Type A** – because the ascending aorta is involved. |\n| **DeBakey** | • **Type I** – originates in the ascending aorta and propagates distally (may also go proximally) <br>• **Type II** – confined to the ascending aorta <br>• **Type III** – originates distal to the left subclavian and propagates distally (IIIa = only thoracic, IIIb = thoraco‑abdominal) | **DeBakey Type I** (origin in the ascending aorta with extension into the arch/descending aorta is most likely; if imaging later shows the flap limited to the ascending aorta only, it would be DeBakey II). |\n\nThus, the **Stanford system** (most widely used in the emergency setting) would label this as **Stanford A**, and the **DeBakey system** would be **Type I** unless the dissection is proven to be limited to the ascending aorta only (then Type II).\n\n---\n\n**3. Immediate priority investigations** \n\n| Goal | Modality (ordered in order of practicality/urgency) |\n|------|------------------------------------------------------|\n| **Confirm diagnosis & define anatomy** | **CT‑angiography (CTA) of the chest** – rapid, highly sensitive, provides 3‑D map of the intimal flap, true/false lumen, branch involvement, and any complications (pericardial effusion, coronary involvement). |\n| **If CTA unavailable or patient unstable** | **Trans‑esophageal echocardiography (TEE)** – bedside, excellent for ascending aorta, aortic valve, pericardial effusion, and can be repeated. |\n| **Alternative when contrast contraindicated** | **MRI/MRA** – gold‑standard but time‑consuming; usually reserved for stable patients or when CTA/TEE equivocal. |\n| **Assess complications** | **Chest X‑ray** – may show mediastinal widening, pleural effusion (quick screen). |\n| **Baseline labs** (already partly obtained) | • CBC, BMP, coagulation panel <br>• Serial cardiac enzymes (to rule out concomitant MI) <br>• D‑dimer (high negative predictive value, but not diagnostic). |\n| **Adjunctive imaging** (if CTA shows branch involvement) | **CT of abdomen/pelvis** (to evaluate for extension into abdominal aorta) or **vascular ultrasound** of carotid/renal arteries if limb ischemia suspected. |\n\n*The **first‑line** in most EDs for a hemodynamically stable but painful patient is a **CTA of the chest with IV contrast**; if the patient becomes unstable (e.g., hypotension, tamponade) proceed directly to **TEE** or emergent surgery.*\n\n---\n\n**4. Initial emergency management (first ≈ 30 min)** \n\n| Step | Details | Rationale |\n|------|---------|-----------|\n| **A. Rapid control of blood pressure & shear stress** | • **IV β‑blocker** (e.g., **esmolol** 50–200 µg/kg/min infusion, titrate to target HR < 60 bpm) **first**. <br>• **Add vasodilator** (e.g., **nicardipine** or **clevidipine**) **only after** β‑blockade is adequate, to bring SBP to **120–140 mm Hg** (or MAP ≈ 65–80 mm Hg). <br>• Goal: HR ≤ 60 bpm, SBP ≤ 120 mm Hg within the first hour, then maintain SBP 100–120 mm Hg. | Reduces aortic wall shear force, limits propagation of the dissection. |\n| **B. Pain control** | • **IV opioids** (e.g., **fentanyl** 25–100 µg bolus, repeat q5‑10 min as needed) or **hydromorphone**. <br>• Consider **IV lidocaine** or **ketamine** if opioid‑refractory. | Severe pain itself raises catecholamines → ↑ BP/shear. |\n| **C. Establish IV access & monitoring** | • Two large‑bore IV lines. <br>• Continuous ECG, arterial line (if possible) for real‑time BP, pulse pressure. <br>• Pulse oximetry, capnography (if intubated). | Enables tight hemodynamic titration and early detection of deterioration. |\n| **D. Anticoagulation/antiplatelet considerations** | **Do NOT** give anticoagulants (heparin, warfarin) or antiplatelet agents unless a concurrent acute coronary syndrome is proven. | Dissection is a *bleeding* problem; anticoagulation increases risk of tamponade or rupture. |\n| **E. Prepare for definitive therapy** | • **Notify cardiothoracic surgery** immediately (the case is a surgical emergency). <br>• **Stat** imaging (CTA/TEE) while BP control ongoing. <br>• Keep **IV fluids** ready (e.g., 500 mL normal saline) to avoid hypotension after β‑blockade. | Early surgical involvement improves outcomes; imaging must be performed before definitive repair. |\n| **F. Non‑pharmacologic measures** | • **Strict bed rest**; keep the patient supine with head of bed ≤30°. <br>• **Avoid Valsalva, coughing, or any activity that raises intrathoracic pressure**. <br>• **Analgesic‑driven sedation** if agitation threatens BP spikes. | Minimises additional shear forces. |\n| **G. Consider adjuncts** | • **Oxygen** (supplemental 2–4 L if SpO₂ < 94%). <br>• **NPO** (nothing by mouth) in anticipation of possible surgery. | Standard supportive care. |\n\n*If the patient becomes unstable (hypotension, signs of tamponade, sudden neurological deficit), skip further imaging and move straight to the operating room (or emergent pericardiocentesis if tamponade).*\n\n---\n\n**5. Key indications for emergent surgical intervention vs. medical (antihypertensive) management**\n\n| Situation | Preferred Management | Why |\n|-----------|----------------------|-----|\n| **Ascending aortic involvement (Stanford A / DeBakey I‑II)** | **Urgent surgical repair** (open graft replacement ± aortic valve repair/replacement). | Mortality rises ~1–2 % per hour without surgery; risk of cardiac tamponade, aortic regurgitation, coronary artery involvement, stroke, or rupture. |\n| **Complications requiring surgery** | • **Cardiac tamponade** (pericardial effusion with hemodynamic compromise) <br>• **Severe aortic regurgitation** (new diastolic murmur, heart failure) <br>• **Myocardial ischemia** from coronary artery extension <br>• **Stroke or neurologic deficit** from carotid involvement <br>• **Extensive branch vessel occlusion** causing limb or visceral ischemia <br>• **Rapid aortic expansion** (>5 mm in 24 h) or **diameter > 5.5–6 cm** (if chronic component) | These are life‑threatening sequelae that cannot be controlled medically. |\n| **Isolated descending aortic dissection (Stanford B / DeBakey III)** | **Initial medical therapy** (β‑blocker + vasodilator) unless complications develop. | Mortality lower; most can be managed medically with strict BP control. |\n| **Complicated Stanford B** (e.g., malperfusion, uncontrolled pain/HTN, expanding aneurysm, rupture) | **Endovascular repair** (TEVAR) or open surgery if anatomy unsuitable. | TEVAR quickly seals the entry tear, restores true lumen flow. |\n| **Contra‑indications to surgery** (e.g., prohibitive comorbidities, end‑stage organ failure) | **Best‑effort medical therapy** (palliative) | Risks of surgery outweigh benefits. |\n\n**In this particular case** – ascending aorta involvement, hypertension, early diastolic murmur suggesting aortic regurgitation, and a high‑risk profile – **emergent operative repair** is indicated. Medical therapy is still initiated **immediately** to bridge to the OR and to limit propagation, but definitive treatment is surgical.\n\n---\n\n### Quick “Cheat‑Sheet” for the ED", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 2 |
| }, |
| "notes": "Comprehensive, clinically accurate, and perfectly structured response. Standard of care for acute aortic dissection diagnosis and emergency management is flawlessly detailed." |
| } |
| }, |
| { |
| "id": 23, |
| "src_id": "Guidelines QA:98506", |
| "subset": "Guidelines QA", |
| "question": "A 62‑year‑old woman tests negative for hepatitis C antibody. Which of the following is true about her result?\nA) She should undergo a hepatitis C RNA test to confirm the negative result.\nB) She is considered not infected unless she has ongoing high‑risk exposures.\nC) She must be retested in 6 months regardless of risk.\nD) She should be referred for liver transplantation evaluation.", |
| "answer": "A negative antibody test in an immunocompetent individual without recent high‑risk exposure indicates no infection, and no further testing is required. Answer: B", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 2 |
| }, |
| "notes": "Accurate, concise, and clinically sound explanation identifying the correct answer according to standard hepatitis C screening guidelines." |
| } |
| }, |
| { |
| "id": 24, |
| "src_id": "Guidelines QA:16716", |
| "subset": "Guidelines QA", |
| "question": "A 12‑year‑old boy (weight 45 kg) is being treated for sinusitis. Which dosing regimen follows the guideline?\nA) 7.5 mg/kg orally every 12 hours for 10 days, not exceeding 1 g/day \nB) 15 mg/kg orally every 12 hours for 5 days, not exceeding 1 g/day \nC) 20 mg/kg orally every 24 hours for 10 days, not exceeding 1 g/day \nD) 250 mg orally every 12 hours for 7 days", |
| "answer": "Pediatric sinusitis dosing is 7.5–15 mg/kg twice daily for 10 days, with a ceiling of 1 g/day. The lower end (7.5 mg/kg) meets the guideline and stays under the ceiling. Answer: A", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 2 |
| }, |
| "notes": "The answer correctly identifies the standard dosing regimen and duration for pediatric sinusitis according to established clinical guidelines." |
| } |
| }, |
| { |
| "id": 25, |
| "src_id": "Synthetic QA:121375", |
| "subset": "Synthetic QA", |
| "question": "Which of the following is the most appropriate initial pharmacologic therapy for a patient with newly diagnosed moderate persistent asthma (requiring step 3 treatment according to GINA guidelines) who has no contraindications to inhaled corticosteroids?\n\nA. Short‑acting β2‑agonist (SABA) as needed only \nB. Low‑dose inhaled corticosteroid (ICS) + long‑acting β2‑agonist (LABA) combination inhaler \nC. Low‑dose inhaled corticosteroid (ICS) alone \nD. Oral leukotriene receptor antagonist (LTRA) monotherapy", |
| "answer": "**Answer: B. Low‑dose inhaled corticosteroid (ICS) + long‑acting β2‑agonist (LABA) combination inhaler** \n\n**Explanation**\n\n- The Global Initiative for Asthma (GINA) 2024 update classifies “moderate persistent” asthma as requiring step 3 therapy. \n- Step 3 is achieved with either **low‑dose ICS + LABA** or **medium‑dose ICS** as the preferred options. \n- A low‑dose ICS + LABA combination provides better symptom control, reduces exacerbations, and improves lung function compared with increasing the ICS dose alone, while maintaining a lower overall corticosteroid exposure. \n- Option A (SABA alone) is insufficient for persistent disease and is now recommended only as a reliever, not as maintenance. \n- Option C (ICS alone) at low dose does not meet step 3 requirements; a medium‑dose ICS would be needed, but the combination therapy is generally preferred because of its superior efficacy and safety profile. \n- Option D (LTRA monotherapy) is considered a step 2 or add‑on option, not first‑line step 3 therapy, and is less effective than an ICS‑containing regimen. \n\nTherefore, the most appropriate initial pharmacologic choice for this patient is a **low‑dose inhaled corticosteroid combined with a long‑acting β2‑agonist**.", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 2 |
| }, |
| "notes": "Accurate, clear, and well-explained answer aligned with current GINA Step 3 asthma management guidelines." |
| } |
| }, |
| { |
| "id": 26, |
| "src_id": "Synthetic MOOVE:7141", |
| "subset": "Synthetic MOOVE", |
| "question": "I am a junior neurologist covering the night shift at a tertiary care center. A 45-year-old woman is brought in by ambulance with sudden onset of severe, throbbing headache that began 2 hours ago while she was at work. She describes the pain as “the worst headache of my life,” localized to the bilateral occipital region, and is associated with nausea, vomiting, and photophobia. She has no focal neurological deficits on examination; cranial nerves are intact, motor strength is 5/5 in all extremities, and sensation is normal. Fundoscopic examination reveals bilateral papilledema. Her past medical history is unremarkable, and she takes no medications. A non‑contrast head CT performed emergently shows a hyperdense, crescent‑shaped collection along the left frontal convexity with surrounding edema, suggestive of a subdural hematoma. There is no evidence of trauma. Laboratory studies are within normal limits, including coagulation profile.\n\nThe on‑call senior physician asks: \n1. What is the most likely diagnosis and underlying pathophysiology in this patient? \n2. What immediate investigations should be ordered to confirm the diagnosis and assess for complications? \n3. Outline the initial management steps, including any indications for surgical intervention, and discuss how you would communicate the situation to the patient and her family.\nPlease provide a concise, evidence‑based answer suitable for a bedside teaching scenario.", |
| "answer": "**1. Most likely diagnosis & pathophysiology** \n\n| Diagnosis | Why it fits the picture |\n|-----------|-------------------------|\n| **Acute non‑traumatic (spontaneous) sub‑dural hematoma (ASDH)** | • CT shows a hyper‑dense crescent‑shaped collection on the convexity – classic for an acute SDH.<br>• “Worst headache of my life”, nausea, vomiting and papilledema → rapid rise in intracranial pressure (ICP).<br>• No focal deficit yet – early stage of mass effect.<br>• No history of head trauma, but spontaneous SDH can occur from sudden rupture of **bridging veins** (often after a Valsalva‑type event, hypertension spike, or occult vascular lesion).<br>• Normal coagulation makes a primary coagulopathy‑related bleed unlikely. |\n\n**Pathophysiology (concise)** \n- **Bridging vein rupture** → blood accumulates in the sub‑dural space between dura and arachnoid. Because the sub‑dural space is a potential space, even a modest volume (≈30–40 mL) can produce a crescent‑shaped collection that conforms to the convexity. \n- **Rapid accumulation** → abrupt increase in ICP → headache, nausea, papilledema. \n- **Secondary mass effect** (edema, mid‑line shift) can quickly compromise cerebral perfusion, producing loss of consciousness or focal deficits if untreated. \n\n*Note:* In a minority of cases the SDH is secondary to a ruptured **intracranial aneurysm** or **cerebral amyloid angiopathy**; therefore a vascular work‑up is essential.\n\n---\n\n**2. Immediate investigations** \n\n| Goal | Test | Rationale / What it tells you |\n|------|------|------------------------------|\n| **Confirm/characterize the bleed** | **Non‑contrast CT (already done)** | Determines acute vs chronic, thickness, midline shift, edema. |\n| **Identify a source (aneurysm, AVM, tumor)** | **CT‑angiography (CTA) of head** (or MR‑angiography if CTA unavailable) | Detects ruptured aneurysm, arteriovenous malformation, dural AV fistula that can cause a “spontaneous” SDH. |\n| **Assess for additional hemorrhage (SAH) or venous thrombosis** | **MRI brain with susceptibility‑weighted imaging (SWI) & FLAIR** (if patient stable) | SWI is sensitive for tiny blood products; FLAIR can show SAH in sulci. |\n| **Rule out venous sinus thrombosis (often mimics thunder‑clap headache)** | **MR venography (MRV) or CT venography (CTV)** | Especially if CTA negative and clinical suspicion remains. |\n| **Baseline labs for peri‑operative safety** | CBC, BMP, coag profile (PT/INR, aPTT, platelet count), type & screen | Even though initial labs are normal, repeat to catch evolving coagulopathy or anemia. |\n| **ICP/neurologic monitoring** | **ICP monitor** (if GCS ≤ 13 or radiologic signs of raised ICP) | Guides medical therapy and timing of surgery. |\n| **If CT had been negative for SAH but suspicion remained** | **Lumbar puncture** (xanthochromia) – *not needed here because CT already shows bleed.* |\n\n---\n\n**3. Initial management & surgical indications** \n\n### A. Stabilisation (ABCs) – bedside first \n\n| Step | Details |\n|------|---------|\n| **Airway & Breathing** | Ensure airway patency; give supplemental O₂ to keep SpO₂ > 94 %. Intubate only if GCS < 8 or airway compromise. |\n| **Circulation** | Maintain MAP ≈ 80–90 mm Hg (or SBP 120‑150 mm Hg) to preserve cerebral perfusion pressure (CPP = MAP‑ICP). Avoid hypotension (<90 mm Hg). |\n| **Rapid‑sequence analgesia/anti‑emesis** | IV fentanyl (1‑2 µg/kg) + ondansetron 4 mg. Avoid NSAIDs that impair platelet function. |\n| **ICP‑lowering measures** | • Head of bed 30°; • Avoid neck flexion/jugular compression; • Analgesia & sedation (propofol infusion if needed). |\n| **Hyperosmolar therapy** | Mannitol 0.25–1 g/kg IV bolus **or** 3 % hypertonic saline (2 mL/kg) – repeat if ICP remains >20 mm Hg. |\n| **Seizure prophylaxis** | Levetiracetam 500 mg IV (or 1 g if weight > 70 kg) then BID; continue for 3–7 days or until hematoma is evacuated. |\n| **Blood pressure control** | If hypertensive surge, nicardipine infusion titrated to SBP < 150 mm Hg. |\n| **Repeat neuro exam** | Every 15 min initially; document any decline (GCS, pupil size, new focal signs). |\n| **Neurosurgical consultation** – **immediate** (within minutes). |\n\n### B. Criteria that push toward **surgical evacuation** (burr‑hole or craniotomy) \n\n| Radiologic / Clinical trigger | Typical threshold |\n|-------------------------------|-------------------|\n| **Hematoma thickness** | > 10 mm (or > 5 mm if rapid expansion on repeat scan). |\n| **Midline shift** | > 5 mm (or any shift with clinical deterioration). |\n| **Neurologic decline** | Decrease in GCS ≥ 2 points, new focal deficit, pupil asymmetry. |\n| **Refractory ICP** | ICP > 20–25 mm Hg despite optimal medical therapy. |\n| **Age > 65 yr or co‑morbidities** | Lower threshold for surgery because of poorer compensatory reserve. |\n| **Evidence of underlying vascular lesion** | Aneurysm or AVM → combined hematoma evacuation + definitive endovascular/surgical treatment. |\n\n*If none of the above are present and the patient remains neurologically stable, a trial of **conservative management** with close ICU monitoring and repeat CT at 6–12 h is acceptable.*\n\n### C. Post‑operative / conservative follow‑up \n\n- **ICU stay** until ICP, GCS, and repeat imaging are stable. \n- **Serial CT** at 6–12 h, then 24 h, then as clinically indicated. \n- **Re‑habilitation planning** if any deficits develop. \n- **Secondary prevention**: control hypertension, avoid anticoagulants/antiplatelets unless indicated, counsel on head‑injury avoidance.\n\n---\n\n**4. Communication strategy (patient‑centered)** \n\n| Audience | Key points & style |\n|----------|--------------------|\n| **Patient (if she is alert)** | • “You have a bleed that has collected between the coverings of your brain. It is causing the severe headache and the swelling we see on the eye exam.”<br>• “Because the blood is", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": -1 |
| }, |
| "notes": "Clarity & Completeness (-1): The response is truncated mid-sentence at the very end of section 4, leaving the communication section incomplete." |
| } |
| }, |
| { |
| "id": 27, |
| "src_id": "Synthetic QA:170693", |
| "subset": "Synthetic QA", |
| "question": "Which of the following is the most appropriate initial empiric antimicrobial therapy for an adult patient (≥18 years) presenting with suspected acute bacterial meningitis in a setting where *Streptococcus pneumoniae* and *Neisseria meningitidis* are the most likely pathogens and there is no known meningococcal outbreak? \nA. Ceftriaxone + vancomycin \nB. Ampicillin + ceftriaxone + vancomycin \nC. Cefotaxime + vancomycin + acyclovir \nD. Meropenem + vancomycin \nE. Ceftriaxone + dexamethasone only", |
| "answer": "<answer>**Answer: A. Ceftriaxone + vancomycin** \n\n**Explanation**\n\nAcute bacterial meningitis in immunocompetent adults most commonly results from *Streptococcus pneumoniae* and *Neisseria meningitidis*. Empiric therapy must provide rapid, high‑level central nervous system (CNS) penetration and cover potential resistant strains.\n\n| Reason | Details |\n|--------|---------|\n| **Ceftriaxone (or cefotaxime)** | Third‑generation cephalosporins achieve excellent CSF concentrations and reliably cover *Neisseria meningitidis* and most *Streptococcus pneumoniae* strains. |\n| **Vancomycin** | Added to address the growing prevalence of penicillin‑ and cephalosporin‑resistant *Streptococcus pneumoniae*. Vancomycin penetrates the inflamed meninges sufficiently when used with a β‑lactam. |\n| **Why not option B (ampicillin added)?** | Ampicillin is required when *Listeria monocytogenes* is a concern (e.g., patients >50 years, immunocompromised, or pregnant). In a typical healthy adult without those risk factors, ampicillin is unnecessary. |\n| **Why not option C (acyclovir)?** | Acyclovir is added only when viral encephalitis (especially HSV) is in the differential. In pure bacterial meningitis suspicion, it is not part of the initial regimen. |\n| **Why not option D (meropenem)?** | Meropenem is reserved for nosocomial or healthcare‑associated meningitis, or for patients allergic to β‑lactams. It is broader than needed for community‑acquired disease. |\n| **Why not option E (dexamethasone only)?** | Dexamethasone is an adjunct that reduces inflammatory complications (e.g., hearing loss) when given before or with the first antibiotic dose, but it does **not** have antimicrobial activity and cannot replace antibiotics. |\n\n**Key point:** The recommended empiric regimen for community‑acquired bacterial meningitis in adults (without specific risk factors for *Listeria* or *Pseudomonas*) is a third‑generation cephalosporin **plus** vancomycin, with dexamethasone administered concurrently if *Streptococcus pneumoniae* is a likely pathogen. \n\n**Therefore, the correct answer is A.**", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 2 |
| }, |
| "notes": "Excellent response. Accurately identifies ceftriaxone plus vancomycin as the standard empiric regimen for standard community-acquired bacterial meningitis in adults and provides clear, correct justifications for ruling out the other options." |
| } |
| }, |
| { |
| "id": 28, |
| "src_id": "Synthetic MOOVE:10299", |
| "subset": "Synthetic MOOVE", |
| "question": "I am a family physician in a rural clinic in New Zealand. A 58‑year‑old woman presents with a 3‑week history of gradual onset of dull, aching pain in the right hip that worsens with weight bearing and improves with rest. She denies any recent trauma, fever, or constitutional symptoms. Her past medical history includes osteoarthritis of the knees and a hysterectomy 10 years ago. On examination, there is limited active and passive flexion of the right hip due to pain, but no swelling, erythema, or warmth. The gait is antalgic, and neurovascular examination of the lower limb is normal. Plain radiographs of the pelvis show mild joint space narrowing but no obvious fracture or erosive changes. Laboratory tests reveal a normal complete blood count, ESR 22 mm/h (reference < 20), CRP 5 mg/L (reference < 5), and calcium, phosphate, and vitamin D levels within normal limits. \n\nConsidering the clinical picture and initial work‑up, what are the most likely differential diagnoses, which additional investigations would you order to narrow the diagnosis, and what would be the appropriate initial management plan?", |
| "answer": "**1. Most likely diagnoses (clinical picture + initial work‑up)** \n\n| Category | Specific entities | Why they fit the picture | “Red‑flag” features that would argue against them |\n|----------|-------------------|--------------------------|---------------------------------------------------|\n| **Degenerative / Mechanical** | • Primary hip osteoarthritis (early) <br>• Trochanteric (greater‑trochanter) bursitis <br>• Gluteus medius/minimus tendinopathy (hip abductor tendinopathy) <br>• Femoro‑acetabular impingement (FAI) <br>• Iliopsoas bursitis | • Age > 50, gradual dull ache that worsens with weight‑bearing and improves with rest. <br>• Plain film shows only mild joint‑space narrowing (early OA). <br>• No systemic signs. | • Marked night pain, severe limp, rapid progression would be atypical for early OA. |\n| **Ischemic / Metabolic** | • Early avascular necrosis (AVN) of the femoral head <br>• Transient osteoporosis of the hip (TOH) <br>• Stress (insufficiency) fracture of the femoral neck | • Pain on weight‑bearing, often with limited ROM, but plain X‑ray may be normal early. <br>• ESR/CRP are usually normal (as seen). | • History of high‑dose steroids, alcohol excess, or sickle‑cell disease would push AVN higher; none present. |\n| **Inflammatory / Infectious** | • Early inflammatory arthropathy (e.g., rheumatoid arthritis, psoriatic arthritis) <br>• Septic arthritis / sub‑acute osteomyelitis <br>• Metastatic bone disease | • Can present with hip pain before obvious radiographic changes. | • Fever, warmth, swelling, markedly raised ESR/CRP – absent. |\n| **Referred pain** | • Lumbar spine degenerative disease (facet or disc) <br>• Sacroiliac joint dysfunction | • May cause hip‑region pain, especially with limited hip flexion. | • Back pain, radicular symptoms, positive straight‑leg raise – not reported. |\n| **Other** | • Pelvic or proximal femur malignancy (primary bone tumour, metastatic) | • Can present with dull ache, normal labs early. | • Systemic symptoms, weight loss, abnormal labs – absent. |\n\n**Top three “most likely” in this patient** \n\n1. **Early primary hip osteoarthritis** – the only abnormality on plain film is mild joint‑space narrowing; age and mechanical pain pattern fit. \n2. **Early avascular necrosis (AVN) of the femoral head** – can be occult on X‑ray for up to 2–3 months; pain is weight‑bearing, night‑time pain may be present (not reported but must be ruled out). \n3. **Trochanteric (greater‑trochanter) bursitis / hip abductor tendinopathy** – common in middle‑aged women, pain worsens with walking, limited hip flexion due to pain, often no radiographic change.\n\n(Transient osteoporosis and stress fracture are also on the differential and should be actively excluded because they may require protected weight‑bearing.)\n\n---\n\n**2. Additional investigations to narrow the diagnosis**\n\n| Investigation | What it detects / why ordered | Practical notes for a rural setting |\n|---------------|------------------------------|--------------------------------------|\n| **MRI of the right hip (hip‑specific protocol, T1, T2‑fat‑sat, STIR, and post‑gadolinium if needed)** | • Highly sensitive for early AVN (double‑line sign) <br>• Detects occult femoral‑neck stress fracture <br>• Shows marrow oedema of transient osteoporosis <br>• Can demonstrate trochanteric bursitis, tendinopathy, early OA changes | MRI is the single best next test. If not available locally, arrange transfer to the nearest tertiary centre (e.g., Dunedin Hospital) – aim for imaging within 1 week because AVN or fracture may need urgent orthopaedic input. |\n| **Hip ultrasound (with Doppler)** | • Evaluates for trochanteric bursitis, iliopsoas bursitis, fluid collection, or rotator‑type tendinopathy <br>• Can guide a therapeutic steroid injection if bursitis is confirmed | Portable; can be performed in‑clinic by a trained GP or sonographer. |\n| **Bone scan (Tc‑99m) or SPECT‑CT** (if MRI unavailable) | • Sensitive for increased bone turnover – picks up stress fracture, AVN, or metastatic disease <br>• Less specific than MRI | Useful when MRI is delayed; however, bone scan may be normal in early AVN. |\n| **Repeat AP pelvis + lateral (frog‑leg) view** | • May reveal subtle sub‑chondral lucency or early collapse not seen on the first film | Simple, can be done locally; repeat if the first film was suboptimal. |\n| **Laboratory panel (if not already done)** | • Rheumatoid factor, anti‑CCP, ANA – if inflammatory arthritis becomes a consideration <br>• Full metabolic panel (including alkaline phosphatase) – if metabolic bone disease suspected <br>• Urine Bence‑Jones protein – if multiple myeloma is in the back‑of‑mind (rare) | These are low‑cost and can be drawn at the same visit. |\n| **Lumbar spine X‑ray (AP & lateral) or MRI of lumbar spine (if pain radiates to back)** | • To rule out lumbar radiculopathy or facet disease that can mimic hip pain | Only if clinical history suggests back involvement (e.g., morning stiffness, radicular pattern). |\n\n**Prioritisation (rural workflow)** \n\n1. **Hip MRI** – arrange urgent referral/transfer. \n2. **If MRI cannot be obtained within 10 days**, obtain a **bone scan** and **hip ultrasound** (the latter can be done locally). \n3. **Repeat plain films** (frog‑leg lateral) while awaiting advanced imaging. \n4. **Blood tests** (RF, anti‑CCP, ANA) can be sent concurrently – results will guide later if inflammatory disease emerges.\n\n---\n\n**3. Initial management while investigations are pending**\n\n| Intervention | Rationale | Practical tips for a rural clinic |\n|--------------|-----------|-----------------------------------|\n| **Analgesia / NSAID therapy** (e.g., ibuprofen 400 mg TID or naproxen 500 mg BID, unless contraindicated) | Controls pain and inflammation; safe first‑line for mechanical hip pain. | Counsel about GI protection (PPIs) if > 65 y or ulcer risk; ensure renal function is acceptable. |\n| **Activity modification** – avoid prolonged weight‑bearing, limit stair climbing, use a cane or walking stick on the right side | Reduces mechanical stress on the hip while preserving mobility. | Provide a sturdy walking aid (can be sourced from community health services). |\n| **Physiotherapy referral** – focus on gentle range‑of‑motion (ROM) exercises, hip abductors and extensors strengthening, core stability, and gait training | Improves muscular support around the hip, may relieve bursitis/abductor tendinopathy and delay OA progression. | If a physiotherapist is not on‑site, arrange a tele‑rehab session or give a home‑exercise sheet (e.g., side‑lying hip abduction, supine bridges, seated hip flexor stretch). |\n| **Heat/Cold therapy** – intermittent ice packs after activity, warm packs to relax muscles | Simple adjunct for pain control. | Instruct patient on safe use (no ice > 20 min, wrap in cloth). |\n| **Education & safety** – advise on fall‑prevention, proper footwear, and to avoid high‑impact activities (running, jumping) until a definitive diagnosis is made. | Prevents secondary injury if a fracture or AVN is present. | Provide written handout; discuss with family. |\n| **Consider a diagnostic/therapeutic intra‑articular steroid injection** *only if*: <br>• MRI later rules", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 1, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": -1 |
| }, |
| "notes": "Clarity & Completeness (-1): The response truncates mid-sentence at the end. Clinical Soundness (+1): Instructing the patient to use a cane on the ipsilateral (right) side is incorrect; it should be used in the contralateral (left) hand to offload the hip." |
| } |
| }, |
| { |
| "id": 29, |
| "src_id": "Synthetic QA:162552", |
| "subset": "Synthetic QA", |
| "question": "A 58‑year‑old man presents to the emergency department with sudden onset of severe, tearing chest pain radiating to his back. He reports a history of hypertension and smoking. On examination, his blood pressure is 180/100 mmHg in the right arm and 140/80 mmHg in the left arm; a new diastolic murmur is heard at the left sternal border. An emergent CT angiogram of the chest shows an intimal flap in the ascending aorta extending into the aortic arch. Which of the following is the most appropriate initial management step for this patient?\n\nA. Immediate administration of intravenous beta‑blocker therapy \nB. Emergent surgical repair of the ascending aorta \nC. Initiation of intravenous nitroprusside infusion \nD. Endovascular stent placement in the aortic arch \nE. Observation in the intensive care unit with serial imaging", |
| "answer": "The presentation is classic for an acute type A aortic dissection (ascending aorta involvement). Type A dissections are surgical emergencies because they carry a high risk of complications such as aortic valve insufficiency, cardiac tamponade, and rupture. The first priority after diagnosis is to **stabilize the patient hemodynamically** while arranging for emergent operative repair.\n\n**Step‑wise initial management**\n\n1. **Control heart rate and blood pressure** to reduce shear stress on the aortic wall. \n * **IV beta‑blockers** (e.g., esmolol, labetalol) are given first to lower the heart rate to ≤ 60 beats/min. \n * Only after the heart rate is controlled should vasodilators (e.g., nitroprusside) be added if further blood‑pressure reduction is needed.\n\n2. **Arrange emergent surgical repair** of the ascending aorta as definitive therapy.\n\nTherefore, the most appropriate *initial* management step is the **immediate administration of an intravenous beta‑blocker** to achieve rapid heart‑rate control while preparing for surgery.\n\n**Correct answer: A. Immediate administration of intravenous beta‑blocker therapy**\n\n**Why the other options are incorrect**\n\n- **B. Emergent surgical repair of the ascending aorta** – This is the definitive treatment, but it follows rapid hemodynamic stabilization; surgery cannot be performed safely while the patient remains hypertensive and tachycardic. \n- **C. Initiation of intravenous nitroprusside infusion** – Nitroprusside is a potent vasodilator that can cause reflex tachycardia, worsening shear stress unless the heart rate is already controlled with a beta‑blocker. It is added *after* beta‑blockade if needed. \n- **D. Endovascular stent placement in the aortic arch** – Endovascular repair is generally reserved for type B dissections (distal to the left subclavian) and is not the standard of care for an ascending aortic (type A) dissection. \n- **E. Observation in the intensive care unit with serial imaging** – Observation alone is inappropriate for a type A dissection, which has a mortality rate of > 50 % within 48 hours without surgery. \n\nIn summary, rapid IV beta‑blockade is the first critical step, followed promptly by surgical repair.", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 2 |
| }, |
| "notes": "Excellent explanation. Accurately identifies anti-impulse therapy with IV beta-blockers as the immediate initial medical step before surgical repair for Type A aortic dissection, explaining the rationale clearly and distinguishing it from definitive surgical management." |
| } |
| }, |
| { |
| "id": 30, |
| "src_id": "Synthetic QA:157673", |
| "subset": "Synthetic QA", |
| "question": "A 58‑year‑old man presents with progressive exertional dyspnea, dry cough, and digital clubbing. High‑resolution CT of the chest shows diffuse subpleural reticulation with honey‑comb formation, predominantly in the lower lobes. Which of the following is the most likely underlying histopathologic pattern?\n\nA. Diffuse alveolar damage \nB. Usual interstitial pneumonia (UIP) \nC. Nonspecific interstitial pneumonia (NSIP) \nD. Organizing pneumonia (OP)", |
| "answer": "**Answer: B. Usual interstitial pneumonia (UIP)** \n\n**Explanation**\n\nThe clinical picture (older male, insidious dyspnea, dry cough, digital clubbing) together with HRCT findings of **subpleural basal reticulation and honey‑comb cysts** is classic for **idiopathic pulmonary fibrosis (IPF)**. The histopathologic correlate of IPF is the **usual interstitial pneumonia (UIP) pattern**.\n\n**Why the other options are less appropriate**\n\n* **A. Diffuse alveolar damage** – This is the histologic hallmark of acute respiratory distress syndrome (ARDS). It shows hyaline membranes and interstitial edema, not the chronic fibrotic changes seen on HRCT.\n\n* **C. Nonspecific interstitial pneumonia (NSIP)** – NSIP typically presents with ground‑glass opacities and fine reticulation, often with a more uniform appearance and less pronounced honey‑comb change. It is more common in connective‑tissue disease and younger patients.\n\n* **D. Organizing pneumonia (OP)** – OP (formerly BOOP) shows patchy consolidations and peripheral “mass‑like” opacities on imaging and histologically features intra‑alveolar granulation tissue plugs (Masson bodies). It does not produce the classic basal honey‑comb pattern.\n\nTherefore, the combination of clinical features and imaging most strongly points to a UIP pattern, the histologic substrate of idiopathic pulmonary fibrosis.", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 2 |
| }, |
| "notes": "Excellent explanation. Accurately identifies Usual Interstitial Pneumonia (UIP) based on classic HRCT and clinical findings, and correctly differentiates it from the other interstitial lung disease patterns." |
| } |
| }, |
| { |
| "id": 31, |
| "src_id": "Synthetic MOOVE:4487", |
| "subset": "Synthetic MOOVE", |
| "question": "A 55-year-old man presents to the emergency department with sudden onset of severe, tearing chest pain radiating to his back, accompanied by shortness of breath and diaphoresis. He describes the pain as constant and “like a belt tightening” around his chest. He has a history of hypertension, chronic smoking (30 pack‑years), and hyperlipidemia, for which he takes amlodipine and simvastatin. On arrival, his blood pressure is 190/110 mm Hg in the right arm and 140/85 mm Hg in the left arm; heart rate is 112 bpm, respiratory rate 24/min, and oxygen saturation 96% on room air. Physical examination reveals a faint diastolic murmur best heard at the left sternal border and a subtle pulsatile abdominal mass. An ECG shows sinus tachycardia without ischemic changes. Bedside transthoracic echocardiography demonstrates a dilated ascending aorta with an intimal flap extending into the descending thoracic aorta. Laboratory tests are pending.\n\nGiven this presentation, what is the most likely diagnosis, what immediate management steps should be taken in the emergency setting, and what definitive treatment is required?", |
| "answer": "**Most likely diagnosis** \n- **Acute Stanford‑type A aortic dissection** (intimal tear involving the ascending aorta and extending distally into the descending thoracic aorta). \n - Classic “tearing” chest pain radiating to the back, blood‑pressure differential between arms, new diastolic murmur (aortic regurgitation from root involvement), and a pulsatile abdominal mass (possible extension into the abdominal aorta) all point to this life‑threatening entity.\n\n---\n\n## Immediate (Emergency‑Department) Management \n\nThe goal in the first minutes is to **halt propagation of the dissection, prevent rupture, and keep the patient stable enough to get definitive imaging and surgery**. The steps are performed in parallel and should not be delayed for any single component.\n\n| Step | What to do | Why / Target |\n|------|------------|--------------|\n| **1. Rapid assessment & monitoring** | • 2 large‑bore IV lines<br>• Continuous ECG, arterial line (if possible) for real‑time BP<br>• Pulse oximetry, capnography (if intubated) | Allows immediate titration of drugs and detection of hemodynamic collapse. |\n| **2. Analgesia** | • IV morphine (2–4 mg, repeat q5‑10 min) or fentanyl as alternative.<br>• Consider low‑dose ketamine only if opioid‑refractory. | Pain‑induced sympathetic surge raises HR and BP; analgesia helps lower both. |\n| **3. Heart‑rate control (first priority)** | • IV β‑blocker: **Esmolol** 0.5 mg/kg bolus (≈30 mg) → infusion 50‑200 µg/kg/min, titrate to HR < 60 bpm.<br>• If esmolol contraindicated, use **IV labetalol** (20 mg bolus, repeat q10 min up to 300 mg) or **nicardipine** (after β‑blockade). | Reducing shear stress (HR < 60 bpm) is more important than BP alone; β‑blockade first prevents reflex tachycardia from vasodilators. |\n| **4. Blood‑pressure reduction (after HR control)** | • Add **IV nitroprusside** (0.3‑10 µg/kg/min) *or* **IV nicardipine** (5‑15 µg/kg/min) to achieve **SBP 100‑120 mm Hg** (MAP ≈ 65‑80 mm Hg).<br>• Aim for a gradual reduction (no > 20 % drop in first 10 min). | Lowering transmural pressure limits extension/rupture of the false lumen. |\n| **5. Anticoagulation & antiplatelet avoidance** | • Do **not** give heparin, aspirin, or thrombolytics. | They can worsen bleeding into the false lumen or precipitate rupture. |\n| **6. Imaging to confirm anatomy (while medical therapy is ongoing)** | • **CT‑angiography of the chest, abdomen, and pelvis** (preferred if patient is hemodynamically stable and contrast‑compatible).<br>• If CT unavailable or patient unstable: **Trans‑esophageal echoc‑ography (TEE)** or **MRI** (if time permits). | Precise delineation of the entry tear, extent of dissection, branch involvement, and presence of complications (pericardial effusion, tamponade, coronary involvement). |\n| **7. Prepare for emergent surgery** | • Call cardiothoracic surgery **immediately**.<br>• Keep patient **NPO**, insert a Foley catheter, obtain baseline labs (CBC, CMP, coagulation profile, type & screen), and cross‑match blood.<br>• Consider central line for rapid volume/medication administration.<br>• If evidence of tamponade → pericardiocentesis as bridge to OR. | Type‑A dissections are surgical emergencies; early operative referral improves survival. |\n| **8. Supportive measures** | • Supplemental O₂ to keep SpO₂ > 94 % (though his baseline is 96 %).<br>• Consider mild sedation (e.g., low‑dose propofol) to reduce anxiety‑driven catecholamine surge, while maintaining spontaneous ventilation.<br>• Treat underlying hypertension chronically after acute phase (e.g., oral β‑blocker, ACE‑I/ARB). | Stabilizes the patient and prevents secondary injury. |\n\n**Key “time‑critical” points**\n\n- **β‑blockade first**, then vasodilator; never give vasodilator alone (risk of reflex tachycardia ↑ shear stress). \n- Target **HR < 60 bpm**, **SBP 100‑120 mm Hg** (or MAP 65‑80). \n- **Analgesia** is not optional—it directly lowers sympathetic drive. \n- **Do not start anticoagulation** or thrombolysis under any circumstance. \n- **Surgical consultation** must be placed **before** imaging is completed; imaging is to guide the surgeon, not to decide whether to operate.\n\n---\n\n## Definitive Treatment \n\n| Dissection type | Definitive therapy | Typical procedure |\n|-----------------|--------------------|-------------------|\n| **Stanford type A** (involves ascending aorta ± arch) | **Urgent open surgical repair** (within hours of presentation). | • Median sternotomy<br>• Cardiopulmonary bypass with deep hypothermic circulatory arrest (if arch involvement).<br>• Resection of the intimal tear and replacement of the diseased segment with a Dacron graft (ascending aortic graft ± hemi‑arch or total arch replacement as required).<br>• Concomitant aortic valve repair/replacement if severe AR is present. |\n| Stanford type B (descending only) | Usually **medical management** (β‑blocker + BP control) unless complications (malperfusion, rupture, uncontrolled pain, expansion). | • Endovascular thoracic aortic stent‑graft (TEVAR) for complicated type B. |\n\nBecause the echo already shows an intimal flap in the **ascending aorta**, the patient meets criteria for **type A** dissection, and **emergent open surgical repair** is the definitive, life‑saving treatment.\n\n---\n\n### Quick “cheat‑sheet” for the ED team \n\n1. **Pain → morphine** \n2. **HR → esmolol** (target < 60) \n3. **BP → nitroprusside/nicardipine** (target SBP 100‑120) \n4. **Imaging** (CT‑angio or TEE) **while** meds are running \n5. **Call cardiothoracic surgery** – OR within 4‑6 h \n6. **No anticoag/antiplatelet, no thrombolysis** \n\nFollowing this algorithm dramatically reduces the 30‑day mortality of acute type‑A aortic dissection (from > 50 % untreated to < 10 % with rapid surgery).", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 2 |
| }, |
| "notes": "Excellent, highly accurate, and comprehensive response. Correctly identifies Stanford Type A aortic dissection, emphasizes beta-blockade prior to vasodilators, provides precise hemodynamic targets, and highlights urgent surgical management appropriately." |
| } |
| }, |
| { |
| "id": 32, |
| "src_id": "Guidelines QA:114227", |
| "subset": "Guidelines QA", |
| "question": "A community nurse is planning staff education for a residential care home. Which of the following components is required by the guideline for dementia‑specific training?\nA) Detailed instruction on the pharmacokinetics of all antipsychotics \nB) A single 30‑minute lecture on dementia prevalence statistics \nC) Training on person‑centred care, communication adaptations, and managing agitation, pain, and distress, with follow‑up feedback sessions \nD) Mandatory certification in neurology for all care staff \nE) Training exclusively on legal aspects of the Mental Capacity Act", |
| "answer": "The guideline specifies that staff training should include person‑centred care, understanding dementia signs, communication, managing agitation, pain, and distress, with follow‑up feedback and mentoring. The other options are either too narrow or unnecessary. Answer: C", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 2 |
| }, |
| "notes": "The response accurately identifies the correct option (C) and provides a clear, medically appropriate rationale aligned with clinical guidelines for dementia care training." |
| } |
| }, |
| { |
| "id": 33, |
| "src_id": "Guidelines QA:92767", |
| "subset": "Guidelines QA", |
| "question": "A 78‑year‑old resident in a nursing home shows signs of depression. Non‑pharmacological interventions have been tried without success. Which medication choice aligns with the guideline’s safety considerations?\nA) Tricyclic antidepressant with strong anticholinergic effects \nB) Selective serotonin reuptake inhibitor (SSRI) without anticholinergic properties \nC) Monoamine oxidase inhibitor requiring dietary restrictions \nD) High‑dose methylphenidate for rapid effect", |
| "answer": "The guideline recommends using antidepressants that lack anticholinergic activity to avoid worsening cognition; SSRIs meet this criterion. Answer: B", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 2 |
| }, |
| "notes": "Accurate and concise explanation. Correctly identifies SSRIs as the safest option in elderly patients to avoid anticholinergic cognitive side effects." |
| } |
| }, |
| { |
| "id": 34, |
| "src_id": "Synthetic MOOVE:13694", |
| "subset": "Synthetic MOOVE", |
| "question": "I am a resident physician in the emergency department of a tertiary care hospital in Zurich. A 58‑year‑old male presents with acute onset of severe, tearing chest pain radiating to the back, accompanied by diaphoresis and mild shortness of breath. He reports a history of hypertension, for which he takes amlodipine 10 mg daily, and a 30‑pack‑year smoking history (1 pack/day). Vital signs on arrival: BP 190/110 mmHg (right arm), 170/100 mmHg (left arm), HR 112 bpm, RR 22/min, SpO₂ 96% on room air, temperature 36.8 °C. Physical examination reveals a new diastolic murmur best heard at the left sternal border and a faint left‑sided pleural rub. ECG shows sinus tachycardia without ischemic changes. Bedside transthoracic echocardiography is limited but suggests a possible aortic root dilatation. Laboratory tests are pending.\n\nWhat is the most appropriate next step in the acute management of this patient? Provide a concise answer.", |
| "answer": "Begin immediate IV blood‑pressure/heart‑rate control – give a rapid‑acting β‑blocker (e.g., esmolol or labetalol) to lower the HR to < 60 bpm and SBP to ≈ 100–120 mm Hg, then proceed with definitive imaging.", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 2 |
| }, |
| "notes": "Excellent, concise management strategy for suspected acute aortic dissection. Correctly prioritizes heart rate and blood pressure control with IV beta-blockers before or alongside definitive imaging." |
| } |
| }, |
| { |
| "id": 35, |
| "src_id": "Synthetic MOOVE:8088", |
| "subset": "Synthetic MOOVE", |
| "question": "I am a primary care physician in a community clinic in Zurich. A 58‑year‑old male presents with progressive dyspnea on exertion over the past 3 months, intermittent dry cough, and recent unintentional weight loss of 5 kg. He has a 30‑pack‑year smoking history (quit 5 years ago) and a known history of hypertension. Physical examination reveals digital clubbing, bibasilar crackles, and a loud P2 heart sound. A chest X‑ray shows bilateral reticular infiltrates with honey‑comb pattern predominately in the lower lobes. The patient’s pulmonary function tests show a restrictive pattern with reduced DLCO. What is the most likely diagnosis, what further diagnostic step is recommended to confirm it, and what initial management should be considered? Please give me a brief answer.", |
| "answer": "**Most likely diagnosis** \n‑ Idiopathic pulmonary fibrosis (IPF) – a usual interstitial pneumonia pattern.\n\n**Next diagnostic step to confirm** \n‑ If a high‑resolution CT (HRCT) has not already been performed, obtain an HRCT of the chest; a typical basal‑predominant honey‑comb pattern on HRCT is diagnostic. \n‑ If the HRCT is indeterminate, a surgical (VATS) lung biopsy is recommended to confirm usual interstitial pneumonia.\n\n**Initial management** \n1. **Disease‑modifying therapy:** start an antifibrotic agent (nintedanib or pirfenidone) as early as possible. \n2. **Supportive care:** \n • Supplemental oxygen for desaturation or exertional dyspnoea. \n • Pulmonary rehabilitation. \n • Vaccinations (influenza, pneumococcal, COVID‑19). \n3. **Referral:** send the patient to a specialised interstitial lung disease centre for further evaluation and transplant assessment (especially given his age and disease progression). \n\nThese steps address diagnosis, confirmation, and the first‑line therapeutic approach for IPF.", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 2 |
| }, |
| "notes": "Excellent, concise, and clinically accurate response. Correctly identifies IPF, the requirement for HRCT/MDD before invasive biopsy, and appropriate initial management including antifibrotics and ILD referral." |
| } |
| }, |
| { |
| "id": 36, |
| "src_id": "Guidelines QA:22394", |
| "subset": "Guidelines QA", |
| "question": "A 60‑year‑old man under general anesthesia develops hypotension. The provider considers using ephedrine, but the patient’s chart notes a known allergy to sulfite preservatives. What should the provider do?\nA) Administer ephedrine because the allergy is irrelevant\nB) Use ephedrine after performing a skin test\nC) Choose an alternative vasopressor\nD) Dilute ephedrine with sterile water instead of saline", |
| "answer": "Allergy to sulfite preservatives contraindicates ephedrine use; an alternative vasopressor should be selected. Answer: C", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 2 |
| }, |
| "notes": "Accurate, clear, and clinically sound answer selecting the correct multiple-choice option with appropriate justification regarding sulfite preservative hypersensitivity." |
| } |
| }, |
| { |
| "id": 37, |
| "src_id": "Synthetic MOOVE:17074", |
| "subset": "Synthetic MOOVE", |
| "question": "A 55-year-old woman presents to the emergency department with a 2‑hour history of central chest pressure radiating to her left arm, associated with shortness of breath and diaphoresis. She describes the pain as a pressure-like sensation, rated 8/10, that began at rest while watching television. She has a past medical history of hypertension, dyslipidemia, and type 2 diabetes mellitus, and she is a current smoker (1 pack per day for 30 years). Her medications include amlodipine 10 mg daily, atorvastatin 40 mg nightly, and metformin 1000 mg twice daily. On examination, she is diaphoretic, blood pressure 150/90 mmHg, heart rate 98 bpm, respiratory rate 22/min, and oxygen saturation 96% on room air. Cardiac exam reveals a regular rhythm with no murmurs; lung fields are clear. ECG performed at bedside shows sinus rhythm with <1 mm ST‑segment depression in leads V4‑V6. Troponin I is pending.\n\nWhat is the most likely diagnosis? List the immediate next steps in management, including any pharmacologic agents, diagnostic tests, and disposition considerations. Additionally, outline the key secondary prevention measures that should be addressed before discharge if the diagnosis is confirmed.", |
| "answer": "**Most likely diagnosis** \nThe picture is classic for an **acute coronary syndrome** (ACS) with **non‑ST‑segment elevation myocardial infarction (NSTEMI)**:\n\n* Typical exertional‑at‑rest chest pressure radiating to the left arm, diaphoresis, dyspnea. \n* Multiple cardiovascular risk factors (HTN, dyslipidemia, DM, 30‑pack‑year smoker). \n* ECG: <1 mm horizontal ST‑segment depression in lateral leads (V4‑V6) – an ischemic change that, together with the clinical scenario, is enough to label the event “high‑risk unstable angina/NSTEMI” while we await a positive troponin. \n* Troponin I is pending – a positive result will confirm NSTEMI; a negative result with ongoing ischemic symptoms would still be managed as high‑risk unstable angina.\n\n---\n\n## Immediate next steps in the Emergency Department \n\n| Step | What to do | Rationale / Details |\n|------|------------|----------------------|\n| **1. Give **O₂** if SpO₂ < 94 %** | 2–4 L/min nasal cannula (or higher flow if needed) | Improves myocardial oxygen delivery; not required if O₂ ≥ 94 % (patient is 96 %). |\n| **2. **Aspirin** 162–325 mg PO (chewable)** | Give now, then 81 mg daily long‑term | Irreversibly inhibits platelet COX‑1 → early mortality benefit. |\n| **3. **P2Y12 inhibitor** (clopidogrel 300 mg PO loading, or ticagrelor 180 mg PO loading)** | Add to dual‑antiplatelet therapy (DAPT). Ticagrelor preferred in most NSTEMI unless contraindicated (bradycardia, AV block, severe asthma). | Further platelet inhibition; needed for at least 12 months. |\n| **4. **Anticoagulation** – UFH bolus 60 U/kg (max 4000 U) then infusion targeting aPTT 1.5–2× control **OR** enoxaparin 1 mg/kg SC q12 h (adjust for renal function) **OR** bivalirudin (if PCI planned and high bleeding risk). | Prevent propagation of thrombus while coronary anatomy is being defined. |\n| **5. **Nitroglycerin** 0.4 mg SL (repeat q5 min up to 3 doses) **or** IV nitro drip if persistent pain & BP allows** | Relieves ischemic pain & reduces preload/afterload. Watch for hypotension (SBP < 90 mmHg) and contraindications (phosphodiesterase‑5 inhibitor use). |\n| **6. **Morphine** 2–4 mg IV (optional, if pain persists after nitrates)** | Analgesia & reduces sympathetic drive; use judiciously (may delay absorption of antiplatelet agents). |\n| **7. **Beta‑blocker** (metoprolol tartrate 5 mg IV q5 min × 3, then PO 25–50 mg q6 h) **provided** no signs of heart failure, bradycardia, or hypotension** | Decreases myocardial O₂ demand; early IV use is recommended in NSTEMI unless contraindicated. |\n| **8. **High‑intensity statin** (atorvastatin 80 mg PO loading now)** | Early plaque‑stabilizing effect; improves outcomes. |\n| **9. **Serial ECGs** (every 15–30 min until stable, then at 1 h, 3 h, 6 h)** | Detect dynamic changes, evolving ST‑segment shifts, or new arrhythmias. |\n| **10. **Serial cardiac biomarkers** (troponin I/T at 0 h, 3 h, 6 h, then per protocol)** | Confirm myocardial necrosis and risk‑stratify. |\n| **11. **Risk stratification** – calculate TIMI and GRACE scores** | Guides intensity of early invasive strategy and ICU vs step‑down admission. |\n| **12. **Chest X‑ray** (optional) | Rule out alternative causes of dyspnea/ischemia (e.g., pneumothorax, aortic pathology). |\n| **13. **Laboratory work‑up** – CBC, BMP, coagulation profile, lipid panel, HbA1c, BNP** | Baseline for therapy adjustments. |\n| **14. **Disposition** – Admit to a monitored unit (Cardiac ICU or high‑acuity step‑down) for early invasive management** | NSTEMI patients with ongoing pain, ST depression, or high TIMI/GRACE scores should be taken for coronary angiography within 24 h (preferably <12 h). |\n\n### Summary of immediate pharmacologic “MONA‑B‑C” for NSTEMI\n| Medication | Dose (initial) | Timing |\n|------------|----------------|--------|\n| **M** – Morphine (if needed) | 2–4 mg IV q5–10 min PRN | After nitrates if pain persists |\n| **O** – Oxygen (if SpO₂ < 94 %) | 2–4 L/min nasal cannula | Immediate |\n| **N** – Nitroglycerin | 0.4 mg SL × 3, then IV if needed | Immediate |\n| **A** – Aspirin | 162–325 mg PO chewable | Immediate |\n| **B** – Beta‑blocker | Metoprolol 5 mg IV bolus (max 15 mg) | Within first hour if no CI |\n| **C** – Clopidogrel/Ticagrelor | Clopidogrel 300 mg PO (or ticagrelor 180 mg PO) | Immediate loading dose |\n| **Anticoag** – UFH/Enoxaparin/Bivalirudin | UFH 60 U/kg bolus → infusion | Immediate |\n\n---\n\n## If the diagnosis is confirmed (NSTEMI)\n\n### In‑hospital secondary‑prevention measures (to be instituted before discharge)\n\n| Domain | Intervention | Target / Details |\n|--------|---------------|-------------------|\n| **Antiplatelet therapy** | **Aspirin** 81 mg daily (indefinite) <br> **P2Y12 inhibitor** (clopidogrel 75 mg daily, ticagrelor 90 mg BID, or prasugrel 10 mg daily if PCI with stent) | Continue DAPT for **12 months** (longer if high‑risk or after complex PCI). |\n| **Lipid management** | **High‑intensity statin** (atorvastatin 80 mg or rosuvastatin 20–40 mg) – start now, continue lifelong. <br> Check LDL‑C in 4–6 weeks; goal **< 55 mg/dL** (or < 40 mg/dL if very high risk). <br> Add ezetimibe or PCSK9‑i if LDL goal not met. | Reduces recurrent events. |\n| **Blood pressure** | **ACE‑I or ARB** (e.g., lisinopril 10 mg daily) – start if SBP > 100 mmHg, especially if diabetes, LV dysfunction, or CKD. <br> Titrate to < 130/80 mmHg (or < 140/90 mmHg per latest guidelines). | Improves remodeling & outcomes. |\n| **Beta‑blocker** | Continue metoprolol succinate (or carvedilol) → target HR 55–60 bpm, unless contraindicated. | Reduces mortality & recurrent ischemia. |\n| **Diabetes control** | Optimize glycemic control (target HbA1c < 7 % in most adults). Consider SGLT2‑inhibitor or GLP‑1 RA", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 1, |
| "Safety": 1, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": -1 |
| }, |
| "notes": "Clarity & Completeness is -1 because the answer is cut off mid-sentence at the end. Note also that routine IV beta-blockers in ACS are generally no longer recommended over early oral dosing due to cardiogenic shock risks." |
| } |
| }, |
| { |
| "id": 38, |
| "src_id": "Guidelines QA:66641", |
| "subset": "Guidelines QA", |
| "question": "A patient who is switching from another oral contraceptive with a 28‑day cycle wants to start Kariva using a Sunday start. When should she take her first Kariva tablet?\nA) The day after finishing the active tablets of her previous contraceptive\nB) The first Sunday after the last inactive tablet of her previous regimen\nC) The second Sunday after the last active tablet of her previous regimen\nD) Immediately, regardless of the day of the week", |
| "answer": "For a Sunday start, the first Kariva tablet should be taken on the second Sunday after the last active tablet of a 21‑day regimen or the first Sunday after the last inactive tablet of a 28‑day regimen. Answer: B", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 2 |
| }, |
| "notes": "Accurate and clear explanation that correctly selects B according to standard oral contraceptive package insert instructions for a Sunday start switch." |
| } |
| }, |
| { |
| "id": 39, |
| "src_id": "Synthetic QA:22737", |
| "subset": "Synthetic QA", |
| "question": "Which of the following statements about the management of acute ischemic stroke with intravenous thrombolysis is CORRECT?\nA. The recommended alteplase dose is 0.9 mg/kg (maximum 90 mg), with 10 % given as an initial bolus.\nB. Intravenous thrombolysis can be administered up to 12 hours after symptom onset if the patient meets imaging criteria.\nC. Prior use of antiplatelet therapy (e.g., aspirin) is an absolute contraindication to alteplase.\nD. Patients must have a baseline systolic blood pressure < 180 mm Hg and diastolic < 110 mm Hg before receiving alteplase.", |
| "answer": "**Answer: A** – The statement that accurately reflects current guidelines for IV alteplase in acute ischemic stroke is **A**.\n\n- **A. Correct** – The standard dosing of recombinant tissue‑type plasminogen activator (alteplase) is **0.9 mg per kilogram of body weight**, not to exceed **90 mg total**. Ten percent of the total dose is administered as an **immediate IV bolus**, and the remaining 90 % is infused over **60 minutes**. This regimen is endorsed by the American Heart Association/American Stroke Association (AHA/ASA) and European Stroke Organisation (ESO) guidelines.\n\n- **B. Incorrect** – The conventional therapeutic window for IV alteplase is **≤ 4.5 hours** from symptom onset (or last known well). While advanced imaging (CT perfusion or MR diffusion‑perfusion mismatch) can identify selected patients who may benefit beyond 4.5 hours, this is **not** the routine “up to 12 hours” rule and is limited to highly specialized centers under strict protocols.\n\n- **C. Incorrect** – Use of antiplatelet agents such as aspirin or clopidogrel **does not** constitute an absolute contraindication to thrombolysis. The presence of antiplatelet therapy alone is permissible; however, concomitant use of **anticoagulants** with elevated INR or recent use of direct oral anticoagulants may be contraindications, depending on laboratory values.\n\n- **D. Incorrect** – The blood‑pressure threshold for initiating alteplase is **systolic < 185 mm Hg and diastolic < 110 mm Hg**. While the values in the statement are close, the systolic limit is **185 mm Hg**, not 180 mm Hg. Patients must have their blood pressure lowered to meet these criteria before treatment.\n\n**Key points for IV thrombolysis in acute ischemic stroke**\n\n| Requirement | Detail |\n|-------------|--------|\n| **Time window** | ≤ 4.5 h from symptom onset (or last known well). Extended windows (up to 24 h) require advanced imaging and are considered “selective” for endovascular therapy rather than standard IV alteplase. |\n| **Dose** | 0.9 mg/kg (max 90 mg); 10 % bolus, 90 % infusion over 60 min. |\n| **Blood‑pressure limit** | SBP < 185 mm Hg **and** DBP < 110 mm Hg before treatment. |\n| **Contraindications** | Recent intracranial hemorrhage, active internal bleeding, recent major surgery/trauma, uncontrolled hypertension, known bleeding diathesis, anticoagulation with INR > 1.7 (for warfarin) or detectable DOAC levels. Antiplatelet use alone is **not** a contraindication. |\n\nThus, option **A** is the only fully correct statement.", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 2 |
| }, |
| "notes": "Excellent explanation. Factually accurate, well-structured, and correctly identifies the standard dosing and guidelines for acute ischemic stroke management with IV alteplase." |
| } |
| }, |
| { |
| "id": 40, |
| "src_id": "Synthetic QA:149135", |
| "subset": "Synthetic QA", |
| "question": "A 58‑year‑old man presents to the emergency department with sudden onset dyspnea and pleuritic chest pain. He is tachycardic (115 bpm), tachypneic (28 breaths/min), and his oxygen saturation is 88 % on room air. His past medical history is notable for hypertension and a recent orthopedic knee replacement performed 10 days ago. A bedside transthoracic echocardiogram shows right‑ventricular dilation with hypokinesis of the free wall (McConnell’s sign). Laboratory testing reveals a D‑dimer of 2.8 µg/mL (reference < 0.5). Which of the following is the most appropriate next step in management?\n\nA. Begin intravenous unfractionated heparin followed by oral warfarin \nB. Administer tissue‑type plasminogen activator (tPA) immediately \nC. Start low‑molecular‑weight heparin (enoxaparin) and arrange for discharge home \nD. Perform a lower‑extremity Doppler ultrasound before initiating therapy \nE. Initiate oral direct factor Xa inhibitor (rivaroxaban) without prior parenteral anticoagulation", |
| "answer": "**B. Administer tissue‑type plasminogen activator (tPA) immediately** – The patient has a high‑risk (massive) pulmonary embolism. Clinical features (hemodynamic instability manifested by tachycardia, hypoxia, and right‑ventricular dysfunction on echocardiography) meet criteria for systemic thrombolysis. In the setting of recent major surgery (knee replacement 10 days ago), the risk of bleeding is heightened, but the mortality risk from an untreated massive PE outweighs this risk, and systemic thrombolysis remains the recommended emergent therapy. \n\n**Why the other options are incorrect:** \n\n- **A. Begin intravenous unfractionated heparin…** \n Heparin is appropriate for submassive or low‑risk PE, but in massive PE with hemodynamic compromise, thrombolysis is indicated first. \n\n- **C. Start low‑molecular‑weight heparin and arrange for discharge…** \n Discharging a patient with a massive PE is unsafe; definitive reperfusion therapy is required. \n\n- **D. Perform a lower‑extremity Doppler ultrasound before initiating therapy** \n Diagnostic imaging can be delayed when the clinical picture is unequivocal for massive PE; waiting for confirmatory studies would increase mortality. \n\n- **E. Initiate oral direct factor Xa inhibitor (rivaroxaban) without prior parenteral anticoagulation** \n Direct oral anticoagulants are suitable for most PE cases, but they are not indicated as first‑line therapy for massive PE requiring rapid reperfusion. \n\n**Key teaching point:** In a patient with massive (high‑risk) pulmonary embolism—characterized by sustained hypotension, shock, or right‑ventricular dysfunction—systemic thrombolysis (e.g., tPA) is the treatment of choice, provided there are no absolute contraindications to fibrinolysis.", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": -2, |
| "Safety": -2, |
| "Contextual Fit": 1, |
| "Appropriate Confidence": 1, |
| "Clarity & Completeness": 1 |
| }, |
| "notes": "Clinical Soundness (-2) and Safety (-2): Tachycardia and hypoxia without documented hypotension define submassive (intermediate-risk) PE, not massive PE. Giving systemic tPA 10 days post-knee surgery without shock is clinically incorrect and carries severe bleeding risks." |
| } |
| }, |
| { |
| "id": 41, |
| "src_id": "Guidelines QA:92650", |
| "subset": "Guidelines QA", |
| "question": "In a setting where both IV and IM routes are available, which route does the WHO prioritize for oxytocin prophylaxis after vaginal birth?\nA) Intravenous infusion because it provides faster uterine contraction\nB) Intramuscular injection because it is easier to administer and equally effective\nC) Intravenous bolus because it reduces the dose needed\nD) Subcutaneous injection as a compromise between IV and IM", |
| "answer": "The WHO prefers the intramuscular route for routine prophylaxis due to its practicality and comparable efficacy to IV administration. Answer: B", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 2 |
| }, |
| "notes": "Accurately identifies the WHO recommended route and rationale for oxytocin prophylaxis during the third stage of labor." |
| } |
| }, |
| { |
| "id": 42, |
| "src_id": "Synthetic QA:184198", |
| "subset": "Synthetic QA", |
| "question": "A 58‑year‑old man presents to the emergency department with sudden onset severe chest pain radiating to his back, described as “tearing.” He is diaphoretic, hypertensive (BP 190/110 mm Hg), and has a new diastolic murmur heard best at the left sternal border. An emergent CT angiogram shows an intimal flap in the descending thoracic aorta distal to the left subclavian artery. Which of the following is the most appropriate next step in management?\n\nA. Immediate administration of intravenous beta‑blocker therapy \nB. Urgent surgical repair of the ascending aorta \nC. Initiation of high‑dose intravenous nitroprusside \nD. Endovascular stent graft placement in the descending aorta", |
| "answer": "**A. Immediate administration of intravenous beta‑blocker therapy**\n\n**Explanation:** \nThe patient’s presentation is classic for an acute Type B aortic dissection (dissection distal to the left subclavian artery). The initial management of uncomplicated Type B dissections is aggressive blood pressure and heart‑rate control to reduce shear stress on the aortic wall. Intravenous beta‑blockers (e.g., esmolol or labetalol) are first‑line because they lower both heart rate and contractility, thereby decreasing aortic wall stress. Once the heart rate is ≤60 bpm, additional vasodilators such as nitroprusside may be added if further blood‑pressure reduction is needed, but they should never be given before adequate beta‑blockade.\n\nSurgical repair (option B) is reserved for complicated Type A dissections (involving the ascending aorta) or for Type B dissections with organ malperfusion, uncontrolled pain, or rapid expansion. Endovascular stent grafting (option D) is considered for complicated Type B dissections after medical therapy has failed or when there is evidence of impending rupture. High‑dose nitroprusside alone (option C) without prior beta‑blockade can lead to reflex tachycardia and increased shear stress, worsening the dissection. Therefore, the most appropriate immediate step is intravenous beta‑blocker therapy.", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 2 |
| }, |
| "notes": "Excellent and accurate clinical reasoning. Selecting IV beta-blockers as first-line medical therapy for an uncomplicated Stanford Type B aortic dissection is correct, including the rationale regarding reflex tachycardia with nitroprusside." |
| } |
| }, |
| { |
| "id": 43, |
| "src_id": "Synthetic MOOVE:17900", |
| "subset": "Synthetic MOOVE", |
| "question": "A 58-year-old male accountant presents to the clinic with intermittent episodes of palpitations, diaphoresis, and tremor over the past 6 months. Episodes occur unpredictably, last 5–15 minutes, and are often relieved by resting or consuming a sugary snack. He denies chest pain, dyspnea, or syncope. Past medical history includes hypertension diagnosed 5 years ago, well-controlled on amlodipine 10 mg daily, and hyperlipidemia treated with rosuvastatin 20 mg daily. He has a 20-pack-year smoking history (quit 3 years ago) and drinks alcohol socially (2–3 glasses of wine per week). Family history is notable for a father who died of myocardial infarction at age 62 and a mother with type 2 diabetes mellitus.\n\nPhysical examination: Blood pressure 138/84 mmHg, heart rate 78 bpm, regular rhythm, no murmurs, clear lungs, abdomen soft, no goiter or thyroid nodules palpable. Neurological exam is normal.\n\nLaboratory tests (fasting): Glucose 102 mg/dL, HbA1c 5.7 %, total cholesterol 210 mg/dL, LDL 130 mg/dL, HDL 45 mg/dL, triglycerides 150 mg/dL, serum calcium 9.2 mg/dL, creatinine 0.9 mg/dL, TSH 2.1 µIU/mL (reference 0.4–4.0), free T4 1.2 ng/dL (reference 0.8–1.8). 24‑hour urinary catecholamines: metanephrine 0.7 mg/24 h (reference <0.5 mg/24 h), normetanephrine 1.2 mg/24 h (reference <0.9 mg/24 h). Plasma free metanephrines drawn after the patient had an episode: metanephrine 0.9 nmol/L (reference <0.5 nmol/L), normetanephrine 1.8 nmol/L (reference <0.9 nmol/L).\n\nAbdominal MRI with contrast shows a 3.2 cm left adrenal mass, well‑circumscribed, hyperintense on T2, with rapid contrast washout.\n\nQuestions:\n1. What is the most likely diagnosis?\n2. What additional tests, if any, are required before definitive management?\n3. Outline the pre‑operative medical preparation required for this patient, including medication choices and target blood pressure/heart rate parameters.\n4. What surgical approach is recommended for this adrenal lesion, and what are the key intra‑operative considerations?\n5. Discuss the postoperative follow‑up plan, including biochemical testing and imaging schedule.", |
| "answer": "**1. Most likely diagnosis** \nThe clinical picture (paroxysmal palpitations, sweating, tremor, relief with sugar), the modest but reproducible elevation of plasma and urinary metanephrines, and the MRI characteristics of a 3‑cm left adrenal mass (well‑circumscribed, T2‑bright, rapid wash‑out) are classic for a **functioning pheochromocytoma** of the left adrenal gland.\n\n---\n\n**2. Additional tests that may be required before definitive management**\n\n| Test | Rationale / What it tells you |\n|------|------------------------------|\n| **Confirmatory biochemical test (optional)** – Clonidine suppression test if there is any doubt about a false‑positive metanephrine result. In this case the elevations are clear and the test is usually not mandatory. |\n| **Genetic screening** – Because up to 30 % of pheochromocytomas/paragangliomas are hereditary, offer panel testing (RET, VHL, NF1, SDHB, SDHD, TMEM127, MAX, etc.) especially in a patient >50 yr with a solitary adrenal lesion and a family history of cardiovascular disease. Results guide long‑term surveillance and family counseling. |\n| **Cardiovascular evaluation** – 12‑lead ECG and transthoracic echocardiogram to look for catecholamine‑induced cardiomyopathy, arrhythmias, or left‑ventricular hypertrophy. This helps risk‑stratify the patient for surgery. |\n| **Baseline plasma/urine electrolytes and glucose** – already done, but repeat after α‑blockade to ensure no hypokalemia (important if a mixed aldosterone‑producing tumour were present). |\n| **MIBG or PET (¹⁸F‑FDG/⁶⁸Ga‑DOTATATE) scan** – Only if there is suspicion of extra‑adrenal disease, multifocal disease, or a malignant phenotype (large size >6 cm, invasive features). Not required for a solitary, well‑circumscribed 3‑cm adrenal mass. |\n| **Pregnancy test** – Not applicable here (male). |\n\n*Bottom line: No further biochemical confirmation is strictly required; the next steps are cardiovascular work‑up, genetic counseling, and ensuring the patient is medically optimized.*\n\n---\n\n**3. Pre‑operative medical preparation**\n\n| Step | Medication / Intervention | Goal / Target |\n|------|---------------------------|---------------|\n| **α‑adrenergic blockade** (first line) | • **Phenoxybenzamine** 10 mg PO BID, titrate every 2–3 days up to 1 mg/kg/day (or until adequate control). <br>• **Selective α1‑blocker** (e.g., doxazosin 1–4 mg PO daily) can be used if phenoxybenzamine is unavailable or if rapid titration is desired. | • Sitting BP ≤ 130/80 mmHg (ideally 110–120/70–80). <br>• No orthostatic SBP drop >20 mmHg or symptomatic dizziness. <br>• HR ≥ 60 bpm (avoid reflex tachycardia). |\n| **Volume expansion** | Liberalized sodium intake (≈ 2 g Na/day) + 1–2 L oral fluids daily for 1–2 weeks after α‑blockade is established. | Expand intravascular volume to prevent postoperative hypotension. |\n| **β‑adrenergic blockade** (only after adequate α‑blockade) | • **Propranolol** 20–40 mg PO q6h, titrate to HR 60–70 bpm, OR <br>• **Atenolol** 25–50 mg PO daily. | Control tachycardia or arrhythmias; avoid unopposed α‑stimulation. |\n| **Calcium‑channel blocker** (optional adjunct) | Amlodipine 5 mg PO daily (already on) can be continued if BP remains borderline after α‑blockade. | Additional BP control without affecting catecholamine release. |\n| **Other preparations** | • **MgSO₄** 2 g IV intra‑operatively if severe hypertension spikes.<br>• **Short‑acting IV agents** ready (phentolamine, nitroprusside, nicardipine).<br>• **Glucose monitoring** – catecholamine excess can cause hyperglycemia; watch for hypoglycemia after tumour removal. | Rapid control of intra‑operative hypertensive surges; prevent peri‑operative hypoglycemia. |\n| **Target parameters before surgery** | • SBP < 130 mmHg (sitting), SBP > 90 mmHg (standing). <br>• DBP < 80 mmHg. <br>• HR 60–70 bpm, no episodes of >100 bpm at rest. <br>• No orthostatic symptoms. | Achieve stable hemodynamics for safe anesthesia and tumour manipulation. |\n\nTypical pre‑op preparation lasts **10–14 days** (phenoxybenzamine) or **5–7 days** (selective α‑blocker) with close monitoring of BP, HR, and electrolytes.\n\n---\n\n**4. Recommended surgical approach & key intra‑operative considerations**\n\n| Item | Details |\n|------|---------|\n| **Approach** | **Laparoscopic trans‑peritoneal adrenalectomy** is the standard for a solitary, well‑circumscribed adrenal tumour ≤ 6 cm without radiologic evidence of local invasion. A retro‑peritoneoscopic approach is an alternative but requires specific expertise. |\n| **Why not open?** | Open adrenalectomy is reserved for tumours > 6 cm, suspicion of malignancy (irregular margins, invasion of adjacent structures), or when a minimally‑invasive platform is unavailable. |\n| **Key intra‑operative steps** | 1. **Early identification and control of the adrenal vein** (left adrenal vein drains into the left renal vein). Securing the vein first minimizes catecholamine surge on tumour manipulation. <br>2. **Minimal tumour handling** – use gentle traction, avoid crushing. <br>3. **Ready vaso‑active agents** – IV phentolamine, nitroprusside, nicardipine, esmolol. <br>4. **Continuous arterial line monitoring** for rapid BP changes. <br>5. **Adequate intravascular volume** – maintain central venous pressure 5–10 mm Hg. <br>6. **Blood glucose monitoring** – hyperglycemia may fall precipitously after tumour removal. |\n| **Anesthetic considerations** | • Induction with agents that do not provoke catecholamine release (e.g., etomidate, propofol). <br>• Short‑acting β‑blocker (esmolol) and vasodilator infusions available", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": -1, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": -1 |
| }, |
| "notes": "The response is clinically accurate for questions 1–4, but completely omits Question 5 regarding the postoperative follow-up plan, resulting in -1 for Contextual Fit and Clarity & Completeness." |
| } |
| }, |
| { |
| "id": 44, |
| "src_id": "Guidelines QA:126200", |
| "subset": "Guidelines QA", |
| "question": "A 66‑year‑old patient with chronic lymphocytic leukemia is participating in a trial of a new BTK inhibitor. He has already received one dose of an authorized COVID‑19 vaccine. The trial protocol lists “no concomitant investigational agents.” How should his vaccination be documented?\nA) Record the vaccine as an exclusionary factor; the patient must withdraw.\nB) Enter the vaccine details as a concomitant medication in the electronic record.\nC) Omit the vaccine information because it is not an investigational drug.\nD) Submit a protocol amendment to reclassify the vaccine as investigational.", |
| "answer": "The vaccine should be treated as a concomitant medication, with dates, dose, and any adverse effects recorded, ensuring accurate trial data without deeming the patient ineligible. Answer: B", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 2 |
| }, |
| "notes": "Accurate clinical trial methodology. An authorized vaccine is standard concomitant therapy, not an investigational agent, so recording it as a concomitant medication is correct." |
| } |
| }, |
| { |
| "id": 45, |
| "src_id": "Synthetic QA:153729", |
| "subset": "Synthetic QA", |
| "question": "Question: A 62‑year‑old woman with a history of hypertension and chronic kidney disease stage 3 presents with worsening dyspnea on exertion. On examination she has a blood pressure of 158/92 mm Hg, a harsh systolic ejection murmur heard best at the right upper sternal border radiating to the carotids, and a sustained apical impulse. An echocardiogram shows a left ventricular ejection fraction of 55 % with concentric left‑ventricular hypertrophy and a peak aortic valve gradient of 45 mm Hg. The most appropriate initial pharmacologic therapy to reduce her afterload and improve symptoms is:\n\nA. ACE inhibitor (e.g., lisinopril) \nB. β‑blocker (e.g., metoprolol succinate) \nC. Calcium‑channel blocker (e.g., amlodipine) \nD. Direct vasodilator (e.g., hydralazine) \nE. Loop diuretic (e.g., furosemide)", |
| "answer": "**Answer: A. ACE inhibitor (e.g., lisinopril)** \n\n**Why ACE inhibition is the best first‑line choice**\n\n| Consideration | Reason it favors ACE‑I | Why the other options are less suitable |\n|---------------|------------------------|------------------------------------------|\n| **Pathophysiology** | The patient has **moderate aortic stenosis** with concentric LV hypertrophy. Reducing systemic vascular resistance (afterload) lowers trans‑valvular gradient and improves forward flow without increasing the gradient across the stenotic valve. ACE‑Is provide a steady reduction in afterload. | |\n| **Evidence‑based guideline** | Current ACC/AHA guidelines for **valvular heart disease** recommend an ACE‑I (or ARB) in patients with aortic stenosis who have hypertension or LV hypertrophy, provided there is no contraindication. | |\n| **Blood‑pressure control** | She is hypertensive (158/92 mm Hg). ACE‑Is effectively lower BP and also have favorable effects on renal hemodynamics, which is important in CKD stage 3. | |\n| **Renal protection** | ACE‑Is reduce intraglomerular pressure and slow progression of CKD, whereas many other antihypertensives (e.g., CCBs, direct vasodilators) lack this benefit. | |\n| **β‑blocker (B)** | β‑blockers decrease heart rate and contractility, which can **reduce cardiac output** in aortic stenosis and may worsen symptoms. They are useful after valve replacement, not as initial afterload‑reduction. |\n| **Calcium‑channel blocker (C)** | While CCBs lower BP, they have little effect on afterload and can cause peripheral edema; they do not address the LV pressure overload as effectively as ACE‑Is. |\n| **Direct vasodilator (D)** | Hydralazine causes reflex tachycardia and may increase myocardial oxygen demand; its effect on afterload is unpredictable and it does not provide renal protection. |\n| **Loop diuretic (E)** | Diuretics relieve congestion but do **not** reduce afterload. In a patient whose primary problem is pressure overload from aortic stenosis, diuretics alone are insufficient and may worsen renal function if over‑diuresed. |\n\n**Key points**\n\n1. **Afterload reduction** is the primary pharmacologic goal in symptomatic aortic stenosis with hypertension. \n2. **ACE inhibitors** achieve this safely, lower systemic blood pressure, and confer renal benefits, making them the optimal initial agent. \n3. Other agents either do not adequately reduce afterload, may worsen cardiac output, or lack renal protective effects.\n\nTherefore, the most appropriate initial medication for this patient is an **ACE inhibitor such as lisinopril**.", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 1, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 2 |
| }, |
| "notes": "Clinical Soundness scored +1 because the answer incorrectly states calcium-channel blockers (e.g., amlodipine) have \"little effect on afterload\"; dihydropyridines are potent systemic arterial vasodilators that reduce afterload. The correct option choice and remaining reasoning are sound." |
| } |
| }, |
| { |
| "id": 46, |
| "src_id": "Synthetic MOOVE:71", |
| "subset": "Synthetic MOOVE", |
| "question": "A 45-year-old woman with a 10‑year history of well‑controlled systemic lupus erythematosus (SLE) presents to the emergency department after a witnessed generalized tonic‑clonic seizure. She reports a 3‑week history of intermittent headaches, mild word‑finding difficulty, and occasional visual “static” in the right visual field. There is no recent medication change, and she has been adherent to hydroxychloroquine 400 mg daily. Physical examination reveals mild right‑sided homonymous hemianopsia and subtle dysarthria; no meningeal signs are present. Laboratory studies show a normal complete blood count, serum electrolytes, and renal function; complement levels (C3, C4) are low, and anti‑dsDNA titers are modestly elevated. A non‑contrast head CT is unremarkable. MRI of the brain with and without gadolinium demonstrates a 2.5 cm, ill‑defined, T2‑hyperintense lesion in the left occipital lobe, with faint peripheral enhancement and no significant mass effect. Diffusion‑weighted imaging shows no restricted diffusion, and MR spectroscopy reveals a mildly elevated choline peak with preserved N‑acetylaspartate.\n\nConsidering the patient’s underlying autoimmune disease, imaging characteristics, and clinical presentation, what are the most likely differential diagnoses, and what is the recommended next diagnostic step to distinguish between them? Include the rationale for your recommendation and any pertinent risks associated with the proposed investigation.", |
| "answer": "**Likely differential diagnoses**\n\n| Category | Specific entity | Why it fits the clinical picture & imaging |\n|----------|----------------|--------------------------------------------|\n| **Inflammatory / autoimmune** | • **Neuro‑lupus (cerebritis/vasculitis)** <br>• **Tumefactive demyelination (e.g., MS‑type lesion)** | • SLE is active (low C3/C4, ↑ anti‑dsDNA) → a focal vasculitic process can produce an ill‑defined, T2‑hyperintense focus with faint peripheral enhancement. <br>• Demyelinating lesions can be solitary, T2‑bright, show mild choline rise, preserve NAA, and lack diffusion restriction. |\n| **Neoplastic** | • **Low‑grade astrocytoma (WHO grade II)** <br>• **Primary CNS lymphoma (PCNSL) – “non‑Hodgkin” type)** | • Low‑grade glioma often appears as a non‑mass‑effect, T2‑hyperintense lesion with faint or no enhancement and mildly elevated choline. <br>• PCNSL in immunocompetent patients may present as a solitary, ill‑defined lesion with modest peripheral enhancement; MR‑spectroscopy can show increased choline and relatively preserved NAA early on. |\n| **Infectious** | • **Focal opportunistic infection (e.g., early cerebral abscess, atypical mycobacterial or fungal focus)** | • The patient is not profoundly immunosuppressed, but chronic hydroxychloroquine does not protect against all infections; early abscesses can lack central diffusion restriction and have only peripheral enhancement. |\n| **Vascular / ischemic** | • **Subacute cortical/subcortical infarct (post‑ischemic gliosis)** | • A subacute infarct can become T2‑hyperintense, lack diffusion restriction, and show faint peripheral enhancement, but the lesion’s size (2.5 cm) and the presence of seizures/visual field loss are less typical. |\n| **Other** | • **Posterior reversible encephalopathy syndrome (PRES)** – atypical focal form | • Usually symmetric, vasogenic edema; the focal, ill‑defined nature and lack of clinical hypertension make this unlikely. |\n\n**Why the list narrows to a few key possibilities**\n\n* **Active SLE** (low complement, ↑ anti‑dsDNA) makes an inflammatory process (cerebritis/vasculitis) relatively high on the list. \n* **Imaging** – the lesion is **ill‑defined, T2‑hyperintense, with faint peripheral enhancement, no diffusion restriction, and a modest choline rise**. This pattern is classic for **low‑grade glioma, tumefactive demyelination, or early PCNSL**; it is *not* typical for a mature abscess (which usually shows central diffusion restriction) or for classic PRES (which is usually diffuse and symmetric). \n* **Clinical presentation** – new‑onset seizure, focal visual field loss, and dysarthria are all compatible with any of the three top contenders (neuro‑lupus, low‑grade glioma, PCNSL). The lack of meningeal signs and a normal CSF (not yet obtained) do not help discriminate. \n\nBecause the imaging features are **non‑specific** and the therapeutic implications of each diagnosis are dramatically different (high‑dose steroids/ cyclophosphamide for vasculitis vs. chemotherapy/radiation for lymphoma vs. surgical resection/temozolomide for glioma vs. disease‑modifying therapy for demyelination), a **definitive tissue diagnosis** is required.\n\n---\n\n## Recommended next diagnostic step: **Image‑guided stereotactic needle biopsy of the occipital lesion** (often combined with concurrent cerebrospinal‑fluid analysis)\n\n### How the procedure would be performed\n\n1. **Pre‑procedure work‑up** \n * Baseline coagulation profile (INR, aPTT, platelet count). \n * Review of antihypertensive/antiplatelet medications; hold agents as needed. \n * MRI with tract‑planning sequences to define the safest trajectory (avoid eloquent visual cortex and major veins). \n\n2. **Procedure** \n * Performed under local anesthesia with conscious sedation (or general anesthesia if needed). \n * A small burr hole is made; a frameless or frame‑based stereotactic system guides a 1.8–2.2 mm biopsy needle to the target. \n * Multiple core samples (typically 4–6) are obtained to increase diagnostic yield. \n\n3. **Post‑procedure care** \n * Immediate non‑contrast CT (or MRI) to rule out hemorrhage. \n * Neurological observation for at least 4–6 h; discharge same day if stable.\n\n### Rationale for choosing stereotactic biopsy\n\n| Reason | Explanation |\n|--------|--------------|\n| **High diagnostic yield** (≈ 90 % for lesions > 1 cm) | The lesion is 2.5 cm, well‑suited for core sampling. |\n| **Minimal morbidity** | Modern techniques carry a low complication rate (≈ 1–2 % symptomatic hemorrhage, < 1 % permanent deficit). |\n| **Allows definitive distinction** between inflammatory vasculitis, demyelination, neoplasm (glioma vs. lymphoma), and infection (by histology, immunohistochemistry, PCR). |\n| **Guides therapy promptly** – e.g., if vasculitis is confirmed, high‑dose IV methylprednisolone ± cyclophosphamide can be started; if lymphoma, methotrexate‑based chemo; if glioma, surgical resection/temozolomide; if demyelinating, disease‑modifying therapy. |\n| **Can be combined with CSF studies** (lumbar puncture) to look for oligoclonal bands, infectious PCRs, cytology, and flow cytometry, increasing overall diagnostic certainty. |\n\n### Risks and how they are mitigated\n\n| Potential risk | Approximate incidence | Mitigation strategies |\n|----------------|-----------------------|-----------------------|\n| **Intracerebral hemorrhage** (symptomatic) | 1–2 % | Careful blood‑pressure control, normal coagulation profile, trajectory avoiding major vessels. |\n| **New seizure** (post‑procedure irritation) | ≤ 1 % | Peri‑procedural antiepileptic coverage (e.g., levetiracetam 500 mg BID) and seizure prophylaxis in high‑risk patients. |\n| **Infection (meningitis, brain abscess)** | < 0.5 % | Sterile technique, prophylactic antibiotics only if indicated (e.g., prior sinusitis). |\n| **Neurological deficit** (visual field worsening) | < 1 % | Precise tract planning to avoid the optic radiations and primary visual cortex; intra‑operative neuro‑navigation. |\n| **Sampling error / nondiagnostic tissue** | 5–10 % (reduced with multiple cores) | Obtain ≥ 4 cores, send for routine histology, immunohistochemistry (CD20, GFAP, Ki‑67), molecular studies (IDH1/2, 1p/19q), and infectious stains/PCR. |\n\n---\n\n## Practical algorithm for this patient\n\n1. **Obtain CSF** (lumbar puncture) **before the biopsy** (unless there is a contraindication such as raised intracranial pressure). \n *", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 1 |
| }, |
| "notes": "The response is clinically excellent, providing a thorough differential diagnosis, rationale, procedural details, and risk mitigation strategies. Scores 1 in completeness only due to minor text truncation at the very end of the final section." |
| } |
| }, |
| { |
| "id": 47, |
| "src_id": "Synthetic MOOVE:5354", |
| "subset": "Synthetic MOOVE", |
| "question": "I am a pediatric endocrinologist consulted for a 7‑year‑old girl who was referred for evaluation of early pubertal signs. Over the past 8 months she has developed breast budding (Tanner stage II) and occasional vaginal spotting. Her height is 130 cm (75th percentile) and weight 38 kg (80th percentile), placing her at a BMI of 22 kg/m² (>95th percentile for age). She reports occasional headaches but no visual disturbances. Her past medical history is notable for premature adrenarche at age 4 (pubic hair stage III) that was observed but not further investigated. Family history reveals that her mother entered menarche at age 12 and her maternal aunt was diagnosed with polycystic ovary syndrome (PCOS). The patient is otherwise well, with normal school performance and no chronic illnesses. \n\nPlease address the following:\n1. Differential diagnosis for precocious puberty in this patient, distinguishing central (gonadotropin‑dependent) versus peripheral (gonadotropin‑independent) causes, and comment on the relevance of her obesity and family history.\n2. Key elements of the focused history and physical examination you would obtain, including any red‑flag symptoms that would prompt urgent investigation.\n3. Initial laboratory and imaging investigations to differentiate central from peripheral precocious puberty, specifying preferred assays, timing (e.g., basal vs. GnRH‑stimulated), and radiologic studies.\n4. Brief outline of the first‑line management strategy for each major category of diagnosis you identify, including the role of GnRH analog therapy, lifestyle modification, and any specialist referrals.\n\nPlease keep your response concise but clinically thorough, suitable for a resident physician preparing for a case discussion.", |
| "answer": "**7‑year‑old girl with Tanner II breasts, intermittent vaginal bleeding, BMI > 95th percentile, prior premature adrenarche** \n\n---\n\n## 1. Differential Diagnosis – Central vs. Peripheral\n\n| Category | Typical Mechanism | How it fits this patient | Key points for this case |\n|----------|-------------------|--------------------------|--------------------------|\n| **Central (gonadotropin‑dependent) precocious puberty (CPP)** | Early activation of the hypothalamic‑pituitary‑gonadal (HPG) axis → pulsatile GnRH → ↑ LH/FSH → ovarian estrogen production. | • Breast development (estrogen‑driven) <br>• Vaginal spotting <br>• Height/weight tracking along normal percentile (accelerated growth) <br>• Prior adrenarche may be an early sign of HPG activation. | • Most common form in girls (≈ 80 %). <br>• Often idiopathic (brain MRI normal). <br>• Obesity can **advance** the timing of puberty but does **not** cause true CPP; labs will still show GnRH‑dependent activation. |\n| **Peripheral (gonadotropin‑independent) precocious puberty (PPP)** | Sex‑steroid production independent of GnRH (ovarian, adrenal, exogenous, or ectopic). | • Could explain isolated breast development with low/normal LH/FSH. <br>• Obesity → higher peripheral aromatization of androgens → modest estrogen rise, but usually insufficient for true breast budding. | • Must be ruled out because treatment differs. |\n| **Specific peripheral causes to consider** | | | |\n| • **Ovarian cyst or tumor** (granulosa‑cell, serous cystadenoma) | Autonomous estrogen secretion | Uncommon at this age; would produce breast development ± vaginal bleeding; often palpable mass or abdominal pain. |\n| • **McCune‑Albright syndrome** | GNAS mutation → autonomous ovarian/adrenal steroidogenesis, café‑au‑lait spots, polyostotic fibrous dysplasia | Look for skin macules, bone pain, asymmetric growth. |\n| • **Congenital adrenal hyperplasia (late‑onset, 21‑hydroxylase)** | ↑ adrenal androgens → peripheral conversion to estrogen | Would present with virilization, advanced bone age, hypertension (if 11‑β). Unlikely with isolated breast changes. |\n| • **Exogenous estrogen exposure** (meds, creams, contaminated foods) | Direct estrogen effect | History of topical products, medications, or family use. |\n| • **Hypothyroidism (very severe)** | ↑ TRH → ↑ prolactin → ↑ ovarian estrogen | Typically presents with growth delay, coarse facial features, constipation – not seen here. |\n| **Obesity‑related pseudo‑precocious puberty** | Increased aromatization of adipose‑derived androgens → modest estrogen rise; may advance the **onset** of true puberty but HPG axis remains GnRH‑independent. | Explains early breast development in many overweight girls; however, true CPP must still be ruled out because LH/FSH will be **suppressed** unless the axis is activated. |\n| **Family history of PCOS** | Genetic predisposition to hyperandrogenism/insulin resistance → earlier thelarche/adrenarche | May predispose to early adrenarche (as seen) and later PCOS, but does **not** cause true CPP. |\n\n**Bottom line:** The leading possibilities are **idiopathic central precocious puberty** (most likely) versus **obesity‑related early thelarche** or a **peripheral estrogen source**. The presence of vaginal bleeding and progressive breast development makes CPP more probable, but the work‑up must exclude peripheral causes.\n\n---\n\n## 2. Focused History & Physical Examination\n\n### History – “Red‑Flag” items\n| Domain | Questions | Why it matters |\n|--------|-----------|----------------|\n| **Onset & progression** | Age at first breast bud, pubic hair, axillary hair, menses; rate of change | Rapid progression → central activation; isolated changes → peripheral. |\n| **Menstrual pattern** | Frequency, volume, duration of spotting | True menses suggest estrogen effect; heavy/irregular may hint at ovarian pathology. |\n| **Growth** | Recent height/weight trajectory, growth spurt, parental heights | Accelerated linear growth & bone age advancement → central. |\n| **Headache/neurologic** | Frequency, duration, severity, visual changes, nausea, vomiting, seizures | Suggests intracranial lesion (hypothalamic hamartoma, tumor). |\n| **Skin/soft‑tissue** | Café‑au‑lait spots, pigmented macules, cutaneous hemangiomas, bruising | MCAS, neurocutaneous syndromes. |\n| **Bone pain, fractures** | History of pain, limp, fractures | Fibrous dysplasia (McCune‑Albright). |\n| **Adrenal symptoms** | Hirsutism, acne, severe odor, salt craving, hyperpigmentation | Late‑onset CAH. |\n| **Exogenous exposures** | Use of creams, oils, herbal supplements, mother’s medications, environmental estrogen sources | Exogenous estrogen. |\n| **Family history** | Early puberty, PCOS, endocrine tumors, genetic syndromes | May point to familial CPP or PCOS predisposition. |\n| **Social/psychosocial** | Bullying, stress, diet, activity level | May affect BMI and compliance. |\n\n### Physical Examination – Key Elements\n| System | What to look for | Interpretation |\n|--------|------------------|----------------|\n| **General** | Height, weight, growth percentiles, BMI, growth velocity (chart over 6‑12 mo) | Accelerated growth suggests CPP. |\n| **Pubertal staging** | Tanner breast, pubic hair, axillary hair, genital exam (clitoral size, labial fusion) | Concordant breast & pubic hair → central; isolated breast → peripheral. |\n| **Skin** | Café‑au‑lait macules (≥ 2 cm, irregular borders), nevus, acne, striae | MCAS, adrenal hyperandrogenism. |\n| **Neurologic** | Visual fields (peripheral), fundoscopic exam for papilledema | Intracranial mass. |\n| **Abdominal** | Palpable ovarian mass, hepatomegaly, adrenal enlargement | Peripheral estrogen source. |\n| **Extremities** | Asymmetric limb length, bone tenderness | Fibrous dysplasia. |\n| **Thyroid** | Enlargement, nodules | Exclude hypothyroidism. |\n| **Blood pressure** | Hypertension | 11‑β‑hydroxylase CAH. |\n\n**Red‑flag findings requiring urgent work‑up:** \n- Persistent or worsening headache, visual changes, vomiting → immediate neuro‑imaging. \n- Rapidly enlarging abdominal mass or severe abdominal pain. \n- Signs of endocrinopathy (e.g., severe hypertension, electrolyte abnormalities). \n\n---\n\n## 3. Initial Laboratory & Imaging Work‑up\n\n| Test | Timing / Specimen | Preferred assay | Interpretation |\n|------|-------------------|-----------------|----------------|\n| **Basal LH** | Early morning (8–10 am) | Ultrasensitive immunochemiluminescent assay (detects < 0.1 IU/L) | **≥ 0.3 IU/L** → suggests central activation; **< 0.1** → indeterminate, need GnRH stimulation. |\n| **Basal FSH** | Same sample | Same assay | Elevated in central; low in peripheral. |\n| **Estradiol (E2)** | Early morning | Sensitive LC‑MS/MS (preferred) | Elevated for age → estrogen effect; helps gauge peripheral source. |\n| **GnRH (or GnRH‑analog) stimulation test** | 100 µg IV/IM; measure LH at 0, 20, 40 min | Same LH assay | **Peak LH > 5 IU/L** (or LH/FSH > 1) → central. |\n| **Sex‑steroid panel** (androstenedione, DHEAS, 17‑OH‑progesterone) | Basal | LC‑MS/MS | Elevated adrenal steroids → CAH or adrenal tumor. |\n| **Thyroid function** (TSH, free T4) | Basal | Immunoassay | Severe hypothyroidism can mimic puberty. |\n| **IGF‑1** (optional) | Basal | Immunoassay | Helps assess overall growth axis. |\n| **Bone age** (left hand/wrist X‑ray) | Single study | Greulich‑Pyle method | **> chronological age** → advanced bone age → supports central/estrogen exposure. |\n| **Pelvic ultrasound** | Transabdominal (or transperineal) | High‑resolution US | Ovarian size, cysts, tumors; uterine length (≥ 3 cm suggests estrogen effect). |\n| **MRI brain (sellar‑pituitary region)** | If basal LH ≥ 0.3 IU/L **or** GnRH‑stimulated LH high **or** any neurologic red flag | 3‑Tesla with gadolinium | Detect hypothalamic hamartoma, pituitary adenoma, glioma. |\n| **Abdominal CT/MRI** (if", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": -1, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": -2 |
| }, |
| "notes": "Contextual Fit (-1): Fails to answer part 4 regarding management strategies due to truncation. Clarity & Completeness (-2): Response cuts off mid-sentence at the end of section 3, leaving the answer incomplete." |
| } |
| }, |
| { |
| "id": 48, |
| "src_id": "Synthetic MOOVE:9393", |
| "subset": "Synthetic MOOVE", |
| "question": "A 7‑year‑old boy is brought to the emergency department by his parents because of sudden onset of severe abdominal pain that began 2 hours ago. The pain is diffuse, constant, and rated 9/10. He also reports nausea and one episode of vomiting. There is no history of trauma, recent travel, or sick contacts. Past medical history is unremarkable; immunizations are up to date. On examination, the child appears distressed, with a temperature of 38.3 °C, heart rate 115 bpm, blood pressure 95/60 mm Hg, and respiratory rate 22 breaths/min. The abdomen is tender to palpation with guarding and rebound tenderness, especially in the right lower quadrant. Laboratory tests show leukocytosis (WBC 15,000 µL) with left shift, elevated C‑reactive protein, and normal serum electrolytes. An abdominal ultrasound demonstrates a non‑compressible, enlarged appendix measuring 9 mm with an adjacent inflamed mesenteric fat stranding.\n\nBased on this presentation, what is the most appropriate next step in management, and what are the key components of peri‑operative care for this patient?", |
| "answer": "**Most appropriate next step**\n\nThe child has classic clinical, laboratory and sonographic findings of **acute appendicitis** (likely uncomplicated, but with fever and peritoneal signs that make perforation a concern). The definitive therapy is **prompt surgical removal of the appendix**. \n\nThe next immediate action in the emergency department is therefore:\n\n1. **Start broad‑spectrum intravenous antibiotics** (to cover gram‑negative rods, streptococci and anaerobes) **and give fluid resuscitation** while the child is prepared for surgery. \n2. **Proceed to the operating room for an urgent (ideally laparoscopic) appendectomy** within the next 30–60 minutes. \n\n> *Why not a trial of antibiotics alone?* \n> In a 7‑year‑old with diffuse guarding, rebound tenderness, fever and an enlarged, non‑compressible appendix, the risk of perforation or progression to generalized peritonitis outweighs the modest benefit of non‑operative management. Early appendectomy shortens hospital stay, reduces complications, and is the standard of care in most pediatric centers.\n\n---\n\n## Peri‑operative care – “ABCs of the Appendicitis Patient”\n\nBelow is a concise checklist that can be used for every pediatric appendectomy, divided into **pre‑operative**, **intra‑operative**, and **post‑operative** phases.\n\n### 1. Pre‑operative (Emergency Department → OR)\n\n| Step | What to do | Why it matters |\n|------|------------|----------------|\n| **Airway, Breathing, Circulation** | • Ensure airway patency; give supplemental O₂ if SpO₂ < 94%.<br>• Establish two large‑bore IV lines. | Stabilizes a child who may become hypovolemic or septic. |\n| **Fluid resuscitation** | 20 mL/kg isotonic crystalloid (e.g., normal saline or Lactated Ringer’s) bolus; repeat as needed to maintain BP > 90 mm Hg systolic and urine output > 1 mL/kg/h. | Corrects relative hypovolemia from third‑spacing and vomiting. |\n| **Antibiotic prophylaxis** | • **Uncomplicated**: Cefazolin 30 mg/kg IV (max 2 g) **plus** Metronidazole 15 mg/kg IV (max 500 mg).<br>• **If perforation suspected/confirmed**: Piperacillin‑tazobactam 100 mg/kg (max 4 g) q6 h **or** Ceftriaxone 50 mg/kg (max 2 g) q24 h **plus** Metronidazole 15 mg/kg q8 h. | Reduces surgical‑site infection and intra‑abdominal abscess rates. |\n| **NPO & gastric decompression** | Keep NPO; consider a small‑bore nasogastric tube if significant vomiting or distension. | Prevents aspiration and reduces intra‑abdominal pressure. |\n| **Analgesia** | IV acetaminophen (15 mg/kg) ± low‑dose fentanyl (1–2 µg/kg) or morphine as needed. Avoid high‑dose opioids that mask peritoneal signs before the surgeon evaluates. | Improves comfort while still allowing clinical assessment. |\n| **Laboratory & blood‑type** | • CBC, CMP, coagulation panel (already done).<br>• Type & screen (cross‑match ready in case of unexpected bleeding). | Ready for intra‑op transfusion if needed. |\n| **Informed consent / family counseling** | Explain diagnosis, need for surgery, risks (bleeding, infection, wound complications), and expected postoperative course. | Ensures family understanding and legal compliance. |\n| **Pre‑operative checklist** | Verify patient identity, allergies, antibiotic dose, weight‑based drug calculations, and “time‑out.” | Reduces errors. |\n\n### 2. Intra‑operative\n\n| Item | Details |\n|------|---------|\n| **Approach** | **Laparoscopic appendectomy** is preferred in children (3‑port technique). Benefits: less wound pain, quicker return to oral intake, shorter LOS, better cosmetic result. If the appendix is grossly gangrenous/perforated or the surgeon lacks laparoscopic expertise, a limited open McBurney incision is acceptable. |\n| **Antibiotic timing** | Administer the first dose **≤ 60 min before skin incision** (already given in the ED). |\n| **Specimen handling** | Send the appendix for pathology; if perforated, obtain peritoneal fluid for culture. |\n| **Peritoneal irrigation** | If perforation or purulent peritonitis is present, copious warm saline irrigation; consider placement of a closed‑suction drain only if there is a large contaminated cavity (most pediatric cases do *not* need a drain). |\n| **Hemostasis & inspection** | Ensure hemostasis, inspect the cecum and terminal ileum for any other pathology. |\n| **Anesthetic considerations** | Maintain normothermia, adequate analgesia (e.g., multimodal: acetaminophen + low‑dose opioid ± regional block such as a TAP block if expertise available). |\n\n### 3. Post‑operative (Recovery → Ward)\n\n| Phase | Key actions |\n|-------|-------------|\n| **Immediate recovery** | • Continue IV fluids (maintenance + 20 mL/kg bolus if needed).<br>• Continue the same antibiotic regimen (usually 24 h IV then oral if stable).<br>• Pain control: acetaminophen scheduled, add low‑dose ibuprofen (if no contraindication) and PRN opioid (e.g., morphine 0.1 mg/kg). |\n| **Monitoring** | • Vital signs q1‑2 h for the first 6 h, then q4 h.<br>• Urine output (> 1 mL/kg/h).<br>• Watch for signs of wound infection, intra‑abdominal abscess, or ileus. |\n| **Diet** | • Clear liquids when fully awake and nausea‑free (usually within 4–6 h).<br>• Advance to regular diet as tolerated (most children tolerate within 12–24 h). |\n| **Antibiotic duration** | • **Uncomplicated** (inflamed but intact appendix): 24 h of IV antibiotics, then 3–5 days oral (often no further antibiotics needed if intra‑op cultures negative).<br>• **Perforated/abscess**: 48–72 h IV then oral antibiotics to complete 5–7 days total (or longer if intra‑abdominal collection persists). |\n| **Early mobilization** | Encourage sitting up, ambulation as soon as pain permits (usually day 0‑1). Reduces atelectasis and venous stasis. |\n| **Discharge criteria** | • Afebrile ≥ 24 h.<br>• Tolerating oral intake.<br>• Pain controlled on oral meds alone.<br>• Normalizing WBC (or trending down).<br>• No signs of wound infection. |\n| **Discharge instructions** | • Keep incision clean and dry; shower after 48 h.<br>• Watch for redness, swelling, discharge, fever, vomiting, or increasing pain – call the surgeon if any occur.<br>• Activity: light play for 1 week, avoid contact sports for 2–3 weeks.<br>• Follow‑up appointment in 7–10 days (or sooner if concerns). |\n| **Vaccination note** | If the child later requires a splenectomy (rare in appendicitis) ensure pneumococcal, meningococcal, and H. influenza vaccines – not needed here, but a reminder for any future abdominal surgery that might affect the spleen. |\n\n---\n\n### Bottom line\n\n- **Next step:** Immediate IV fluid resuscitation, broad‑spectrum IV antibiotics, and urgent **laparoscopic appendectomy** (within the hour). \n- **Peri‑operative care** revolves around: \n 1. **Resuscitation & NPO/antibiotics** before the OR, \n 2. **Safe, minimally invasive removal of the appendix** with intra‑op irrigation as needed, and \n 3. **Post‑op monitoring, early feeding/ambulation, appropriate antibiotic duration, pain control", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 2 |
| }, |
| "notes": "The response provides an exemplary, clinically accurate, and comprehensive guide for managing pediatric acute appendicitis, including accurate weight-based antibiotic dosing, pre-operative resuscitation, intra-operative considerations, and post-operative discharge planning." |
| } |
| }, |
| { |
| "id": 49, |
| "src_id": "Guidelines QA:115967", |
| "subset": "Guidelines QA", |
| "question": "A 62‑year‑old man is scheduled for an elective laparoscopic colorectal resection under general anaesthesia expected to last 2 hours. He has no significant comorbidities. According to current best practice, which of the following should be done pre‑operatively to reduce his risk of peri‑operative hypothermia?\nA) Order a pre‑operative chest X‑ray\nB) Assess his risk of hypothermia and plan warming measures if high risk\nC) Give a prophylactic dose of intravenous antibiotics\nD) Schedule the surgery first on the list to minimise fasting time", |
| "answer": "The patient should be assessed for risk of peri‑operative hypothermia and, if at higher risk, appropriate warming measures should be planned. This aligns with the standard recommendation for hypothermia prevention. Answer: B", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 2 |
| }, |
| "notes": "Accurately identifies option B as the correct choice according to perioperative hypothermia management guidelines." |
| } |
| }, |
| { |
| "id": 50, |
| "src_id": "Synthetic QA:13813", |
| "subset": "Synthetic QA", |
| "question": "A 58‑year‑old man presents with progressive shortness of breath on exertion and peripheral edema. Echocardiography shows a left ventricular ejection fraction of 35 % with global hypokinesis. He is started on standard heart‑failure therapy, including an ACE inhibitor, a β‑blocker, and a loop diuretic. Which of the following additional agents has been shown to **reduce cardiovascular mortality** in patients with symptomatic HFrEF (LVEF ≤ 40 %) and is now recommended in guideline‑directed medical therapy?", |
| "answer": "**Answer: C. Sacubitril/valsartan**\n\n**Explanation**\n\n- **Sacubitril/valsartan** (an angiotensin‑receptor neprilysin inhibitor, ARNI) was shown in the PARADIGM‑HF trial to significantly lower cardiovascular death and heart‑failure hospitalization compared with enalapril in patients with HFrEF (LVEF ≤ 40 %). Consequently, contemporary guidelines (ACC/AHA/HFSA, ESC) recommend switching eligible patients from an ACE‑I or ARB to an ARNI as part of guideline‑directed medical therapy (GDMT).\n\n- **Digoxin** can improve symptoms and reduce hospitalizations but has **no proven mortality benefit** in contemporary trials; its use is now limited to selected patients with persistent symptoms despite GDMT.\n\n- **Ivabradine** lowers heart rate in patients with sinus rhythm ≥70 bpm who remain symptomatic despite maximally tolerated β‑blocker therapy. It reduces heart‑failure hospitalizations but **does not demonstrate a mortality benefit**.\n\n- **Spironolactone** (a mineralocorticoid receptor antagonist) does reduce mortality in HFrEF and is part of GDMT; however, in the context of the question—“which additional agent has been shown to reduce cardiovascular mortality and is now recommended”—the **most recent and specific mortality‑reducing agent** that is added **after** standard ACE‑I/β‑blocker therapy is **sacubitril/valsartan**.\n\nThus, the correct answer is **C. Sacubitril/valsartan**.", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 2 |
| }, |
| "notes": "Accurate, clear, and clinically sound explanation of guideline-directed medical therapy in HFrEF and the mortality benefits demonstrated in the PARADIGM-HF trial." |
| } |
| }, |
| { |
| "id": 51, |
| "src_id": "Synthetic MOOVE:22566", |
| "subset": "Synthetic MOOVE", |
| "question": "A 68‑year‑old male farmer from the highlands of Ethiopia presents to the district hospital with progressive shortness of breath over the past 2 weeks, worsening orthopnea, bilateral ankle swelling, and a dry cough. He reports a recent 5‑day trek to a neighboring valley at 3,200 m altitude, during which he experienced intermittent chest tightness and palpitations, but continued the trek. He denies fever, night sweats, hemoptysis, or recent travel abroad. Past medical history is notable for poorly controlled hypertension and a 30‑pack‑year smoking history. He is not on any regular medications.\n\nOn examination: BP 150/90 mmHg, HR 112 bpm (regular), RR 24 /min, SpO₂ 88 % on room air, temperature 36.7 °C. Jugular venous pressure is elevated. Cardiac auscultation reveals a faint S3 gallop and a grade III/VI holosystolic murmur best heard at the apex radiating to the axilla. Lung fields have bibasilar crackles. There is 2+ pitting edema up to the mid‑calf bilaterally. No peripheral cyanosis or clubbing is noted.\n\n1. List the five most likely differential diagnoses for this presentation, considering the regional epidemiology and the patient’s recent high‑altitude exposure.\n2. Propose the initial diagnostic work‑up, specifying which investigations are most readily available in a typical Ethiopian district hospital and which would need referral to a regional center.\n3. Outline a step‑by‑step management plan for the most probable diagnosis, including pharmacologic and non‑pharmacologic interventions that can be implemented in a low‑resource setting.\n4. Identify three potential complications of the primary disease and the early warning signs that should prompt urgent escalation of care.", |
| "answer": "**1. Five most likely differential diagnoses** \n(ordered by how well the presentation fits the clinical picture and the local epidemiology, while keeping the recent high‑altitude exposure in mind)\n\n| # | Diagnosis | Why it fits the case / Regional relevance |\n|---|-----------|-------------------------------------------|\n| 1 | **Acute decompensated left‑sided heart failure (HF) secondary to hypertensive heart disease ± functional mitral regurgitation** | • Progressive dyspnoea, orthopnoea, bibasal crackles, JVP ↑, peripheral oedema, S3 and a holosystolic MR murmur. <br>• Hypertension and long‑standing smoking are common precipitants in Ethiopian adults. |\n| 2 | **High‑altitude pulmonary edema (HAPE)** | • Recent 5‑day trek to 3 200 m, intermittent chest tightness and palpitations, rapid onset dyspnoea, hypoxaemia (SpO₂ 88 %). <br>• HAPE can coexist with underlying cardiac disease and may precipitate overt HF. |\n| 3 | **Acute coronary syndrome (NSTEMI/unstable angina) with secondary pump failure** | • Age > 60, heavy smoking, hypertension → high prevalence of coronary artery disease in Ethiopia. <br>• Tachycardia, new/worsening murmur (functional MR from papillary‑muscle ischemia), dyspnoea. |\n| 4 | **Pulmonary embolism (PE) – “high‑altitude‑associated” or provoked by prolonged trekking** | • Sudden dyspnoea, tachycardia, hypoxaemia, leg oedema (may be pre‑existent). <br>• Long treks, relative immobility, dehydration are recognised risk factors. |\n| 5 | **Chronic obstructive pulmonary disease (COPD) exacerbation with cor‑pulmonale** | • 30‑pack‑year smoking history, dry cough, basal crackles, peripheral oedema from right‑sided overload. <br>• COPD is common in rural Ethiopian smokers and can decompensate at altitude. |\n\n*Other possibilities (e.g., pneumonia, rheumatic mitral regurgitation, chronic mountain sickness) are less consistent with the acute, bilateral “wet” picture and the lack of fever or cyanosis.*\n\n---\n\n**2. Initial diagnostic work‑up**\n\n| Investigation | Availability in a typical Ethiopian district hospital | Would need referral / higher‑level centre |\n|----------------|-------------------------------------------------------|-------------------------------------------|\n| **Focused history & physical exam** (incl. orthopnoea, daily weight, medication review) | ✔︎ | – |\n| **Pulse oximetry & bedside SpO₂ trend** | ✔︎ | – |\n| **12‑lead ECG** | ✔︎ (most district labs have a basic ECG machine) | – |\n| **Chest X‑ray (PA & lateral)** | ✔︎ (portable X‑ray units are common) | – |\n| **Point‑of‑care cardiac & lung ultrasound** (if a trained clinician is present) | ✔︎ in some centres (hand‑held device) | – (formal echo if image quality inadequate) |\n| **Basic labs** – CBC, serum creatinine, electrolytes, fasting glucose | ✔︎ | – |\n| **Serum BNP or NT‑proBNP** | Usually **not** available | Referral (regional lab) |\n| **Cardiac troponin I/T** | Often unavailable; if the lab can run it, use it | Referral if not on‑site |\n| **Arterial blood gas (ABG)** | May be available on larger district labs; otherwise **not** | Referral |\n| **Formal transthoracic echocardiography** (2‑D, colour Doppler) | Rarely available on‑site | **Referral** to regional hospital or cardiac centre |\n| **CT pulmonary angiography (CTPA) or V/Q scan** | Not available | **Referral** for suspected PE |\n| **Spirometry** (post‑acute phase) | Usually not on‑site | Referral if COPD is a strong consideration |\n| **Serology for endemic infections** (e.g., *Mycobacterium* spp., *Schistosoma*) – only if fever/other clues | Not needed for current picture | – |\n\n**Suggested immediate work‑up sequence (can be completed within the first few hours)** \n\n1. **Vitals, oxygen saturation, and repeat physical exam** (look for pulmonary crackles, S3, murmur, JVP, peripheral edema). \n2. **12‑lead ECG** – look for ischaemic changes, left‑bundle‑branch block, atrial fibrillation. \n3. **Chest X‑ray** – assess for pulmonary congestion/vascular redistribution, interstitial edema, pleural effusions, or alternative diagnoses (pneumonia, TB). \n4. **Bedside lung ultrasound** (if device & skill exist) – B‑lines (interstitial edema) vs. consolidations. \n5. **Point‑of‑care cardiac US** – evaluate LV size/function, estimate EF, look for MR severity, RV size (PE clue). \n6. **Basic labs** – CBC (rule out anaemia/infection), electrolytes & creatinine (guide diuretic dosing), glucose. \n7. **If available, bedside BNP** – helps differentiate cardiac vs. primary pulmonary cause. \n8. **If ECG shows ischaemia or troponin is obtainable, send troponin** – to rule in ACS. \n\n**If any of the following are found, arrange urgent referral:** \n- EF < 30 % or severe MR on echo. \n- Evidence of massive PE on CT/echo (RV dilatation, McConnell sign). \n- Persistent hypoxaemia (SpO₂ < 85 % despite O₂) or worsening respiratory distress. \n- Renal failure or electrolyte imbalance that cannot be managed locally.\n\n---\n\n**3. Step‑by‑step management plan for the most probable diagnosis** \n*Most probable: Acute decompensated left‑sided HF (hypertensive heart disease ± functional MR), possibly precipitated by high‑altitude exposure.*\n\n| Step | Action | Rationale & Practical Tips for a Low‑Resource Setting |\n|------|--------|-------------------------------------------------------|\n| **A. Initial stabilisation** | • **Oxygen** 2–4 L/min via nasal cannula or face mask to keep SpO₂ ≥ 92 % (target higher if possible). <br>• **Position**: semi‑upright (30–45°) or sitting; elevate head of bed. | Oxygen concentrators are common; if limited, prioritise use for this patient. |\n| **B. Rapid fluid assessment** | • **IV loop diuretic** – Furosemide 40 mg IV bolus, repeat every 30 min (max 120 mg) until adequate diuresis (≥ 500 mL urine) and clinical improvement. <br>• **Monitor** urine output, blood pressure, electrolytes (if labs available). | Furosemide is inexpensive and widely stocked. If IV not available, give oral 80 mg and repeat", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 1, |
| "Contextual Fit": -1, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": -2 |
| }, |
| "notes": "Contextual Fit (-1): Incomplete response, completely omitting question 4. Clarity & Completeness (-2): Answer is severely truncated mid-sentence during part 3, leaving part 3 unfinished and part 4 completely missing." |
| } |
| }, |
| { |
| "id": 52, |
| "src_id": "Synthetic MOOVE:20366", |
| "subset": "Synthetic MOOVE", |
| "question": "A 45‑year‑old woman presents to the primary care clinic with a 3‑month history of intermittent palpitations, heat intolerance, and unintentional weight loss of 6 kg. She reports occasional tremor, increased bowel movements, and difficulty sleeping. Physical examination reveals a diffuse, non‑tender goiter, fine tremor of the outstretched hands, and a heart rate of 112 bpm with occasional premature atrial contractions. Laboratory tests show suppressed TSH (<0.01 µIU/mL) and elevated free T4 (2.8 ng/dL, reference 0.8–1.8). Thyroid peroxidase antibodies are negative, while TSH‑receptor antibodies are markedly elevated. A thyroid ultrasound demonstrates a heterogeneous, mildly enlarged gland without discrete nodules. \n\nConsidering this presentation:\n1. What is the most likely diagnosis and its pathophysiological basis?\n2. Outline the first‑line treatment options, including indications for each modality (antithyroid drugs, radioactive iodine, surgery).\n3. Discuss the specific considerations for managing this patient if she plans to become pregnant within the next year.\n4. Identify potential complications of untreated disease and the monitoring parameters required during therapy.", |
| "answer": "**1. Most likely diagnosis & pathophysiology** \n\n| Diagnosis | Graves disease (autoimmune hyper‑thyroidism) |\n|-----------|----------------------------------------------|\n| Key clinical clues | • 3‑mo history of palpitations, heat intolerance, weight loss, tremor, diarrhoea, insomnia <br>• Diffuse non‑tender goiter <br>• Suppressed TSH, elevated free T4 <br>• **TSH‑receptor‑stimulating antibodies (TRAb) markedly positive** <br>• Heterogeneous enlarged gland on ultrasound, no nodules | \n| Pathophysiological basis | • Auto‑antibodies (IgG) directed against the **TSH‑receptor** bind the receptor on thyroid follicular cells and **mimic TSH**, leading to: <br> – ↑ cAMP → ↑ thyroid hormone synthesis & release (T4/T3) <br> – Hyperplasia & hypertrophy of follicular cells → diffuse goiter <br>• The same antibodies can stimulate orbital fibroblasts → Graves ophthalmopathy (not yet present in this patient). |\n\n---\n\n**2. First‑line treatment options & when each is preferred**\n\n| Modality | How it works | Typical first‑line indications (including this patient) | Major pros / cons |\n|----------|--------------|--------------------------------------------------------|-------------------|\n| **Antithyroid drugs (ATDs)** – Methimazole (MMI) 5–30 mg daily or Propylthiouracil (PTU) 100–300 mg q6‑8 h | Inhibit thyroid peroxidase → ↓ organification of iodide & coupling of tyrosine residues; PTU also blocks peripheral conversion of T4→T3. | • First‑line for most newly diagnosed adults who are **not pregnant** and have **mild‑to‑moderate disease**.<br>• Useful when rapid control is needed (e.g., symptomatic tachyarrhythmia) but definitive therapy can be delayed.<br>• Preferred when patient wants to avoid radiation (e.g., future pregnancy, active ophthalmopathy). | **MMI** – 1‑week onset, once‑daily dosing, lower risk of severe hepatotoxicity, but risk of agranulocytosis (≈0.1‑0.5%).<br>**PTU** – slower onset, requires multiple daily doses, higher risk of idiosyncratic liver injury; reserved for first trimester of pregnancy or when MMI intolerance. |\n| **Radioactive iodine (RAI; ^131I)** | ^131I taken up by thyroid → β‑radiation destroys thyroid follicular cells → permanent reduction in hormone output. | • Definitive therapy for **most adults** who are **≥35 y**, have **no desire for pregnancy for ≥6 mo**, and have **no severe ophthalmopathy**.<br>• Preferred when patient prefers a **single, non‑surgical** treatment and can tolerate a brief period of hypothyroidism before levothyroxine replacement. | Pros: outpatient, no scar, high success (≈90‑95%); Cons: may worsen ophthalmopathy, contraindicated in pregnancy/lactation, takes 4‑8 weeks for full effect, may require lifelong levothyroxine. |\n| **Surgery (total/near‑total thyroidectomy)** | Complete removal of thyroid tissue → immediate cure of hyper‑thyroidism. | • Indicated when: <br> – Large goiter causing compressive symptoms or cosmetic concern.<br> – Suspicion of malignancy.<br> – Intolerable side‑effects from ATDs.<br> – Severe, active Graves ophthalmopathy (RAI can aggravate).<br> – Patient prefers a **rapid, definitive cure** and is a good surgical candidate. | Pros: immediate control, no radiation, histology obtained.<br>Cons: surgical risks (recurrent laryngeal nerve injury, hypocalcemia), need for lifelong levothyroxine, peri‑operative preparation (β‑blocker + ATD). |\n\n*In this 45‑year‑old woman with moderate disease, a diffuse goiter, and no eye disease, **either methimazole** (first‑line) **or RAI** (if she does not plan pregnancy soon) would be appropriate. Surgery is reserved for specific anatomic or refractory reasons.*\n\n---\n\n**3. Management if she plans to become pregnant within the next year**\n\n| Issue | Recommendation |\n|-------|----------------|\n| **Achieve a euthyroid state before conception** | Target **free T4 in the upper‑normal range** and **TSH 0.5‑2.5 µIU/mL** for at least 3 months before trying to conceive. |\n| **Choice of antithyroid drug** | • **First trimester**: **PTU** 100–150 mg q8 h (or q6 h if needed) because methimazole is associated with rare congenital malformations (aplasia cutis, choanal atresia, etc.).<br>• **After 12 weeks gestation**: many clinicians **switch back to methimazole** (20‑30 mg daily) because PTU carries a higher risk of severe hepatotoxicity with prolonged use. |\n| **Radioactive iodine** | **Contra‑indicated** in pregnancy and **must be avoided** for at least 6‑12 months after therapy (women should wait until the radioactivity is cleared and the gland is euthyroid). Therefore, if she intends pregnancy within a year, **RAI is not a suitable definitive option** unless she postpones conception. |\n| **Surgery** | If definitive therapy is preferred **and pregnancy is imminent**, a **total thyroidectomy in the second trimester (weeks 13‑24)** is the safest surgical window. Pre‑operative preparation with PTU (or MMI) and β‑blocker is required to achieve euthyroidism and avoid thyroid storm. |\n| **Fetal monitoring** | • Maternal free T4/TSH every 4‑6 weeks throughout pregnancy.<br>• Adjust ATD dose to keep free T4 **just above the non‑pregnant reference range** (to avoid fetal hypothyroidism).<br>• Screen for fetal tachycardia or goiter by obstetric ultrasound if maternal T4 is markedly elevated. |\n| **Post‑partum** | • Watch for **post‑partum thyroiditis** or relapse; re‑check TRAb at 6 weeks postpartum (high TRAb predicts neonatal hyper‑thyroidism).<br>• Breast‑feeding is compatible with low‑dose PTU or methimazole (both excreted in minimal amounts). |\n\n---\n\n**4. Potential complications of untreated disease & monitoring during therapy**\n\n| Complication (if hyper‑thyroidism persists) | Clinical impact |\n|---------------------------------------------|-----------------|\n| **Cardiovascular** – atrial fibrillation, high‑output heart failure, premature ventricular/atrial ectopy, hypertension. |\n| **Skeletal** – accelerated bone turnover → osteoporosis, especially in post‑menopausal women. |\n| **Metabolic/Neuro** – weight loss, muscle wasting, tremor, anxiety, insomnia, heat intolerance. |\n| **Thyroid storm** – life‑threatening decompensation (fever, severe tachyarrhythmia, altered mental status). |\n| **Graves ophthalmopathy** – proptosis, diplopia, exposure keratopathy; can worsen with RAI. |\n| **Pregnancy‑related** – miscarriage, pre‑eclampsia, pre‑term delivery, low birth‑weight, fetal/neonatal hyper‑thyroidism. |\n\n| Monitoring parameter | Frequency & target (initial treatment) | Why it matters |\n|----------------------|---------------------------------------|----------------|\n| **Serum TSH, free T4 (or free T3)** | Every **4‑6 weeks** until euthyroid, then every 3‑6 months. | Guides dose adjustments; TSH may lag behind free T4 changes. |\n| **Complete blood count (CBC) with differential** | Baseline, then **every 2‑3 months** while on ATDs (especially methimazole) to detect agranulocytosis. |\n| **Liver function tests (ALT, AST, bilirubin)** | Baseline, then **monthly** for the first 3 months on PTU (or if symptoms of hepatitis). | PTU can cause severe hepatotoxicity; methimazole less so but still", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 1 |
| }, |
| "notes": "Comprehensive, highly accurate, and well-structured answer. A minor deduction in Clarity & Completeness is given due to a brief text truncation at the very end of the final table." |
| } |
| }, |
| { |
| "id": 53, |
| "src_id": "Guidelines QA:123620", |
| "subset": "Guidelines QA", |
| "question": "A 4‑year‑old child with a history of tetralogy of Fallot repair presents with increasing right ventricular pressures. Imaging shows a narrowed conduit between the right ventricle and pulmonary artery. Which statement best reflects the evidence on the success of balloon dilatation for this condition?\nA) Technical success rates are consistently above 90%\nB) Technical success rates are around 60% in reported series\nC) There is no evidence of any technical success\nD) Success is defined only by a reduction in pressure gradient of at least 10 mmHg", |
| "answer": "Studies cited report a technical success rate of approximately 60% for balloon dilatation in this setting. Answer: B", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 2 |
| }, |
| "notes": "Accurate response correctly identifying the success rate of balloon dilatation for RV-PA conduit stenosis." |
| } |
| }, |
| { |
| "id": 54, |
| "src_id": "Synthetic MOOVE:790", |
| "subset": "Synthetic MOOVE", |
| "question": "I am a pediatric resident in a tertiary children's hospital. A 6‑year‑old boy is brought in with a 4‑day history of fever, vomiting, and a progressively worsening headache. He now has a bulging fontanelle, papilledema on fundoscopic exam, and a neck stiffness that is more pronounced on the left side. His temperature is 38.9 °C, heart rate 112 bpm, blood pressure 105/68 mmHg, and respiratory rate 22 breaths/min. Laboratory studies show a white blood cell count of 14,000 µL with a left shift, CRP 85 mg/L, and CSF obtained via lumbar puncture reveals an opening pressure of 280 mmH₂O, cloudy appearance, glucose 30 mg/dL (serum glucose 90 mg/dL), protein 210 mg/dL, and neutrophilic predominance. Gram stain is pending. What is the most likely diagnosis, immediate management steps, and the empiric antimicrobial regimen appropriate for this age group pending culture results?", |
| "answer": "**Most likely diagnosis** \nThe presentation is classic for **acute bacterial meningitis** with raised intracranial pressure (bulging fontanelle, papilledema, high opening pressure). In a previously healthy 6‑year‑old the two most common pathogens are *Streptococcus pneumoniae* and *Neisseria meningitidis* (the CSF pattern – low glucose, high protein, neutrophilic pleocytosis – fits bacterial infection). \n\n---\n\n## Immediate management steps (do‑it‑now)\n\n| Step | What to do | Why / Key points |\n|------|------------|------------------|\n| **1. Stabilize airway, breathing, circulation (ABCs)** | • Ensure a patent airway; give O₂ if SpO₂ < 94%.<br>• Establish 2 large‑bore IV lines.<br>• Give isotonic fluid bolus (20 mL/kg NS) if any sign of hypotension or poor perfusion. | Prevent hypoxia and hypotension, which worsen cerebral ischemia. |\n| **2. Rapid bedside neuro‑monitoring** | • Elevate head of bed to 30° (helps CSF drainage).<br>• Insert a Foley catheter for accurate urine output.<br>• Continuous cardiac & pulse‑ox monitoring. | Reduces ICP and allows early detection of deterioration. |\n| **3. Obtain cultures *before* antibiotics** | • Draw **blood cultures** (2 sets, from separate sites).<br>• CSF already obtained – send for Gram stain, culture, PCR, antigen tests. | Guides definitive therapy; antibiotics should be given **within 20 min** of first culture draw. |\n| **4. Empiric antimicrobial therapy** (see detailed regimen below) | • Give the first dose **immediately** (do not wait for Gram stain). | Early antibiotics are the single most important factor in outcome. |\n| **5. Adjunctive dexamethasone** | • **0.15 mg/kg IV** (max 10 mg) **push** **before or with** the first antibiotic dose, then q6 h for 2–4 days. | Reduces inflammatory‑mediated neurologic complications (especially hearing loss) when the pathogen is *S. pneumoniae* or *H. influenzae* type b. |\n| **6. ICP‑lowering measures (because opening pressure ≈ 280 mmH₂O)** | • Keep head elevated, avoid neck flexion.<br>• Consider **IV mannitol 0.5–1 g/kg** (or hypertonic saline 3 % bolus) if there are signs of herniation or rapidly worsening neuro status.<br>• Consult pediatric neurosurgery early – may need external ventricular drain if ICP cannot be controlled medically. | Prevent secondary brain injury from herniation. |\n| **7. Supportive care** | • Antipyretic (acetaminophen 15 mg/kg PO/IV).<br>• Analgesia as needed (e.g., ibuprofen).<br>• Seizure prophylaxis only if seizure occurs or high risk. | Comfort & fever control, avoid febrile seizures. |\n| **8. Infection‑control precautions** | • Droplet precautions (mask, eye protection) for *N. meningitidis* until ruled out.<br>• Notify public‑health for possible close‑contact chemoprophylaxis. | Prevent nosocomial spread. |\n| **9. Notify senior team & arrange ICU admission** | • This child has signs of increased ICP and systemic inflammation → needs close monitoring, possible mechanical ventilation. | Guarantees rapid escalation if status changes. |\n\n---\n\n## Empiric antimicrobial regimen for a 6‑year‑old (≥ 1 month, < 18 yr)\n\n| Drug | Dose (IV) | Frequency | Duration (typical) | Rationale |\n|------|-----------|-----------|--------------------|-----------|\n| **Ceftriaxone** (or Cefotaxime) | 100 mg/kg (max 2 g) | q12 h | 10–14 days (adjust after culture) | Broad‑spectrum β‑lactam covering *S. pneumoniae*, *N. meningitidis*, *H. influenzae*. |\n| **Vancomycin** | 15 mg/kg (max 1 g) | q6 h (adjust for trough 15–20 µg/mL) | 10–14 days (adjust after culture) | Adds coverage for penicillin‑resistant *S. pneumoniae* (and other resistant Gram‑positives). |\n| **Ampicillin** (optional) | 200 mg/kg (max 2 g) | q6 h | 10–14 days | Added **only** if the child is immunocompromised, has a history of exposure to *Listeria* (e.g., unpasteurized dairy, farm animals) or if local epidemiology shows > 5 % Listeria in this age group. In a healthy 6‑yr‑old it is usually omitted, but many institutions keep it “just in case” because *Listeria* can still occur. |\n| **Adjunct** – **Dexamethasone** | 0.15 mg/kg (max 10 mg) | q6 h | 2–4 days (stop after 48 h if *N. meningitidis* confirmed) | Reduces inflammatory complications. |\n| **If allergic to β‑lactams** | Consider **meropenem** 40 mg/kg q8 h + **rifampin** 10–20 mg/kg q6 h (or vancomycin + aztreonam) | – | – | Use only after allergy verification. |\n\n**Key points about the regimen**\n\n* **Start ceftriaxone + vancomycin** **immediately**; add ampicillin only if there is a specific indication (immunodeficiency, Listeria risk, or local high Listeria prevalence). \n* **Dexamethasone must precede or be given with the first dose of the β‑lactam**; it should not be started after antibiotics have already been given for > 30 min. \n* **Adjust dosing** for renal/hepatic function and for weight‑based maximums. \n* **Re‑evaluate after Gram stain** (if Gram‑positive cocci in pairs → *S. pneumoniae*; Gram‑negative diplococci → *N. meningitidis*; Gram‑positive rods → *Listeria*). De‑escalate or switch accordingly. \n* **If CSF Gram stain shows *N. meningitidis***, you can stop vancomycin after confirming susceptibility and may consider a **single‑dose ceftriaxone** (or continue for the full course). \n* **If *S. pneumoniae* is identified** and the isolate is penicillin‑susceptible, you may drop vancomycin and continue ceftriaxone alone. \n\n---\n\n### Quick “cheat‑sheet” for the bedside\n\n1. **ABCs → IV fluids** \n2. **Blood cultures → then antibiotics** (within 20 min) \n3. **Ceftriaxone + Vancomycin** (± Ampicillin) **+ Dexamethasone** \n4. **ICP control:** head‑up, mannitol/hypertonic saline if needed, neurosurgery consult. \n5. **ICU admission, droplet precautions, notify public health.** \n\nFollowing these steps gives the child the best chance of a good neurologic outcome while you await the definitive microbiology results. Good luck on the ward!", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 2 |
| }, |
| "notes": "Excellent, well-structured response. Accurately identifies acute bacterial meningitis, details proper empiric coverage (ceftriaxone + vancomycin + dexamethasone), and provides appropriate immediate resuscitation and ICP-lowering management steps." |
| } |
| }, |
| { |
| "id": 55, |
| "src_id": "Synthetic QA:44643", |
| "subset": "Synthetic QA", |
| "question": "A 45‑year‑old woman presents to the clinic for evaluation of newly diagnosed hypertension. She reports occasional muscle cramps and fatigue. Her blood pressure is 158/96 mm Hg on two separate visits. Laboratory studies reveal a serum potassium of 3.2 mmol/L (reference 3.5–5.0) and a bicarbonate of 30 mmol/L (reference 22–28). Plasma renin activity is 0.8 ng/mL/h (reference 0.5–4.0) and plasma aldosterone concentration is 25 ng/dL (reference 4–31). Which of the following is the most appropriate next step in the diagnostic work‑up of this patient?", |
| "answer": "<answer>**Answer: C. Saline infusion test to assess aldosterone suppression** \n\n*Rationale*: The patient has hypertension, hypokalemia, metabolic alkalosis, and a low‑normal plasma renin activity with a relatively high aldosterone level, raising suspicion for primary aldosteronism (PA). Current guidelines recommend a two‑step approach: first, a screening test (e.g., plasma aldosterone‑renin ratio). Because the ratio is already suggestive (aldosterone ≥ 15 ng/dL with renin ≤ 1 ng/mL/h), the next step is a confirmatory test to demonstrate autonomous aldosterone secretion that is not suppressible by volume expansion. The **saline infusion test** (infusing 2 L of isotonic saline over 4 hours) is the most widely used confirmatory test; failure of aldosterone to suppress below 5 ng/dL confirms PA. \n\n- **Option A** (oral sodium loading) is another confirmatory method but is less commonly used and more cumbersome than the saline infusion test. \n- **Option B** (CT of the adrenal glands) is an imaging study performed **after** biochemical confirmation of PA to differentiate unilateral adenoma from bilateral hyperplasia. \n- **Option D** (urinary catecholamines) is used to evaluate pheochromocytoma, which presents with paroxysmal hypertension, tachycardia, and diaphoresis, not with hypokalemia. \n- **Option E** (overnight dexamethasone suppression test) screens for Cushing syndrome, which would present with features such as central obesity, moon facies, and glucose intolerance. \n\nTherefore, the appropriate next step is to perform a **saline infusion confirmatory test** to verify autonomous aldosterone production.", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 2 |
| }, |
| "notes": "Excellent clinical rationale for primary aldosteronism diagnostic workup. Accurately details screening, confirmatory testing via saline infusion, and sub-classification steps." |
| } |
| }, |
| { |
| "id": 56, |
| "src_id": "Synthetic QA:14985", |
| "subset": "Synthetic QA", |
| "question": "A 55‑year‑old woman presents to the emergency department with sudden onset dyspnea, pleuritic chest pain, and mild tachycardia (HR 110 bpm). She has no history of recent surgery, immobilization, or known malignancy. Her oxygen saturation on room air is 92 %. Physical examination is unremarkable except for a faint right‑sided pleural rub. Which of the following is the most appropriate **initial** diagnostic test to evaluate for a pulmonary embolism in this patient?\n\nA. D‑dimer assay \nB. Computed tomography pulmonary angiography (CTPA) \nC. Ventilation‑perfusion (V/Q) scan \nD. Lower‑extremity compression ultrasonography", |
| "answer": "**Answer: B. Computed tomography pulmonary angiography (CTPA)** \n\n**Rationale**\n\n- The patient has a moderate pre‑test probability for pulmonary embolism (PE) (acute dyspnea, pleuritic chest pain, tachycardia, and mild hypoxemia). \n- In patients with **intermediate or high clinical probability**, guidelines (e.g., ACCP, ESC) recommend proceeding directly to **imaging** rather than a D‑dimer test, because a negative D‑dimer would not be sufficiently reliable and a positive result would still require imaging. \n- **CTPA** is the preferred first‑line imaging modality for most patients because it:\n - Provides direct visualization of emboli in the pulmonary arteries. \n - Has high sensitivity (≈ 95 %) and specificity (≈ 95 %). \n - Allows concurrent assessment of alternative diagnoses (e.g., pneumonia, pneumothorax). \n- **Ventilation‑perfusion (V/Q) scan** is reserved for patients with contraindications to iodinated contrast or when CTPA is not feasible (e.g., severe renal insufficiency, contrast allergy). \n- **Lower‑extremity compression ultrasonography** is useful when CTPA is unavailable or when a proximal deep‑vein thrombosis (DVT) would be sufficient to confirm a PE diagnosis, but it is not the first step in a patient with an intermediate‑to‑high probability of PE. \n- **D‑dimer** is most useful in patients with low clinical probability; a negative result can safely exclude PE, but in this scenario it would not be the optimal initial test.\n\n**Therefore, the most appropriate initial diagnostic test for this patient is a CT pulmonary angiography.**", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 2 |
| }, |
| "notes": "The answer correctly identifies CTPA as the most appropriate initial diagnostic test given the moderate/high pre-test probability (Wells score > 4) and provides sound clinical rationale for excluding other options." |
| } |
| }, |
| { |
| "id": 57, |
| "src_id": "Synthetic MOOVE:14755", |
| "subset": "Synthetic MOOVE", |
| "question": "A 58-year-old woman with a 20-year‑pack‑year smoking history presents to the clinic with a 3‑month history of progressive dyspnea on exertion and a non‑productive cough. She reports occasional wheezing and has noticed a recent unintentional weight loss of 6 kg. Past medical history is notable for well‑controlled hypertension and a remote episode of community‑acquired pneumonia 5 years ago. Physical examination reveals mild digital clubbing, scattered fine crackles over the bilateral lower lung fields, and no peripheral edema. Pulmonary function tests show a forced expiratory volume in 1 second (FEV₁) of 68 % predicted, forced vital capacity (FVC) of 72 % predicted, and a reduced diffusion capacity for carbon monoxide (DLCO) of 55 % predicted. High‑resolution CT of the chest demonstrates bilateral, peripheral, subpleural reticulations with areas of traction bronchiectasis, predominantly in the lower lobes, and no significant lymphadenopathy. Laboratory workup, including ANA, RF, and anti‑CCP, is negative. \n\nGiven this presentation, what is the most appropriate next diagnostic step to confirm the underlying etiology, and what initial management strategy should be instituted while awaiting definitive diagnosis?", |
| "answer": "**Most appropriate next diagnostic step**\n\nThe HRCT shows a *probable* usual interstitial‑pneumonia (UIP) pattern (bilateral, peripheral, sub‑pleural reticulations with traction bronchiectasis in the lower lobes, no honey‑comb cysts, no significant mediastinal nodes, and a negative autoimmune screen). \nAccording to current ATS/ERS/JRS/ALAT IPF guidelines, when the HRCT is **probable** rather than classic UIP, a tissue diagnosis is required to exclude other interstitial lung diseases (e.g., chronic hypersensitivity pneumonitis, connective‑tissue‑disease–associated ILD, smoking‑related interstitial fibrosis).\n\nTherefore the next step is **obtaining lung tissue**:\n\n* **Video‑assisted thoracoscopic (VATS) surgical lung biopsy** – the gold‑standard, providing adequate size and architectural detail for a definitive UIP diagnosis. \n* If the patient’s operative risk is high, a **trans‑bronchial cryobiopsy** performed in a center experienced with the technique is an acceptable alternative, as it yields larger samples than conventional forceps biopsies and has a diagnostic yield approaching that of VATS in experienced hands.\n\n**Initial management while awaiting the definitive diagnosis**\n\nEven before a histologic confirmation, the clinical picture is highly suggestive of an idiopathic progressive fibrosing ILD, and early therapy is associated with better outcomes. The following measures should be instituted promptly:\n\n| Intervention | Rationale / Practical Points |\n|--------------|------------------------------|\n| **Smoking cessation** | The only modifiable risk factor; counseling, nicotine‑replacement, or pharmacologic aid (varenicline/bupropion). |\n| **Supplemental oxygen** (if resting SpO₂ < 88 % or significant desaturation on exertion) | Improves dyspnea, exercise tolerance, and survival in hypoxemic ILD. |\n| **Referral to an ILD multidisciplinary team** (pulmonology, radiology, pathology, rheumatology) | Ensures coordinated assessment, timely biopsy, and consensus on diagnosis/treatment. |\n| **Consider early anti‑fibrotic therapy** (nintedanib 150 mg bid **or** pirfenidone 801 mg tid) | Both agents slow FVC decline and are recommended for IPF and for other progressive fibrosing ILDs when the probability of IPF is high. Initiation can be started while awaiting biopsy results if the treating team judges the pre‑test probability to be > 80 %. |\n| **Pulmonary rehabilitation** | Improves exercise capacity, dyspnea, and quality of life; can be started immediately. |\n| **Vaccinations** (influenza annually, COVID‑19 booster, pneumococcal) | Reduce risk of superimposed infection, which can precipitate acute exacerbations. |\n| **Avoid systemic steroids or immunosuppressants** (unless a non‑IPF ILD is later identified) | Steroids have not shown benefit in IPF and increase infection risk. |\n\nIn summary, the next step is to obtain a definitive histologic sample—preferably via VATS surgical lung biopsy (or cryobiopsy if surgical risk is prohibitive). While awaiting that result, institute smoking cessation, oxygen as needed, pulmonary rehabilitation, appropriate vaccinations, and, given the high pre‑test probability of a progressive fibrosing ILD, start an anti‑fibrotic agent (nintedanib or pirfenidone) together with multidisciplinary ILD team involvement.", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 2 |
| }, |
| "notes": "Excellent, highly accurate answer. Correctly identifies HRCT findings as a probable UIP pattern per ATS/ERS guidelines, recommends surgical/cryobiopsy, and outlines safe, standard initial management strategies." |
| } |
| }, |
| { |
| "id": 58, |
| "src_id": "Guidelines QA:39774", |
| "subset": "Guidelines QA", |
| "question": "During a routine check, a clinician notices a slight cloudiness in a Lactated Ringer’s bag that has been opened for 30 minutes. What is the appropriate action?\nA) Continue the infusion because cloudiness is normal after opening.\nB) Filter the solution through a 0.22 µm filter before use.\nC) Discard the bag and obtain a new, clear solution.\nD) Add a small amount of sodium bicarbonate to clear the cloudiness.", |
| "answer": "Any cloudiness indicates possible contamination; the bag should be discarded. Answer: C", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 2 |
| }, |
| "notes": "Correctly identifies that cloudiness in an IV solution indicates potential contamination or precipitation, requiring immediate disposal of the bag." |
| } |
| }, |
| { |
| "id": 59, |
| "src_id": "Synthetic QA:11233", |
| "subset": "Synthetic QA", |
| "question": "In a hemodynamically stable patient with acute pulmonary embolism (PE) and a low‑intermediate risk profile, which of the following is the most appropriate initial management strategy?\nA. Immediate systemic thrombolysis \nB. Anticoagulation with a direct oral anticoagulant (DOAC) alone \nC. Surgical embolectomy \nD. Placement of an inferior vena cava (IVC) filter", |
| "answer": "**Correct answer: B. Anticoagulation with a direct oral anticoagulant (DOAC) alone** \n\n**Rationale**\n\n| Option | Why it is **incorrect** or **less appropriate** |\n|--------|---------------------------------------------------|\n| **A. Immediate systemic thrombolysis** | Thrombolysis is reserved for patients with *high‑risk (massive) PE* who are hypotensive or in shock. In a hemodynamically stable patient, the bleeding risk of systemic thrombolysis outweighs its benefit. |\n| **C. Surgical embolectomy** | This invasive procedure is indicated only when thrombolysis is contraindicated **and** the patient is deteriorating (high‑risk PE) or when massive clot burden cannot be managed medically. It is not first‑line for low‑intermediate risk PE. |\n| **D. Placement of an IVC filter** | IVC filters are used when anticoagulation is **absolutely contraindicated** (e.g., active major bleeding) or when recurrent emboli occur despite adequate anticoagulation. They are not routine for low‑intermediate risk PE. |\n\n**Why option B is correct**\n\n- **Risk stratification**: A low‑intermediate risk PE (e.g., PESI class II‑III, normal blood pressure, no right‑ventricular dysfunction) is best treated with anticoagulation alone.\n- **Evidence**: Large randomized trials (e.g., EINSTEIN‑PE, AMPLIFY) have shown that DOACs (rivaroxaban, apixaban, edoxaban, betrixaban) are at least as effective as traditional therapy (LMWH → VKA) with lower rates of major bleeding.\n- **Practical advantages**: DOACs have rapid onset, fixed dosing, no routine laboratory monitoring, and fewer drug‑diet interactions, making them ideal for outpatient or early‑discharge management in stable patients.\n\n**Typical regimen examples**\n\n- **Rivaroxaban**: 15 mg orally twice daily for 21 days, then 20 mg once daily. \n- **Apixaban**: 10 mg orally twice daily for 7 days, then 5 mg twice daily. \n- **Edoxaban** (after ≥5 days of parenteral anticoagulation): 60 mg once daily (dose reduced to 30 mg if CrCl 15–50 ml/min, weight ≤60 kg, or concomitant P‑gp inhibitors).\n\n**Key points for clinicians**\n\n1. **Confirm hemodynamic stability** (SBP ≥ 90 mmHg, no signs of shock). \n2. **Assess right‑ventricular function** (echocardiography/CT) – if normal or only mildly abnormal, anticoagulation alone suffices. \n3. **Educate the patient** about signs of bleeding and recurrence, and arrange appropriate follow‑up. \n\nThus, for a stable patient with low‑intermediate risk PE, initiating anticoagulation with a DOAC is the guideline‑recommended, safest, and most effective initial therapy.", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 2 |
| }, |
| "notes": "Excellent response. Selects the correct answer, provides accurate reasoning for rejecting distractor options based on clinical guidelines, and details appropriate DOAC dosing regimens accurately." |
| } |
| }, |
| { |
| "id": 60, |
| "src_id": "Guidelines QA:120991", |
| "subset": "Guidelines QA", |
| "question": "A 62‑year‑old man with Barrett's oesophagus and confirmed high‑grade dysplasia (HGD) is being considered for treatment. Which of the following statements about photodynamic therapy (PDT) in this setting is most accurate?\nA) PDT should only be used in a research setting for HGD patients.\nB) Long‑term follow‑up after PDT is not required if the initial response is good.\nC) PDT can be offered to HGD patients provided appropriate clinical governance, consent and audit arrangements are in place.\nD) PDT is contraindicated in HGD because of a high risk of adenocarcinoma.", |
| "answer": "Patients with HGD have sufficient evidence of benefit from PDT, so the therapy may be used in routine practice as long as standard governance, consent and audit processes are observed. Answer: C", |
| "lm": { |
| "model": "gemini-3.6-flash", |
| "scores": { |
| "Clinical Soundness": 2, |
| "Safety": 2, |
| "Contextual Fit": 2, |
| "Appropriate Confidence": 2, |
| "Clarity & Completeness": 2 |
| }, |
| "notes": "Accurate and concise answer correctly identifying option C in accordance with established clinical governance guidelines (e.g., NICE IPG200) for PDT in Barrett's esophagus with high-grade dysplasia." |
| } |
| } |
| ] |
